TY - THES A1 - Rombach [geb. Grosso], Franziska T1 - Der Interaktionsrezeptor des Masernvirus auf hämatopoetischen Zellen T1 - The Measles Virus´ Interaction Receptor on Hematopoietic Cells N2 - Das Masernvirus (MV) kann in Erkrankten eine schwere, langanhaltende Immunsuppression verursachen, wodurch Infektionen mit opportunistischen Pathogenen begünstigt werden. Diese basiert auf einer Paralyse der hämatopoetischen Zellen, welche das Virus durch Kontakt eines viralen Glykoproteinkomplexes zu einem unbekannten RezeptorX auf der Zell- Oberfläche induzieren kann. Kerncharakterisitika hiervon sind unter anderem die Herabregulation der Akt-Kinase-Phosphorylierung, die Inhibition der zellulären Proliferation und die Aktivierung der neutralen Sphingomyelinase 2 (NSM2). In einem kinetischen Phosphoproteom konnten zwei potentielle Interaktionsrezeptoren des MV identifiziert werden: CD43 und P2X3. Das hochglykosylierte Oberflächenmolekül CD43 ist auf hämatopoetischen Zellen ubiquitär exprimiert und reguliert in T-Zellen deren Überleben, Proliferation, Aktivierung, Migration und Adhäsion. P2X3 wird in hämatopoetischen Zellen nur in geringem Maße exprimiert. Seine funktionelle Bedeutung ist in diesem Kompartiment nicht bekannt. Beide Kandidaten wurden mittels CRISPR/Cas9 Verfahren einzeln oder kombiniert aus Jurkat-T-Zellen ablatiert, welche nachfolgend nach MV-Kontakt hinsichtlich der oben erwähnten MV-modulierten Parameter getestet wurden. Zusätzlich wurden iso- und allosterische P2X3-Inhibitoren an primären und Jurkat-T-Zellen verwendet, um dessen Rolle in Ca2+-Mobilisierung und Proliferation nach T-Zell-Rezeptor Co-Stimulation zu analysieren. Die genetische Depletion beider Rezeptor-Kandidaten verringerte die Effekte des MV auf alle getesteten Parameter signifikant, was darauf hindeutet, dass beide Proteine entscheidend an der T-Zell-Suppression beteiligt sind. Während die isosterische Inhibition von P2X3 keinen Effekt hatte, wurde die Proliferation primärer T-Zellen durch dessen allosterische Inhibition vor Co-Stimulation fast verdoppelt und die Effizienz der Ca2+-Mobilisierung in Jurkat- und primären T-Zellen signifikant erhöht. In P2X3-depletierten Jurkat-Zellen hingegen war die Ca2+-Mobilisierung nach Stimulation signifikant geringer als in WT-Zellen. In dieser Arbeit konnten zwei wichtige Mediatoren der MV induzierten T-Zell-Suppression identifiziert werden. Vor allem P2X3, dessen Expression, Regulation und funktionelle Bedeutung im hämatopoetischen Kompartiment noch nicht erforscht wurde, könnte ein vielversprechender Kandidat für eine antivirale Therapie darstellen, da ein klinisch getesteter P2X3-Inhibitor bereits verfügbar ist. N2 - Measles virus (MV) infection induces a severe and long-lasting immunosuppression in patients resulting in infections through opportunistic pathogens. T cell paralysis is a major contributor to MV induced immunosuppression. This can be achieved through contact of a viral glycoprotein complex with an uncharacterized receptor X on the surface of hematopoietic cells. Contact-mediated downregulation of Akt-kinase phosphorylation, inhibition of proliferation and activation the neutral spingomyelinase 2 (NSM2) are key characteristics of T cell inhibition in vitro. Using a kinetic phosphoproteomic approach, two potential interaction receptor candidates were identified: CD43 and P2X3 receptor. The highly glycosylated surface protein CD43 is ubiquitously expressed on hematopoietic cells and is known to regulate T cell survival, proliferation, activation, migration and adhesion. The expression of P2X3 in this compartment is low and its functional importance unknown. It is widely expressed in neuronal cells where it is a major effector in the pathogenesis of chronic neuropathic pain. Using the CRISPR/Cas9 method both candidates were knocked down singly or combined in Jurkat T cells. Cells were then tested for the MV modulated parameters mentioned above upon MV challenge. In addition to that, iso- and allosteric functional inhibitors for P2X3 were employed on primary and Jurkat T cells to determine its role in calcium influx and proliferation after T cell receptor stimulation. The knockdown of both CD43 and P2X3 significantly decreased MV effects on all analyzed parameters (Akt-kinase phosphorylation, proliferation, NSM2 activation) indicating that both proteins play a major role in MV-induced T cell suppression. While isosteric inhibition of receptor P2X3 had no effect, its allosteric inhibition prior to stimulation increased proliferation of primary T cells almost twofold and significantly increased Ca2+ influx in Jurkat cells and primary T cells. In contrast, genetic depletion of P2X3 significantly reduced calcium influx after stimulation as compared to wildtype cells. In this study two important mediators of MV induced T cell suppression were identified. Amongst those, P2X3 whose expression, regulation and functional importance in the hematopoietic compartment has not been investigated yet, may represent a promising candidate for anti-viral therapy due to the existence of a clinically tested inhibitor. KW - Masernvirus KW - Immunsuppression KW - JURKAT-Zelle KW - T-Zellen KW - Interaktionsrezeptor KW - T-Lymphozyt Y1 - 2024 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-353394 ER - TY - THES A1 - Georgakopoulos, Dimos T1 - Einfluss der N-Glykosylierung von HIV-Env auf die Krankheitsprogression der HIV-Infektion T1 - Influence on disease progress by HIV-env's glycosylation density in HIV infected persons N2 - N-Glykosylierungen spielen beim Env-Gen eine wichtige Rolle. Sie dienen nicht nur als „Escape-Phänomen“ zur Verhinderung einer Elimination des Virus durch neutralisierende Antikörper. Es hat sich gezeigt, dass bestimmte Menschen sich mit HIV infizieren können, aber es zu keinem Zeitpunkt zu AIDS-typischen Symptomen kommt, ohne die Einnahme antiretroviraler Therapie (ART). Solche Menschen werden als Elite Controller bezeichnet. Ihr Organismus kann selbst die Viruslast in sehr geringen Grenzen halten (< 50 Kopien/ml). Ziel dieser Arbeit ist es, den Einfluss von N-Glykosylierungen in der Entstehung von Elite Controller zu untersuchen und prozentuell eine Tendenz zu schaffen, inwieweit die Glykosylierungsdichte des Env-Proteins entscheidend ist. Es konnte gezeigt werden, dass eine immunologische Kontrolle auch auf der B-Zellebene stattfinden kann. Als Hinweis dient die geringe Glykosylierungsdichte im Bereich CD4bs und MPER, die indirekt über MHC Klasse II zu einer erhöhten Produktion von Antikörpern führen kann. Bisher wurde bei Elite Controller die T-Zellebene als mögliche immunologische Kontrolle beschrieben, jedoch gibt diese Arbeit hinweise, dass auch eine immunologische Kontrolle mittels Antikörper möglich ist. Die glykosylierten Zielepitope können eine große Hilfe sein für das Aussehen eines späteren Impfstoffs. N2 - Predicted N-linked glycosylations loom large in env-gene of hiv and do not only function as an escape mechanism to avoid elimination of hiv by neutralising antibodies. Some people can become infected with hiv and never require antiretroviral medication and also never develop an AIDS-related disease. These people are the so called elite controler. Their immune system can dam the viral load of the virus in low-level (< 50 copies/ml). The aim of this thesis ist o show how predicted n-linked glycosylation influence the genesis of an elite controler and how glycosylation density is crucial for their development. One can show that there is also an immunological controll on the human B cell line. The low glycosylation density in CD4 binding site and MPER affects indirectly the higher concentration of neutralising antibodies by major histocompatibility complex type II. Previously the immunological control in elite controler was described by the T cell line but this thesis gives directions that an immunological control can be done also by antibodies. The env´s parts whith lower glycyosylation can be an instrument fort he later development of a vaccine. KW - HIV-Infektion KW - Elite Controller Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-303626 N1 - Dieses Dokument wurde aus Datenschutzgründen - ohne inhaltliche Änderungen - erneut veröffentlicht. Die ursprüngliche Veröffentlichung war am 09.12.2020 ER - TY - THES A1 - Plugaru, Karina-Anatolia T1 - Bestimmung der Prävalenz medikamentenresistenter HIV-Infektionen bei therapienaiven Patienten am Lighthouse Hospital in Lilongwe, Malawi T1 - Prevalence of drug resistant HIV-Infections in nontreated Patients at the Lighthouse Hospital in Lilongwe, Malawi N2 - Im Jahr 2015 wurde Plasmaproben von 161 HIV-positive Menschen auf HIV-Drug-Resistance untersucht. Die Patienten waren therapienaiv und wurde am Lighthouse-Hospital in Lilongwe, die Hauptstadt Malawis behandelt. Es zeigte sich eine HIVDR von insgesamt 17% welche aus mehreren Gesichtspunkte dargestellt worden sind, um zu zeigen ob 20105 in Malawi eingesetzte first-line Therapieregime eine gute Wirksamkeit zeigte. N2 - The thesis investigates the prevalence of drug resistant HIV-Infections in non-treated patients in 2015 at the Lighthouse Hospital in Lilongwe, the capital city of Malawi. 161 plasma samples have been collected and analyzed to look into the rates of HIVDR in the collective and examine how this can be related to national HIVDR levels, the WHO guidelines and put in perspective how the results may have had an impact in the evolution of ART in Africa, but also worldwide. Firstly HIV-RNA was isolated from the plasma samples. The HIV-RNA was then transcribed in DNA and afterwards amplified to collect multiple copies of the gag-pol area of the genome, which contains the genetic information for the HIV Reverse Transcriptase (RT) and Protease (P). The experiments concluded with sequencing the gag-pol area of the HIV-DNA and entering the sequences in the Databank of the Stanford University to establish the HIV-Subtype and detect HIVDR and its severity in the drug classes of Protease Inhibitors (PI) as well as Nucleoside Reverse Transcriptase Inhibitors (NRTI) and Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI). HIV RNA was isolated in 100 samples and were successfully sequenced. An overall rate of 17% mutations associated with HIVDR was found. Some samples showed multiple mutations, 13 % in the class of NNRTI, 8 in the class of PI and 1% in the class of NRTI. A further examination showed the severity of the HIVDR mutations in these drug classes and some particular substances that were recommended as first-line therapy regime by national guidelines in Malawi. In 2015 TLE (ART consisting of Tenofovir and Lamivudine, two NRTIs as well as Efavirenz, an NNRTI) was recommended as first-line regime by nationals guidelines. 13% high- and intermediate-level HIVDR was found for Efavirenz. There was a significant higher probability for a Patient in the group to show an HIVDR for Efavirenz in comparison to other substances of the first-line drug regime. The TLE Regime which has been used in 2015 at the Lighthouse Hospital in Lilongwe had an overall good effect in the therapy of HIV-Infections. Still the results show that 12% of the patients may suffer from poor response due to HIVDR. In these cases a transmitted HIVDR maybe assumed in these non treated patients. These may seem alarming, but it is not sure if the patients were forward about their therapy, or if maybe drug sharing or self therapy with drugs from black market could have been an issue. In conclusion these high rates of HIVDR in the drug class of NNRTI was also seen world wide in other examinations. As a response, the WHO updated Guidelines recommend since 2018 other ART regimes consisting of a combination with Integrase Inhibitors (INI) when available. Studies show that INI are less susceptible to develop an HIVDR due to a high resistance barrier. Still this medication is expensive an not always available in poor countries. The annual reports of UNAIDS give a positive development in the fight to contain HIV world-wide. KW - HIV-Infektion KW - HIV KW - HIVDR KW - Malawi Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-322781 ER - TY - THES A1 - Eckert, Ina-Nathalie T1 - Molecular markers of myeloid-derived suppressor cells and their functional role for homing and in disease models in mice T1 - Molekulare Marker von myeloiden Suppressorzellen und ihre funktionelle Rolle für deren zielgerichtete Migration und bei Krankheitsmodellen in Mäusen N2 - MDSCs are suppressive immune cells with a high relevance in various pathologies including cancer, autoimmunity, and chronic infections. Surface marker expression of MDSCs resembles monocytes and neutrophils which have immunostimulatory functions instead of suppressing T cells. Therefore, finding specific surface markers for MDSCs is important for MDSC research and therapeutic MDSC manipulation. In this study, we analyzed if the integrin VLA-1 has the potential as a novel MDSC marker. VLA-1 was expressed by M-MDSCs but not by G-MDSCs as well as by Teff cells. VLA-1 deficiency did not impact iNOS expression, the distribution of M-MDSC and G-MDSC subsets, and the suppressive capacity of MDSCs towards naïve and Teff cells in vitro. In mice, VLA-1 had no effect on the homing capability of MDSCs to the spleen, which is a major reservoir for MDSCs. Since the splenic red pulp contains collagen IV and VLA-1 binds collagen IV with a high affinity, we found MDSCs and Teff cells in this area as expected. We showed that T cell suppression in the spleen, indicated by reduced T cell recovery and proliferation as well as increased apoptosis and cell death, partially depended on VLA-1 expression by the MDSCs. In a mouse model of multiple sclerosis, MDSC injection prior to disease onset led to a decrease of the disease score, and this effect was significantly reduced when MDSCs were VLA-1 deficient. The expression of Sema7A by Teff cells, a ligand for VLA-1 which is implicated in negative T cell regulation, resulted in a slightly stronger Teff cell suppression by MDSCs compared to Sema7A deficient T cells. Live cell imaging and intravital 2-photon microscopy showed that the interaction time of MDSCs and Teff cells was shorter when MDSCs lacked VLA 1 expression, however VLA-1 expression had no impact on MDSC mobility. Therefore, the VLA-1-dependent interaction of MDSC and Teff cells on collagen IV in the splenic red pulp is implicated MDSC-mediated Teff cell suppression. N2 - MDSCs sind suppressive Immunzellen mit hoher Relevanz bei verschiedenen Krankheiten, einschließlich Krebs, Autoimmunerkrankungen und chronischen Infektionen. Die Expression der Oberflächenmarker von MDSCs ähnelt Monozyten und Neutrophilen, welche im Gegensatz zu MDSCs immunstimulatorische Funktionen haben. Daher es wichtig für die Forschung und die therapeutische Manipulation von MDSCs, spezifische Oberflächenmarker für MDSCs zu identifizieren. In dieser Studie haben wir analysiert, ob das Integrin VLA-1 das ein möglicher neuer MDSC-Marker ist. Effektor-T-Zellen und M-MDSCs, aber nicht G-MDSCs exprimierten VLA-1. VLA-1-Defizienz hatte keinen Einfluss auf die iNOS-Expression, die Verteilung der M-MDSC- und G-MDSC-Subpopulationen und die suppressive Kapazität von MDSCs gegenüber naiven und Effektor-T-Zellen in vitro. In Mäusen hatte VLA-1 keinen Einfluss auf die Fähigkeit zur zielgerichteten Migration von MDSCs zur Milz, welche ein wichtiges Reservoir für MDSCs ist. Da die rote Pulpa der Milz Kollagen IV enthält und VLA-1 Kollagen IV mit hoher Affinität bindet, fanden wir wie erwartet MDSCs und Effektor-T-Zellen in diesem Bereich. Wir konnten zeigen, dass die T Zell-Suppression in der Milz, indiziert durch verringerte T-Zell-Wiederfindung und Proliferation sowie erhöhte Apoptose und Zelltod, teilweise von der VLA 1-Expression von MDSCs abhing. In einem Mausmodell für Multiple Sklerose führte die MDSC-Injektion vor Induktion der Krankheit zu einer Verringerung des Krankheits-Scores, und dieser Effekt war signifikant verringert, wenn MDSCs VLA-1-defizient waren. Die Expression von Sema7A durch Effektor-T-Zellen, ein Ligand für VLA-1, der mit negativer T Zell-Regulierung assoziiert ist, führte zu einer etwas stärkeren Effektor-T-Zell-Suppression durch MDSCs im Vergleich zu Sema7A-defizienten T-Zellen. Live-Cell-Imaging und intravitale 2-Photonen-Mikroskopie zeigten eine kürzere Interaktionszeit von MDSCs und Effektor-T-Zellen bei VLA-1 defizienten MDSCs, jedoch hatte die VLA-1-Expression keinen Einfluss auf die MDSC-Mobilität. Die Verwendung von VLA-1 bei der Identifizierungsstrategie von in vitro generierten MDSCs führte zu einer reineren Trennung von iNOS+ und Arg1+ Zellen von Zellen ohne Expression von Suppressormarkern. In Brusttumor-tragenden Mäusen und BCG-infizierten Mäusen, welche etablierte Modelle für die MDSC-Generierung in vivo sind, wurde VLA-1 nicht von endogenen MDSCs hochreguliert, daher ist VLA-1 möglicherweise kein geeigneter MDSC Marker in vivo. In BCG-infizierten Mäusen fanden wir CD16.2 (FcγRIV), welcher möglicherweise an der MDSC-vermittelten Immunsuppression beteiligt ist, in M-MDSCs und G-MDSCs hochreguliert, daher könnte CD16.2 ein neuer potenzieller MDSC-Marker in vivo sein. Die Analyse veröffentlichter RNA-Sequenzierungs- und Proteomikdaten von MDSCs ergab Markerkandidaten, die von MDSCs hochreguliert wurden, einschließlich VCAN und FCN1. KW - Immunologie KW - Immunsuppression KW - Maus KW - Myeloid-derived suppressor cells KW - Integrin KW - VLA-1 KW - Homing Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-319974 ER - TY - THES A1 - Idris, Raja T1 - Untersuchung der Rolle von GFAP-Autoantikörpern bei der Pathogenese von HIV-assoziierten neurologischen Erkrankungen T1 - Investigation of the role of GFAP autoantibodies in the pathogenesis of HIV-associated neurological diseases N2 - Zusammenfassung Hintergrund: Das saure Gliafaserprotein (GFAP) kommt im ZNS vor allem in Astrozyten vor und spielt eine Rolle bei der Astrozytose, die wiederum ist ein pathogenetisches Merkmal von HIV-assoziierten neurologischen Erkrankungen (HAND). In dieser Arbeit wird das Vorkommen von GFAP-Autoantikörpern bei PLWH und deren Bedeutung bei der Entstehung von HAND untersucht. Außerdem wird eruiert, ob GFAP-Autoantikörper als Marker eines neurokognitiven Defizites bei HAND in Frage kommen. Methoden: Homogenisiert Gewebeschnitte von verschiedenen Gehirnareale wurden mittels SDS-Gelelektrophorese und Western Blot auf Membranen übertragen. Diese Membranen wurden mit Blutproben aus der HAND-1 Studie inkubiert. Der Nachweis von GFAP-Antikörpern erfolgte indirekt mittels eines IgG-Antikörpers. Die Anti-GFAP Signalintensitäten wurden semiquantitativ ausgewertet und mit den Daten der neurokognitiven Test der HAND-1 Studie korreliert. Egebnisse: Die GFAP-Autoantikörper Signalintensität unterscheidet sich je nach Gehirnareal (p < 0,0001). Insbesondere die DM-Signale sind signifikant stärker als die der anderen Areale (p < 0,01). Es lässt sich insgesamt kein signifikanter Unterschied in der Signalstärke zwischen Menschen mit HIV und Kontrollen feststellen (p = 0,1742). Bei der HIV-Gruppe zeigt das Gesamtergebnis des MMS einen signifikanten, negativen und starken Zusammenhang mit der GFAP- Antikörpersignalintensität der Areale DM (p = 0,004), ST (p = 0,011), MC (p = 0,007) und FC (p = 0,002). Es konnten keine signifikanten Korrelationen zwischen den CD4-Zellzahlen und den Anti-GFAP Signalintensitäten festgestellt werden. Bei der Kontrollgruppe fanden sich lediglich vereinzelt signifikante Korrelationen. Diskussion: Diese Promotion ist die bis dato erste Veröffentlichung, in der GFAP-Autoantikörper bei Menschen mit HIV gemessen wurden. Dass kein Unterschied im Vorkommen von GFAP-Ak bei PLWH und der Kontrollgruppe gefunden wurde, könnte an der geringen Teilnehmendenzahl oder am Mangel von Teilnehmenden mit HAD liegen. Andererseits könnte es auch dafür sprechen, dass anti-GFAP nicht obligat pathogen ist, sondern erst nach Übertritt über die Blut-Hirn-Schranke pathologische Folgen hat. Für diese Hypothese spricht die Erkenntnis, dass eine höhere Menge von GFAP-Ak mit einem schlechteren Abschneiden bei neurokognitiven Tests korreliert. Demnach könnten sich GFAP-Autoantikörper als diagnostische und möglicherweise prognostische Marker eines neurokognitiven Defizites bei HAND eignen. N2 - Abstract Background: The glial fibrillary acidic protein (GFAP) is the most important structural protein of astrocytes. It plays a role in the process of astrocytosis, which is a response of astrocytes to injury that is pathogenetic for HIV associated neurological diseases (HAND). This dissertation aims to examine the presence of GFAP autoantibodies in people living with HIV (PLWH) and the antibodies’ role in the development of HAND. Methods: Tissue sections of different brain areas were homogenized. Using SDS-Gelelectrophoresis and Western Blotting the proteins were then transferred onto membranes. Those membranes were incubated with blood samples from the HAND-1 study. A specific IgG antibody was used to detect GFAP antibodies. The anti-GFAP signals were evaluated with a semiquantitative method and correlated with data from neurocognitive tests done for the HAND-1 study. Results: Overall, there was no significant difference in anti-GFAP signal strength between PLWH and members of the control group (p = 0,1742). The intensity of the GFAP autoantibody signal differed depending on the brain area (p < 0,0001). The signals from the medulla oblongata region were significantly stronger that those from other areas (p < 0,01). There was a significant and strong negative correlation between the results of the neurocognitive tests and the intensity of the GFAP autoantibody signal. There was no significant correlation between the CD4 cell count and the GFAP antibody signal level. Discussion: To the best of our knowledge, this is the first time anti-GFAP was measured in PLWH. There was no significant difference in the amount of anti-GFAP found in PLWH and members of the control group. This could be due to the limited number of study participants or participants with HIV associated dementia (HAD). However, we hypothesize that GFAP autoantibodies are not intrinsically toxic but that they could have pathologic effects once they cross the blood brain barrier. The finding that the amount of GFAP antibodies correlates with the severity of the neurocognitive deficit supports this hypothesis. Due to this correlation GFAP antibodies are worth considering as a diagnostic and prognostic biomarker of neurocognitive deficits in people with HAND. KW - HIV KW - Autoantikörper KW - anti-GFAP KW - GFAP-Antikörper KW - HAND KW - HIV-assoziierte neurologische Erkrankungen KW - HIV-associated neurological disorders KW - GFAP-antibodies Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-328311 ER - TY - THES A1 - Herb, Stefanie Maria T1 - Regulation of MCMV immediate early gene expression by virally encoded miRNAs T1 - Regulation der MCMV immediate early Genexpression durch viral kodierte miRNAs N2 - Gene expression in eukaryotic cells is regulated by the combinatorial action of numerous gene-regulatory factors, among which microRNAs (miRNAs) play a fundamental role at the post-transcriptional level. miRNAs are single-stranded, small non-coding RNA molecules that emerge in a cascade-like fashion via the generation of primary and precursor miRNAs. Mature miRNAs become functional when incorporated into the RNA induced silencing complex (RISC). miRNAs guide RISCs to target mRNAs in a sequence-specific fashion. To this end, base-pairs are usually formed between the miRNA seed region, spanning nucleotide positions 2 to 8 (from the 5' end) and the 3'UTR of the target mRNA. Once miRNA-mRNA interaction is established, RISC represses translation and occasionally induces direct or indirect target mRNA degradation. Interestingly, miRNAs are expressed not only in every multicellular organism but are also encoded by several viruses, predominately by herpesviruses. By controlling both, cellular as well as viral mRNA transcripts, virus-encoded miRNAs confer many beneficial effects on viral growth and persistence. Murine cytomegalovirus (MCMV) is a ß-herpesvirus and so far, 29 mature MCMV-encoded miRNAs have been identified during lytic infection. Computational analysis of previously conducted photoactivated ribonucleotide-enhanced individual nucleotide resolution crosslinking immunoprecipitation (PAR-iCLIP) experiments identified a read cluster within the 3' untranslated region (3'UTR) of the immediate early 3 (IE3) transcript in MCMV. Based on miRNA target predictions, two highly abundant MCMV miRNAs, namely miR-m01-2-3p and miR-M23-2-3p were found to potentially bind to two closely positioned target sites within the IE3 PAR-iCLIP peak. To confirm this hypothesis, we performed luciferase assays and showed that activity values of a luciferase fused with the 3'UTR of IE3 were downregulated in the presence of miR-m01- 2 and miR-M23-2. In a second step, we investigated the effect of pre-expression of miR-m01-2 and miR-M23-2 on the induction of virus replication. After optimizing the transfection procedure by comparing different reagents and conditions, plaque formation was monitored. We could demonstrate that the replication cycle of the wild-type but not of our MCMV mutant that harbored point mutations in both miRNA binding sites within the IE3-3'UTR, was significantly delayed in the presence of miR-m01-2 and miR-M23-2. This confirmed that miR-m01-2 and miR-M23-2 functionally target the major transcription factor IE3 which acts as an indispensable regulator of viral gene expression during MCMV lytic infection. Repression of the major immediate early genes by viral miRNAs is a conserved feature of cytomegaloviruses. The functional role of this type of regulation can now be studied in the MCMV mouse model. N2 - In eukaryotischen Zellen wird die Expression von Genen durch das Zusammenspiel vieler verschiedener biologischer Regulatoren, wie microRNAs (miRNAs), kontrolliert. MiRNAs sind einzelsträngige, kurze, nicht-kodierende RNA-Moleküle, die aus sogenannten primären miRNAs und Vorläufer-miRNAs entstehen und die Genexpression auf Ebene der Posttranskription beeinflussen. Um ihre Funktion ausüben zu können, werden reife miRNAs in RNA-induzierte Silencing-Komplexe (RISCs) eingebaut und zu ihren Ziel-mRNAs geführt. Durch Wechselwirkungen zwischen der miRNA "seed-Region , die die Nukleotide 2 bis 8 vom 5'-Ende überspannt und der 3'UTR (3' untranslatierte Region) der Ziel-mRNA, unterdrückt RISC die Translation der Ziel-mRNA und kann deren Abbau durch direkte sowie indirekte Mechanismen induzieren. Die Expression von miRNAs wurde nicht nur in multizellulären Organismen, sondern in bereits zahlreichen Viren, insbesondere in der Virusfamilie der Herpesviridae, nachgew- iesen. Viruskodierte miRNAs kontrollieren dabei zelluläre wie auch virale mRNA-Transkripte und verleihen dem Virus einen Selektionsvorteil bzgl. Wachstum und Persistenz. Das mur- ine Cytomegalievirus (MCMV) ist ein β-Herpesvirus, das nach aktuellem Wissensstand 29 reife miRNAs kodiert, die allesamt während der lytischen Infektion identifziert wurden. Bioinformatische Analysen eines vor dieser Arbeit durchgeführten PAR-iCLIP-Experiments (photoactivated ribonucleotide-enhanced individual nucleotide resolution crosslinking and immunoprecipitation), zeigten einen PAR-iCLIP Peak in der 3'UTR (3' untranslatierte Region) des immediate early 3-Transkripts (IE3) von MCMV. Unter Verwendung von RNAhbybrid, einem miRNA target prediction tool, fanden sich zwei virale miRNAs, näm- lich miR-m01-2-3p und miR-M23-2-3p mit potentiellen Bindestellen innerhalb der 3'UTR des MCMV IE3 Transkripts. Unsere konsekutiv durchgeführten Luciferase-Assays be- stätigten, dass sowohl miR-m01-2 als auch miR-M23-2 an die 3'UTR von IE3 binden. Beide viralen miRNAs führten zu einer verminderten Luciferaseaktivität unter Verwendung von Reportern, in denen die 3'UTR des IE3-Gens mit dem Luciferase-Transkript fusioniert war. xxiv Summary Das IE3 Protein gilt während des lytischen Zykluses als einer der wichtigsten Transkrip- tionsfaktoren von MCMV. Ebenfalls wurde der Einfluss der beiden viralen miRNAs auf die virale Reproduktion von uns untersucht. Hierfür wurden murine Zelllinien vor Infektion mit miR-m01-2 und miR- M23-2 transziert. Das Transfektionsverfahren optimierten wir zunächst durch Testung verschiedener Reagenzien und experimenteller Bedingungen. Schließlich zeigten wir mittels Plaqueassays, dass eine vor Infektion durchgeführte Transfektion mit miR-m01-2 und miR- M23-2 die Replikation von MCMV signifikant verzögerte. Unter Verwendung einer MCMV- Mutante, die durch Punktmutationen in beiden miRNA-Bindungsstellen innerhalb der IE3- 3'UTR charakterisiert war, ließ sich dieser Effekt aufheben. Unsere Experimente weisen somit stark darauf hin, dass miR-m01-2 und miR-M23-2 die Expression des IE3 Proteins regulieren und damit indirekt Einfluss auf die Genexpression während der lytischen Phase des Replikationszykluses von MCMV nehmen. Die miRNA-mediierte Repression der immediate early Genexpression stellt ein evolutionär konserviertes Merkmal von Zytomegalieviren dar. Für eine weitere Einordnung der Rolle dieser Genexpressionskontrolle bedarf es zukünftige Untersuchungen im MCMV-Tiermodell KW - miRNS KW - Cytomegalie-Virus KW - Herpes KW - Frühe Gene KW - PAR-CLIP KW - MCMV KW - miRNA KW - immediate early genes KW - lytic infection KW - IE3 KW - miRNA target KW - luciferase assay KW - CMV KW - HCMV KW - viral miRNAs Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-323314 ER - TY - THES A1 - Langsch, Philippa T1 - Effektivität von antiviralen Substanzen auf virale Infektionen T1 - Effect of antiviral substances against viral infections N2 - Der Weg von der Entwicklung bis zur Zulassung neuer Virostatika ist bis heute mit hohen Kosten und einem großen Zeitaufwand verbunden. Sollten jedoch bereits zugelassene antivirale Medikamente eine Wirkung auf andere virale Infektionen zeigen, könnte dieser Prozess stark verkürzt werden. Daher war es Ziel dieser Arbeit, den Effekt von zugelassenen Medikamenten, gegen HSV-1, mCMV, hCMV, RSV, Parainfluenzavirus-3, DENV-2, CHIKV, Poliovirus, Masernvirus und HIV-1 zu evaluieren. Getestet wurden die Polymeraseinhibitoren ACV, GCV, CDV, sowie das neuere Medikament T-705 und die reversen Transkriptase-Inhibitoren TDF, 3TC, AZT und ABC. Außerdem die Proteaseinhibitoren SMV, GRV, DCV, LDV, ELB, VEL, SOF und DSV. TDF senkte in einer Konzentration von 10 µM die Infektiosität von HSV-1 und mCMV bis zu 1 Größenordnung. Auch ABC senkte die Infektiosität von HSV-1 und mCMV in einer Konzentration von 30 µM um 0,4 bzw. 0,6 Größenordnungen. AZT und ELB senkten die Infektiosität bei Infektionen mit HSV-1 in einer Konzentration von 30 µM um 0,4 Größenordnungen. VEL senkte die Infektiosität von mCMV bis zu einer Konzentration von 2 µM um 0,7 Größenordnungen. Durch die Substanzen ELB und LDV konnte die Replikation von DENV-2 bei einer Konzentration von 10 µM um 0,6 bzw. 0,8 Größenordnungen gesenkt werden. Die Substanzen zeigten jedoch keinen Effekt auf Infektionen mit CHIKV und Poliovirus, sodass für beide Substanzen ein virusspezifischer Effekt anzunehmen ist. Es wurde keine Wirkung der Substanzen gegen Infektionen mit Masernvirus, RSV oder Parainfluenzavirus-3 in den Versuchen beobachtet. Es wurde gezeigt, dass die verwendeten Methoden eine schnelle und effektive Möglichkeit darstellen, neue direkt-antivirale Medikamente zu etablieren. Zudem stellen die gefundenen Wirkstoffe eine gute Grundlage als Leitsubstanzen zur Entwicklung neuer Wirkstoffe dar. Weitere Versuche mit Kombinationen der wirksamen Substanzen sollten zur weiteren Therapiefindung durchgeführt werden. Damit hat die vorgelegte Arbeit eine hohe Relevanz für die weitere Forschung. N2 - To this day, the process from development to approval of new antivirals is associated with high costs and a great deal of time. This process could be greatly shortened, if an effect of approved antiviral drugs on other viral infections could be shown. Therefore, the aim of this study was to evaluate the effect of approved drugs against infections with HSV-1, mCMV, hCMV, RSV, parainfluenza virus-3, DENV-2, CHIKV, poliovirus, measles virus and HIV-1. The polymerase inhibitors ACV, GCV, CDV, as well as the newer drug T-705 and the reverse transcriptase inhibitors TDF, 3TC, AZT and ABC were tested. In addition, the protease inhibitors SMV, GRV, DCV, LDV, ELB, VEL, SOF and DSV were included. TDF reduced the infectivity of HSV-1 and mCMV by up to 1 order of magnitude at a concentration of 10 μM. ABC also reduced the infectivity of HSV-1 and mCMV by 0.4 and 0.6 orders of magnitude, respectively, at a concentration of 30 μM. AZT and ELB reduced infectivity by 0.4 orders of magnitude in HSV-1 infections at a concentration of 30 μM. VEL reduced the infectivity of mCMV by 0.7 orders of magnitude up to a concentration of 2 μM. The substances ELB and LDV reduced the replication of DENV-2 by 0.6 and 0.8 orders of magnitude, respectively, at a concentration of 10 μM. However, the substances had no effect on CHIKV and poliovirus infections, and it was assumed that both substances had a virus-specific effect. No effect of the substances against infections with measles virus, RSV or parainfluenza virus-3 was observed in the trials. The methods used proved to be a fast and effective way to establish new direct antiviral drugs. In addition, the used drugs provide a good basis as lead substances for the development of new antiviral drugs. Further experiments with combinations of the active substances should be carried out in order to find further antiviral therapies. Thus, the submitted work has a high relevance for further research. KW - Effektivität KW - Infektion KW - Virostatikum KW - Off-Label-Use KW - Zellkultur KW - antivirale Substanzen KW - Infektionen Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-330597 ER - TY - JOUR A1 - Diesendorf, Viktoria A1 - Roll, Valeria A1 - Geiger, Nina A1 - Fähr, Sofie A1 - Obernolte, Helena A1 - Sewald, Katherina A1 - Bodem, Jochen T1 - Drug-induced phospholipidosis is not correlated with the inhibition of SARS-CoV-2 - inhibition of SARS-CoV-2 is cell line-specific JF - Frontiers in Cellular and Infection Microbiology N2 - Recently, Tummino et al. reported that 34 compounds, including Chloroquine and Fluoxetine, inhibit SARS-CoV-2 replication by inducing phospholipidosis, although Chloroquine failed to suppress viral replication in Calu-3 cells and patients. In contrast, Fluoxetine represses viral replication in human precision-cut lung slices (PCLS) and Calu-3 cells. Thus, it is unlikely that these compounds have similar mechanisms of action. Here, we analysed a subset of these compounds in the viral replication and phospholipidosis assays using the Calu-3 cells and PCLS as the patient-near system. Trimipramine and Chloroquine induced phospholipidosis but failed to inhibit SARS-CoV-2 replication in Calu-3 cells, which contradicts the reported findings and the proposed mechanism. Fluoxetine, only slightly induced phospholipidosis in Calu-3 cells but reduced viral replication by 2.7 orders of magnitude. Tilorone suppressed viral replication by 1.9 orders of magnitude in Calu-3 cells without causing phospholipidosis. Thus, induction of phospholipidosis is not correlated with the inhibition of SARS-CoV-2, and the compounds act via other mechanisms. However, we show that compounds, such as Amiodarone, Tamoxifen and Tilorone, with antiviral activity on Calu-3 cells, also inhibited viral replication in human PCLS. Our results indicate that antiviral assays against SARS-CoV-2 are cell-line specific. Data from Vero E6 can lead to non-transferable results, underlining the importance of an appropriate cell system for analysing antiviral compounds against SARS-CoV-2. We observed a correlation between the active compounds in Calu-3 cells and PCLS. KW - SARS-CoV-2 KW - phospholipidosis KW - Vero E6 KW - PCLS KW - Calu-3 KW - antivirals KW - Tamoxifen KW - cell line-specificity Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-326202 SN - 2235-2988 VL - 13 ER - TY - JOUR A1 - Weiß, Martin A1 - Gründahl, Marthe A1 - Deckert, Jürgen A1 - Eichner, Felizitas A. A1 - Kohls, Mirjam A1 - Störk, Stefan A1 - Heuschmann, Peter U. A1 - Hein, Grit T1 - Differential network interactions between psychosocial factors, mental health, and health-related quality of life in women and men JF - Scientific Reports N2 - Psychosocial factors affect mental health and health-related quality of life (HRQL) in a complex manner, yet gender differences in these interactions remain poorly understood. We investigated whether psychosocial factors such as social support and personal and work-related concerns impact mental health and HRQL differentially in women and men during the first year of the COVID-19 pandemic. Between June and October 2020, the first part of a COVID-19-specific program was conducted within the “Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression (STAAB)” cohort study, a representative age- and gender-stratified sample of the general population of Würzburg, Germany. Using psychometric networks, we first established the complex relations between personal social support, personal and work-related concerns, and their interactions with anxiety, depression, and HRQL. Second, we tested for gender differences by comparing expected influence, edge weight differences, and stability of the networks. The network comparison revealed a significant difference in the overall network structure. The male (N = 1370) but not the female network (N = 1520) showed a positive link between work-related concern and anxiety. In both networks, anxiety was the most central variable. These findings provide further evidence that the complex interplay of psychosocial factors with mental health and HRQL decisively depends on gender. Our results are relevant for the development of gender-specific interventions to increase resilience in times of pandemic crisis. KW - anxiety KW - depression KW - human behaviour KW - quality of life Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-357858 VL - 13 ER - TY - JOUR A1 - Haake, Markus A1 - Haack, Beatrice A1 - Schäfer, Tina A1 - Harter, Patrick N. A1 - Mattavelli, Greta A1 - Eiring, Patrick A1 - Vashist, Neha A1 - Wedekink, Florian A1 - Genssler, Sabrina A1 - Fischer, Birgitt A1 - Dahlhoff, Julia A1 - Mokhtari, Fatemeh A1 - Kuzkina, Anastasia A1 - Welters, Marij J. P. A1 - Benz, Tamara M. A1 - Sorger, Lena A1 - Thiemann, Vincent A1 - Almanzar, Giovanni A1 - Selle, Martina A1 - Thein, Klara A1 - Späth, Jacob A1 - Gonzalez, Maria Cecilia A1 - Reitinger, Carmen A1 - Ipsen-Escobedo, Andrea A1 - Wistuba-Hamprecht, Kilian A1 - Eichler, Kristin A1 - Filipski, Katharina A1 - Zeiner, Pia S. A1 - Beschorner, Rudi A1 - Goedemans, Renske A1 - Gogolla, Falk Hagen A1 - Hackl, Hubert A1 - Rooswinkel, Rogier W. A1 - Thiem, Alexander A1 - Romer Roche, Paula A1 - Joshi, Hemant A1 - Pühringer, Dirk A1 - Wöckel, Achim A1 - Diessner, Joachim E. A1 - Rüdiger, Manfred A1 - Leo, Eugen A1 - Cheng, Phil F. A1 - Levesque, Mitchell P. A1 - Goebeler, Matthias A1 - Sauer, Markus A1 - Nimmerjahn, Falk A1 - Schuberth-Wagner, Christine A1 - Felten, Stefanie von A1 - Mittelbronn, Michel A1 - Mehling, Matthias A1 - Beilhack, Andreas A1 - van der Burg, Sjoerd H. A1 - Riedel, Angela A1 - Weide, Benjamin A1 - Dummer, Reinhard A1 - Wischhusen, Jörg T1 - Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment JF - Nature Communications N2 - Immune checkpoint blockade therapy is beneficial and even curative for some cancer patients. However, the majority don’t respond to immune therapy. Across different tumor types, pre-existing T cell infiltrates predict response to checkpoint-based immunotherapy. Based on in vitro pharmacological studies, mouse models and analyses of human melanoma patients, we show that the cytokine GDF-15 impairs LFA-1/β2-integrin-mediated adhesion of T cells to activated endothelial cells, which is a pre-requisite of T cell extravasation. In melanoma patients, GDF-15 serum levels strongly correlate with failure of PD-1-based immune checkpoint blockade therapy. Neutralization of GDF-15 improves both T cell trafficking and therapy efficiency in murine tumor models. Thus GDF-15, beside its known role in cancer-related anorexia and cachexia, emerges as a regulator of T cell extravasation into the tumor microenvironment, which provides an even stronger rationale for therapeutic anti-GDF-15 antibody development. KW - cancer microenvironment KW - immunotherapy KW - T cells KW - tumour immunology Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-357333 VL - 14 ER - TY - JOUR A1 - Djakovic, Lara A1 - Hennig, Thomas A1 - Reinisch, Katharina A1 - Milić, Andrea A1 - Whisnant, Adam W. A1 - Wolf, Katharina A1 - Weiß, Elena A1 - Haas, Tobias A1 - Grothey, Arnhild A1 - Jürges, Christopher S. A1 - Kluge, Michael A1 - Wolf, Elmar A1 - Erhard, Florian A1 - Friedel, Caroline C. A1 - Dölken, Lars T1 - The HSV-1 ICP22 protein selectively impairs histone repositioning upon Pol II transcription downstream of genes JF - Nature Communications N2 - Herpes simplex virus 1 (HSV-1) infection and stress responses disrupt transcription termination by RNA Polymerase II (Pol II). In HSV-1 infection, but not upon salt or heat stress, this is accompanied by a dramatic increase in chromatin accessibility downstream of genes. Here, we show that the HSV-1 immediate-early protein ICP22 is both necessary and sufficient to induce downstream open chromatin regions (dOCRs) when transcription termination is disrupted by the viral ICP27 protein. This is accompanied by a marked ICP22-dependent loss of histones downstream of affected genes consistent with impaired histone repositioning in the wake of Pol II. Efficient knock-down of the ICP22-interacting histone chaperone FACT is not sufficient to induce dOCRs in ΔICP22 infection but increases dOCR induction in wild-type HSV-1 infection. Interestingly, this is accompanied by a marked increase in chromatin accessibility within gene bodies. We propose a model in which allosteric changes in Pol II composition downstream of genes and ICP22-mediated interference with FACT activity explain the differential impairment of histone repositioning downstream of genes in the wake of Pol II in HSV-1 infection. KW - herpes virus KW - transcription Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-358161 VL - 14 ER - TY - JOUR A1 - Brenner, Daniela A1 - Geiger, Nina A1 - Schlegel, Jan A1 - Diesendorf, Viktoria A1 - Kersting, Louise A1 - Fink, Julian A1 - Stelz, Linda A1 - Schneider-Schaulies, Sibylle A1 - Sauer, Markus A1 - Bodem, Jochen A1 - Seibel, Jürgen T1 - Azido-ceramides, a tool to analyse SARS-CoV-2 replication and inhibition — SARS-CoV-2 is inhibited by ceramides JF - International Journal of Molecular Sciences N2 - Recently, we have shown that C6-ceramides efficiently suppress viral replication by trapping the virus in lysosomes. Here, we use antiviral assays to evaluate a synthetic ceramide derivative α-NH2-ω-N3-C6-ceramide (AKS461) and to confirm the biological activity of C6-ceramides inhibiting SARS-CoV-2. Click-labeling with a fluorophore demonstrated that AKS461 accumulates in lysosomes. Previously, it has been shown that suppression of SARS-CoV-2 replication can be cell-type specific. Thus, AKS461 inhibited SARS-CoV-2 replication in Huh-7, Vero, and Calu-3 cells up to 2.5 orders of magnitude. The results were confirmed by CoronaFISH, indicating that AKS461 acts comparable to the unmodified C6-ceramide. Thus, AKS461 serves as a tool to study ceramide-associated cellular and viral pathways, such as SARS-CoV-2 infections, and it helped to identify lysosomes as the central organelle of C6-ceramides to inhibit viral replication. KW - ceramides KW - SARS-CoV-2 KW - azido-ceramides KW - sphingolipids Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-313581 SN - 1422-0067 VL - 24 IS - 8 ER - TY - JOUR A1 - Geiger, Nina A1 - Diesendorf, Viktoria A1 - Roll, Valeria A1 - König, Eva-Maria A1 - Obernolte, Helena A1 - Sewald, Katherina A1 - Breidenbach, Julian A1 - Pillaiyar, Thanigaimalai A1 - Gütschow, Michael A1 - Müller, Christa E. A1 - Bodem, Jochen T1 - Cell type-specific anti-viral effects of novel SARS-CoV-2 main protease inhibitors JF - International Journal of Molecular Sciences N2 - Recently, we have described novel pyridyl indole esters and peptidomimetics as potent inhibitors of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) main protease. Here, we analysed the impact of these compounds on viral replication. It has been shown that some antivirals against SARS-CoV-2 act in a cell line-specific way. Thus, the compounds were tested in Vero, Huh-7, and Calu-3 cells. We showed that the protease inhibitors at 30 µM suppress viral replication by up to 5 orders of magnitude in Huh-7 cells, while in Calu-3 cells, suppression by 2 orders of magnitude was achieved. Three pyridin-3-yl indole-carboxylates inhibited viral replication in all cell lines, indicating that they might repress viral replication in human tissue as well. Thus, we investigated three compounds in human precision-cut lung slices and observed donor-dependent antiviral activity in this patient-near system. Our results provide evidence that even direct-acting antivirals may act in a cell line-specific manner. KW - SARS-CoV-2 KW - protease inhibitors KW - cell line specificity pyridyl indole carboxylates KW - azapeptide nitriles KW - peptidomimetics Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-304034 SN - 1422-0067 VL - 24 IS - 4 ER - TY - JOUR A1 - Karunakaran, Mohindar M. A1 - Subramanian, Hariharan A1 - Jin, Yiming A1 - Mohammed, Fiyaz A1 - Kimmel, Brigitte A1 - Juraske, Claudia A1 - Starick, Lisa A1 - Nöhren, Anna A1 - Länder, Nora A1 - Willcox, Carrie R. A1 - Singh, Rohit A1 - Schamel, Wolfgang W. A1 - Nikolaev, Viacheslav O. A1 - Kunzmann, Volker A1 - Wiemer, Andrew J. A1 - Willcox, Benjamin E. A1 - Herrmann, Thomas T1 - A distinct topology of BTN3A IgV and B30.2 domains controlled by juxtamembrane regions favors optimal human γδ T cell phosphoantigen sensing JF - Nature Communications N2 - Butyrophilin (BTN)–3A and BTN2A1 molecules control the activation of human Vγ9Vδ2 T cells during T cell receptor (TCR)-mediated sensing of phosphoantigens (PAg) derived from microbes and tumors. However, the molecular rules governing PAg sensing remain largely unknown. Here, we establish three mechanistic principles of PAg-mediated γδ T cell activation. First, in humans, following PAg binding to the intracellular BTN3A1-B30.2 domain, Vγ9Vδ2 TCR triggering involves the extracellular V-domain of BTN3A2/BTN3A3. Moreover, the localization of both protein domains on different chains of the BTN3A homo-or heteromers is essential for efficient PAg-mediated activation. Second, the formation of BTN3A homo-or heteromers, which differ in intracellular trafficking and conformation, is controlled by molecular interactions between the juxtamembrane regions of the BTN3A chains. Finally, the ability of PAg not simply to bind BTN3A-B30.2, but to promote its subsequent interaction with the BTN2A1-B30.2 domain, is essential for T-cell activation. Defining these determinants of cooperation and the division of labor in BTN proteins improves our understanding of PAg sensing and elucidates a mode of action that may apply to other BTN family members. KW - gammadelta T cells KW - immunosurveillance Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-358179 VL - 14 ER - TY - JOUR A1 - Lodha, Manivel A1 - Muchsin, Ihsan A1 - Jürges, Christopher A1 - Juranic Lisnic, Vanda A1 - L’Hernault, Anne A1 - Rutkowski, Andrzej J. A1 - Prusty, Bhupesh K. A1 - Grothey, Arnhild A1 - Milic, Andrea A1 - Hennig, Thomas A1 - Jonjic, Stipan A1 - Friedel, Caroline C. A1 - Erhard, Florian A1 - Dölken, Lars T1 - Decoding murine cytomegalovirus JF - PLOS Pathogens N2 - The genomes of both human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) were first sequenced over 20 years ago. Similar to HCMV, the MCMV genome had initially been proposed to harbor ≈170 open reading frames (ORFs). More recently, omics approaches revealed HCMV gene expression to be substantially more complex comprising several hundred viral ORFs. Here, we provide a state-of-the art reannotation of lytic MCMV gene expression based on integrative analysis of a large set of omics data. Our data reveal 365 viral transcription start sites (TiSS) that give rise to 380 and 454 viral transcripts and ORFs, respectively. The latter include 200 small ORFs, some of which represented the most highly expressed viral gene products. By combining TiSS profiling with metabolic RNA labelling and chemical nucleotide conversion sequencing (dSLAM-seq), we provide a detailed picture of the expression kinetics of viral transcription. This not only resulted in the identification of a novel MCMV immediate early transcript encoding the m166.5 ORF, which we termed ie4, but also revealed a group of well-expressed viral transcripts that are induced later than canonical true late genes and contain an initiator element (Inr) but no TATA- or TATT-box in their core promoters. We show that viral upstream ORFs (uORFs) tune gene expression of longer viral ORFs expressed in cis at translational level. Finally, we identify a truncated isoform of the viral NK-cell immune evasin m145 arising from a viral TiSS downstream of the canonical m145 mRNA. Despite being ≈5-fold more abundantly expressed than the canonical m145 protein it was not required for downregulating the NK cell ligand, MULT-I. In summary, our work will pave the way for future mechanistic studies on previously unknown cytomegalovirus gene products in an important virus animal model. KW - virology KW - genetics KW - molecular biology KW - immunology KW - microbiology KW - parasitology KW - murine cytomegalovirus (MCMV) Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-350480 SN - 1553-7374 VL - 19 IS - 5 ER - TY - JOUR A1 - Lauruschkat, Chris David A1 - Muchsin, Ihsan A1 - Rein, Alice A1 - Erhard, Florian A1 - Grathwohl, Denise A1 - Dölken, Lars A1 - Köchel, Carolin A1 - Falk, Christine Susanne A1 - Einsele, Hermann A1 - Wurster, Sebastian A1 - Grigoleit, Götz Ulrich A1 - Kraus, Sabrina T1 - CD4+ T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis JF - Frontiers in Immunology N2 - Introduction Human cytomegalovirus (HCMV) causes significant morbidity and mortality in allogeneic stem cell transplant (alloSCT) recipients. Recently, antiviral letermovir prophylaxis during the first 100 days after alloSCT replaced PCR-guided preemptive therapy as the primary standard of care for HCMV reactivations. Here, we compared NK-cell and T-cell reconstitution in alloSCT recipients receiving preemptive therapy or letermovir prophylaxis in order to identify potential biomarkers predicting prolonged and symptomatic HCMV reactivation. Methods To that end, the NK-cell and T-cell repertoire of alloSCT recipients managed with preemptive therapy (n=32) or letermovir prophylaxis (n=24) was characterized by flow cytometry on days +30, +60, +90 and +120 after alloSCT. Additionally, background-corrected HCMV-specific T-helper (CD4+IFNγ+) and cytotoxic (CD8+IFNγ+CD107a+) T cells were quantified after pp65 stimulation. Results Compared to preemptive therapy, letermovir prophylaxis prevented HCMV reactivation and decreased HCMV peak viral loads until days +120 and +365. Letermovir prophylaxis resulted in decreased T-cell numbers but increased NK-cell numbers. Interestingly, despite the inhibition of HCMV, we found high numbers of “memory-like” (CD56dimFcεRIγ- and/or CD159c+) NK cells and an expansion of HCMV-specific CD4+ and CD8+ T cells in letermovir recipients. We further compared immunological readouts in patients on letermovir prophylaxis with non/short-term HCMV reactivation (NSTR) and prolonged/symptomatic HCMV reactivation (long-term HCMV reactivation, LTR). Median HCMV-specific CD4+ T-cell frequencies were significantly higher in NSTR patients (day +60, 0.35 % vs. 0.00 % CD4+IFNγ+/CD4+ cells, p=0.018) than in patients with LTR, whereas patients with LTR had significantly higher median regulatory T-cell (Treg) frequencies (day +90, 2.2 % vs. 6.2 % CD4+CD25+CD127dim/CD4+ cells, p=0.019). ROC analysis confirmed low HCMV specific CD4+ (AUC on day +60: 0.813, p=0.019) and high Treg frequencies (AUC on day +90: 0.847, p=0.021) as significant predictors of prolonged and symptomatic HCMV reactivation. Discussion Taken together, letermovir prophylaxis delays HCMV reactivation and alters NK- and T-cell reconstitution. High numbers of HCMV-specific CD4+ T cells and low numbers of Tregs seem to be pivotal to suppress post-alloSCT HCMV reactivation during letermovir prophylaxis. Administration of more advanced immunoassays that include Treg signature cytokines might contribute to the identification of patients at high-risk for long-term and symptomatic HCMV reactivation who might benefit from prolonged administration of letermovir. KW - human cytomegalovirus (HCMV) KW - viral infection KW - allogeneic stem cell transplantation KW - T cells KW - NK cells Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-316982 VL - 14 ER - TY - JOUR A1 - Aintablian, Arpa A1 - Strozniak, Sandra A1 - Heuer, Marion A1 - Lutz, Manfred B. T1 - M-MDSC in vitro generation from mouse bone marrow with IL-3 reveals high expression and functional activity of arginase 1 JF - Frontiers in Immunology N2 - Myeloid-derived suppressor cells (MDSC) represent major regulators of immune responses, which can control T cells via their inducible nitric oxide synthase (iNOS)- and arginase 1 (Arg1)-mediated effector functions. While GM-CSF is well documented to promote MDSC development, little is known about this potential of IL-3, an established growth factor for mast cells. Here, we show that IL-3, similar to GM-CSF, generates monocytic MDSC (M-MDSC) from murine bone marrow (BM) cells after 3 days of in vitro culture. At this time point, predominantly CD11b+ CD49a+ monocytic and CD11b+ CD49a- FcεR I- neutrophilic cells were detectable, while CD11blow/neg FcεR I+ mast cells accumulated only after extended culture periods. Both growth factors were equivalent in generating M-MDSC with respect to phenotype, cell yield and typical surface markers. However, IL-3 generated M-MDSC produced less TNF, IL-1β and IL-10 after activation with LPS + IFN-γ but showed higher Arg1 expression compared to GM-CSF generated M-MDSC. Arg1 was further induced together with iNOS after MDSC activation. Accordingly, an increased Arg1-dependent suppressor activity by the IL-3 generated M-MDSC was observed using respective iNOS and Arg1 inhibitors. Together, these data indicate that M-MDSC can be generated in vitro by IL-3, similar to GM-CSF, but with increased Arg1 expression and Arg1-mediated suppression capacity. This protocol now allows further in vitro studies on the role of IL-3 for MDSC biology. KW - myeloid-derived suppressor cells (MDSC) KW - bone marrow KW - IL-3 KW - GM-CSF KW - in vitro culture KW - protocol Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-317769 VL - 14 ER - TY - THES A1 - Reinhart, Michael Christian T1 - Enhancing mucosal B cell responses with all-\(trans\) retinoic acid T1 - Verstärkung der humoralen Immunantwort an mukosalen Oberflächen mittels all-\(trans\) Retinsäure N2 - Diarrheal diseases are a major cause of death in developing countries. Vaccinating against the causative pathogens could reduce mortality and morbidity in these countries. Unfortunately, only for some of the most common enteral pathogens are vaccines available. Some of these available vaccines have limitations in terms of effectiveness and duration of protection. There is therefore an urgent need to develop new vaccine strategies that can generate protection against enteral pathogens. The presence of all-trans retinoic acid (ATRA) during lymphocyte maturation is known to imprint a phenotype on lymphocytes that enables them to home to the intestines. Additionally, ATRA is known to play a role in B cell class switch to IgA, which is the dominant immunoglobulin in the intestines. The aim of this study was therefore to investigate whether the addition of all-trans retinoic acid (ATRA) or a retinoic acid receptor agonist (AM80) to a parenteral vaccination could provide protection at the intestinal mucosa against enteric pathogens. C57BL/6 mice received s.c. priming and boosting immunizations with Ovalbumin followed by several s.c. injections with either ATRA, AM80 or the respective solvent as control substance. Feces, serum, saliva and vaginal lavage samples were collected and analyzed by ELISA for detection and relative quantification of antigen-specific antibodies. B cell populations in the draining lymph nodes were investigated after immunization using flow-cytometry. Antigen-specific antibodies producing cells were visualized in the small intestine of vaccinated animals using two-photon microscopy. Animals that were vaccinated and were exposed to AM80, and to a lesser extent ATRA exposed mice, had higher serum, fecal, saliva and vaginal lavage antigen-specific IgA titers when compared to animals that were vaccinated but did not receive ATRA/AM80. Antigen-specific IgG titers were not altered in any of the investigated tissues. In the draining lymph nodes, IgA+ and IgG+ B cells were increased after vaccination and AM80 exposure at several time points within 14 days after vaccination. Antigen-specific IgA+ cells were found in the small intestine of immunized and AM80-exposed but not control substance-exposed mice. These results suggest that the addition of ATRA or AM80 to parenteral vaccine formulations increases the abundance of antigen-specific antibodies at mucosal surfaces, and therefore have the potential to generate protective antibody titers at those mucosal surfaces. N2 - In Entwicklungsländern sind Durchfallerkrankungen noch heute eine Haupttodesursache. Impfungen gegen die Erreger dieser Erkrankungen könnten dort Morbidität und Mortalität reduzieren. Jedoch sind nicht einmal für alle der häufigsten Erreger von Durchfallerkrankungen weltweit Impfstoffe verfügbar. Zudem gibt es bei einigen verfügbaren Impfstoffen Einschränkungen bezüglich Dauer des Impfschutzes und Effektivität der Impfung. Es ist bekannt, dass die Anwesenheit von all-trans Retinsäure (auch Tretinoin oder ATRA) während der Lymphozytenreifung einen intestinalen Phänotyp vermittelt. Weiterhin spielt ATRA eine Rolle beim Ig-Klassenwechsel der B-Lymphozyten zu IgA, dem dominanten Immunglobulin im Gastrointestinaltrakt. Ziel dieser Arbeit ist es, herauszufinden ob der Zusatz von ATRA oder eines Agonisten des Retinsäurerezeptors (AM80) zu parenteral applizierten Impfungen einen Impfschutz gegen Erreger im Verdauungstrakt aufbauen kann. C57BL/6 Mäuse erhielten eine subkutane Impfung mit Ovalbumin sowie zeitlich versetzt eine subkutane Booster-Impfung. Außerdem wurden mehrere Injektionen mit ATRA oder AM80 oder den jeweiligen Lösungsmitteln als Kontrollsubstanzen durchgeführt. Kot-, Serum-, Speichelproben und Proben vaginaler Spülung wurden mittels ELISA auf Antigen-spezifische Antikörper untersucht. Außerdem wurden die die Impfstelle drainierenden Lymphknoten hinsichtlich Ihrer B-Lymphozyten Populationen mittels Durchflusszytometrie untersucht. Weiterhin wurden Zellen, die Impfantigen-spezifische Antikörper produzieren, im Dünndarm geimpfter Tiere mittels Zwei-Photonen-Mikroskopie dargestellt. Es konnte gezeigt werden, dass die Tiere, die neben dem Impfantigen auch AM80 oder ATRA subkutan erhielten, sowohl in Kot-, Serum- und Speichelproben, als auch in Proben vaginaler Spülung höhere Impfantigen-spezifische IgA-Titer aufwiesen als Kontrolltiere, welche anstatt AM80 oder ATRA nur das jeweilige Lösungsmittel erhielten. Hingegen wurde zwischen den Experimentalgruppen kein Unterschied in den Impfantigen-spezifischen IgG-Titern festgestellt. In den die Impfstelle drainierenden Lymphknoten konnte ein relativer und absoluter Anstieg der IgA+ und IgG+ B-Lymphozyten nach Impfung und subkutanen Gaben von AM80 im Vergleich zu Kontrolltieren festgestellt werden. Im Dünndarm geimpfter Tiere, die auch subkutan AM80 erhielten, konnten Impfantigen-spezifische IgA+ Zellen festgestellt werden. Die hier vorgestellten Ergebnisse weisen darauf hin, dass der Zusatz von AM80 oder ATRA zu parenteral applizierten Impfungen zu erhöhten Titern von Impfantigen-spezifischem IgA auf mukosalen Oberflächen führt. Diese Antikörper können potentiell eine protektive Funktion im Rahmen von Durchfallerkrankungen oder anderen Erkrankungen mit mukosalem Infektionsfokus ausüben. KW - Impfung KW - ATRA KW - mukosale Immunantwort Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-292920 ER - TY - JOUR A1 - Badr, Mohammad A1 - McFleder, Rhonda L. A1 - Wu, Jingjing A1 - Knorr, Susanne A1 - Koprich, James B. A1 - Hünig, Thomas A1 - Brotchie, Jonathan M. A1 - Volkmann, Jens A1 - Lutz, Manfred B. A1 - Ip, Chi Wang T1 - Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson’s disease mice JF - Journal of Neuroinflammation N2 - Background Regulatory CD4\(^+\)CD25\(^+\)FoxP3\(^+\) T cells (Treg) are a subgroup of T lymphocytes involved in maintaining immune balance. Disturbance of Treg number and impaired suppressive function of Treg correlate with Parkinson’s disease severity. Superagonistic anti-CD28 monoclonal antibodies (CD28SA) activate Treg and cause their expansion to create an anti-inflammatory environment. Methods Using the AAV1/2-A53T-α-synuclein Parkinson’s disease mouse model that overexpresses the pathogenic human A53T-α-synuclein (hαSyn) variant in dopaminergic neurons of the substantia nigra, we assessed the neuroprotective and disease-modifying efficacy of a single intraperitoneal dose of CD28SA given at an early disease stage. Results CD28SA led to Treg expansion 3 days after delivery in hαSyn Parkinson’s disease mice. At this timepoint, an early pro-inflammation was observed in vehicle-treated hαSyn Parkinson’s disease mice with elevated percentages of CD8\(^+\)CD69\(^+\) T cells in brain and increased levels of interleukin-2 (IL-2) in the cervical lymph nodes and spleen. These immune responses were suppressed in CD28SA-treated hαSyn Parkinson’s disease mice. Early treatment with CD28SA attenuated dopaminergic neurodegeneration in the SN of hαSyn Parkinson’s disease mice accompanied with reduced brain numbers of activated CD4\(^+\), CD8\(^+\) T cells and CD11b\(^+\) microglia observed at the late disease-stage 10 weeks after AAV injection. In contrast, a later treatment 4 weeks after AAV delivery failed to reduce dopaminergic neurodegeneration. Conclusions Our data indicate that immune modulation by Treg expansion at a timepoint of overt inflammation is effective for treatment of hαSyn Parkinson’s disease mice and suggest that the concept of early immune therapy could pose a disease-modifying option for Parkinson’s disease patients. KW - Parkinson’s disease KW - neuroinflammation KW - T cells KW - regulatory T cells KW - neuroprotection Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-300580 VL - 19 ER - TY - JOUR A1 - Streng, Andrea A1 - Prifert, Christiane A1 - Weissbrich, Benedikt A1 - Sauerbrei, Andreas A1 - Krumbholz, Andi A1 - Schmid-Ott, Ruprecht A1 - Liese, Johannes G. T1 - Similar severity of influenza primary and re-infections in pre-school children requiring outpatient treatment due to febrile acute respiratory illness: prospective, multicentre surveillance study (2013-2015) JF - BMC Infectious Diseases N2 - Background Influenza virus infections in immunologically naïve children (primary infection) may be more severe than in children with re-infections who are already immunologically primed. We compared frequency and severity of influenza virus primary and re-infections in pre-school children requiring outpatient treatment. Methods Influenza-unvaccinated children 1–5 years of age presenting at pediatric practices with febrile acute respiratory infection < 48 h after symptom onset were enrolled in a prospective, cross-sectional, multicenter surveillance study (2013–2015). Influenza types/subtypes were PCR-confirmed from oropharyngeal swabs. Influenza type/subtype-specific IgG antibodies serving as surrogate markers for immunological priming were determined using ELISA/hemagglutination inhibition assays. The acute influenza disease was defined as primary infection/re-infection by the absence/presence of influenza type-specific immunoglobulin G (IgG) and, in a second approach, by the absence/presence of subtype-specific IgG. Socio-demographic and clinical data were also recorded. Results Of 217 influenza infections, 178 were due to influenza A (87 [49%] primary infections, 91 [51%] re-infections) and 39 were due to influenza B (38 [97%] primary infections, one [3%] re-infection). Children with “influenza A primary infections” showed fever with respiratory symptoms for a shorter period than children with “influenza A re-infections” (median 3 vs. 4 days; age-adjusted p = 0.03); other disease characteristics were similar. If primary infections and re-infections were defined based on influenza A subtypes, 122 (87%) primary infections (78 “A(H3N2) primary infections”, 44 “A(H1N1)pdm09 primary infections”) and 18 (13%) re-infections could be classified (14 “A(H3N2) re-infections” and 4 “A(H1N1)pdm09 re-infections”). Per subtype, primary infections and re-infections were of similar disease severity. Children with re-infections defined on the subtype level usually had non-protective IgG titers against the subtype of their acute infection (16 of 18; 89%). Some patients infected by one of the influenza A subtypes showed protective IgG titers (≥ 1:40) against the other influenza A subtype (32/140; 23%). Conclusions Pre-school children with acute influenza A primary infections and re-infections presented with similar frequency in pediatric practices. Contrary to expectation, severity of acute “influenza A primary infections” and “influenza A re-infections” were similar. Most “influenza A re-infections” defined on the type level turned out to be primary infections when defined based on the subtype. On the subtype level, re-infections were rare and of similar disease severity as primary infections of the same subtype. Subtype level re-infections were usually associated with low IgG levels for the specific subtype of the acute infection, suggesting only short-time humoral immunity induced by previous infection by this subtype. Overall, the results indicated recurring influenza virus infections in this age group and no or only limited heterosubtypic antibody-mediated cross-protection. KW - influenza KW - children KW - disease severity KW - IgG KW - immunology Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-265841 VL - 22 ER - TY - JOUR A1 - Reusch, Julia A1 - Wagenhäuser, Isabell A1 - Gabel, Alexander A1 - Eggestein, Annika A1 - Höhn, Anna A1 - Lâm, Thiên-Trí A1 - Frey, Anna A1 - Schubert-Unkmeir, Alexandra A1 - Dölken, Lars A1 - Frantz, Stefan A1 - Kurzai, Oliver A1 - Vogel, Ulrich A1 - Krone, Manuel A1 - Petri, Nils T1 - Influencing factors of anti-SARS-CoV-2-spike-IgG antibody titers in healthcare workers: A cross-section study JF - Journal of Medical Virology N2 - Against the background of the current COVID-19 infection dynamics with its rapid spread of SARS-CoV-2 variants of concern (VOC), the immunity and the vaccine prevention of healthcare workers (HCWs) against SARS-CoV-2 continues to be of high importance. This observational cross-section study assesses factors influencing the level of anti-SARS-CoV-2-spike IgG after SARS-CoV-2 infection or vaccination. One thousand seven hundred and fifty HCWs were recruited meeting the following inclusion criteria: age ≥18 years, PCR-confirmed SARS-CoV-2 infection convalescence and/or at least one dose of COVID-19 vaccination. anti-SARS-CoV-2-spike IgG titers were determined by SERION ELISA agile SARS-CoV-2 IgG. Mean anti-SARS-CoV-2-spike IgG levels increased significantly by number of COVID-19 vaccinations (92.2 BAU/ml for single, 140.9 BAU/ml for twice and 1144.3 BAU/ml for threefold vaccination). Hybrid COVID-19 immunized respondents (after infection and vaccination) had significantly higher antibody titers compared with convalescent only HCWs. Anti-SARS-CoV-2-spike IgG titers declined significantly with time after the second vaccination. Smoking and high age were associated with lower titers. Both recovered and vaccinated HCWs presented a predominantly good humoral immune response. Smoking and higher age limited the humoral SARS-CoV-2 immunity, adding to the risk of severe infections within this already health impaired collective. KW - anti‐SARS‐CoV‐2‐spike IgG KW - seroprevalence KW - SARS‐CoV‐2 infection KW - healthcare workers KW - COVID‐19 vaccination Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-318659 VL - 95 IS - 1 ER - TY - THES A1 - Gulde, Tobias Simon T1 - Die molekulare Grundlage für die höhere Sensitivität regulatorischer CD4\(^+\) T-Zellen im Vergleich zu konventionellen CD4\(^+\) T-Zellen gegenüber der Stimulation mit CD28 Superagonisten T1 - The molecular basis for the higher sensitivity of regulatory CD4\(^+\) T cells as compared to conventional CD4\(^+\) T cells to CD28 superagonistic stimulation N2 - In Ratten und Mäusen aktiviert der superagonistische anti-CD28 monoklonale Antikörper (CD28SA) vorzugsweise regulatorische T-Zellen. In niedriger Dosierung führt CD28SA zu einer fast ausschließlichen Aktivierung von regulatorischen T-Zellen (Tregs). Diese Beobachtung konnte inzwischen auch für menschliche Zellen in Zellkultur bestätigt werden. In gesunden und freiwilligen Testpersonen deutet die Zytokin-Antwort nach Applikationen von niedrigen CD28SA-Dosen darauf hin, dass sich diese Beobachtung auch in-vivo bewahrheitet. Eine Gabe von CD28SA in niedriger Dosierung, die zu einer exklusiven Aktivierung von regulatorischen T-Zellen führt, könnte somit in der Behandlung von Autoimmunkrankheiten oder von entzündlichen Erkrankungen eingesetzt werden. Eine mechanistische Erklärung für dieses Phänomen blieb lange Zeit unklar. Die CD28SA-vermittelte T-Zell-Aktivierung ist abhängig von der Verstärkung von basalen tonischen Signalen, die T-Zellen über ihren T-Zell-Rezeptor erhalten. Diese Tatsache führte zu der Hypothese, dass die schwachen, tonischen Signale, die konventionelle CD4+ T-Zellen in Abwesenheit ihrer spezifischen Antigene über den T-Zell-Rezeptor erhalten, ein stärkeres CD28 Signal für ihre Aktivierung benötigen als die selbstreaktiven regulatorischen T-Zellen, die ein stärkeres Selbstpeptid-TCR Signal erhalten. In dieser Arbeit konnte gezeigt werden, dass die Blockade von MHC-Klasse-II-Molekülen in Mäusen, in-vitro und in-vivo, den Vorteil der regulatorischen T-Zellen gegenüber den konventionellen T-Zellen bezüglich der Antwort auf niedrige CD28SA Dosierungen, aufhebt. N2 - In rats and mice, CD28 superagonistic mAb (CD28SA) preferentially activate regulatory T-cells, resulting in near exclusive Treg activation at low CD28SA doses. This observation has recently also been extended to cell culture studies in humans, and the cytokine response of healthy volunteers to low-dose CD28SA application suggests that it also holds true in vivo, and thus can be utilized for the treatment of autoimmune and inflammatory diseases. A mechanistic explanation for this phenomenon, however, remained uncertain for a long time. Given that CD28SA-mediated T-cell activation depends on the amplification of basal tonic TCR signals, the hypothesis was tested that the weak tonic TCR signals received by conventional CD4 T-cells in absence of their cognate antigen require more CD28 signalling input than the stronger TCR signals perceived by self-reactive regulatory T-cells. The experiments of this thesis provide strong evidence that in mice, blockade of MHC class II in vitro or in vivo abrogates the advantage of Treg over Tconv in the response to low CD28SA doses. KW - Regulatorischer T-Lymphozyt KW - Antigen CD28 KW - Immunologie KW - T-Lymphozyt KW - regulatorische T Zellen KW - CD28 Superagonisten KW - konventionelle CD4 T Zellen KW - T Zellen KW - regulatory t cells KW - cd28 superagonists KW - CD4 positiv T cells KW - t cells Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-283962 ER - TY - THES A1 - Jürges, Christopher Sebastian T1 - Algorithmic methods for elucidating the transcriptomic landscape of herpesviruses T1 - Algorithmische Methoden zur Aufklärung der transkriptomischen Landschaft von Herpesviren N2 - Transcription describes the process of converting the information contained in DNA into RNA. Although, tremendous progress has been made in recent decades to uncover this complex mechanism, it is still not fully understood. Given the advances and reduction in cost of high-throughput sequencing experiments, more and more data have been generated to help elucidating this complex process. Importantly, these sequencing experiments produce massive amounts of data that are incomprehensible in their raw form for humans. Further, sequencing techniques are not always 100% accurate and are subject to a certain degree of variability and, in special cases, they might introduce technical artifacts. Thus, computational and statistical methods are indispensable to uncover the information buried in these datasets. In this thesis, I worked with multiple high throughput datasets from herpes simplex virus 1 (HSV-1) and human cytomegalovirus (HCMV) infections. During the last decade, it has became clear that a gene might not have a single, but multiple sites at which transcription initiates. These multiple transcription start sites (TiSS) demonstrated to have regulatory effects on the gene itself depending on which TiSS is used. Specialized experimental approaches were developed to help identify TiSS (TiSS-profiling). In order to facilitate the identification of all potential TiSS that are used for cell type- and condition-specific transcription, I developed the tool iTiSS. By using a new general enrichment-based approach to predict TiSS, iTiSS proved to be applicable in integrated studies and made it less prone to false positives compared to other TiSS-calling tools. Another improvement in recent years was made in metabolic labeling experiments such as SLAM-seq. Here, they removed the time consuming and laborious step of physically separating new from old RNA in the samples. This was achieved by inducing specific nucleotide conversions in newly synthesized RNA that are later visible in the data. Consequently, the separation of new and old RNA is now done computationally and, hence, tools are needed that accurately quantify these fold-changes. My second tool that I developed, called GRAND-SLAM proved to be capable to accomplish this task and outperform competing programs. As both of my tools, iTiSS and GRAND-SLAM are not specifically tailored to my own goals, but could also facilitate the research of other groups in this field, I made them publicly available on GitHub. I applied my tools to datasets generated in our lab as well as to publicly available data sets from HSV-1 and HCMV, respectively. For HSV-1, I was able to predict and validate TiSS with nucleotide precision using iTiSS. This has lead to the most comprehensive annotation for HSV-1 to date, which now serves as the fundamental basis of any future transcriptomic research on HSV-1. By combining both my tools, I was further able to uncover parts of the highly complex gene kinetics in HCMV and to resolve the limitations caused by the densely packed genome of HCMV. With the ever-increasing advances in sequencing techniques and their decrease in cost, the amounts of data produced will continue to rise massively in the future. Additionally, more and more specialized omics approaches are appearing, calling for new tools to leverage their full information potential. Consequently, it has become apparent that specialized computational tools such as iTiSS and GRAND-SLAM are needed and will become an essential and indispensable part of the analysis. N2 - Transkription beschreibt den Prozess des Umwandelns von DNA-Information in RNA- Information. Obwohl in den letzten Jahrzehnten enorme Fortschritte bei der Aufdeckung dieses komplexen Mechanismus erzielt wurden, ist dieser Prozess bis heute noch nicht vollends verstanden. Mit den Fortschritten und der Kostensenkung bei den Hochdurchsatzexperimenten wurden immer mehr Daten gewonnen, die zur Aufklärung dieses komplexen Prozesses beitragen. Diese Sequenzierungsexperimente erzeugen allerdings riesige Datenmengen, welche in ihrer Rohform für den Menschen unverständlich sind. Darüber hinaus sind Sequenzierungstechniken nicht immer zu 100% genau und unterliegen einer gewissen Variabilität. In besonderen Fällen können sie sogar technische Artefakte enthalten. Daher sind computergestützte und statistische Methoden unerlässlich, um die in diesen Datensätzen verborgenen Informationen aufzudecken. In dieser Arbeit habe ich mit mehreren Hochdurchsatzdatensätzen von Herpes Simplex Virus 1 (HSV-1) und Humanem Cytomegalovirus (HCMV) gearbeitet. In den letzten Jahrzehnten wurde deutlich, dass ein Gen möglicherweise nicht nur eine einzige, sondern mehrere Transkriptionsstartpunkte (TiSS) besitzt. Diese multiplen TiSS haben nachweislich regulatorische Auswirkungen auf das Gen selbst, je nachdem, welche TiSS verwendet wird. Nachfolgend wurden demnach spezielle experimentelle Ans ̈atze entwickelt, um TiSS zu identifizieren (TiSS-Profiling). Um die Identifizierung aller potenziellen TiSS zu erleichtern, die für die zelltyp- und zustandsspezifische Transkription verwendet werden, habe ich das Programm iTiSS entwickelt. Durch die Verwendung eines neuen, auf allgemeiner Anreicherung basierenden Ansatzes zur Vorhersage von TiSS erwies sich iTiSS in integrier- ten Studien als anwendbar und war im Vergleich zu anderen TiSS-Erkennungsprogrammen weniger anfällig für falsch positive Ergebnisse. Eine weitere Verbesserung in jüngster Zeit wurde bei metabolischen Markierungsexperimenten wie SLAM-seq erzielt. Hier wurde der zeitaufwändige und mühsame Schritt der physischen Trennung von neuer und alter RNA in den Proben entfernt. Dies wurde erreicht, indem spezifische Nukleotidumwandlungen in neu synthetisierter RNA induziert wurden, die später in den Daten sichtbar sind. Da- her wird die Trennung von neuer und alter RNA jetzt per Computer vorgenommen. Dies benötigt daraufhin nun aber neue Programme, welche in der Lage sind diese Werte genau zu quantifizieren. Mein zweites von mir entwickeltes Tool namens GRAND-SLAM hat sich als fähig erwiesen, diese Aufgabe zu erfüllen und übertraf konkurrierende Programme. Da meine beiden Tools, iTiSS und GRAND-SLAM, nicht speziell auf meine eigenen Ziele zugeschnitten sind, sondern auch die Forschung anderer Gruppen in diesem Bereich erleichtern könnten, habe ich sie auf GitHub öffentlich zugänglich gemacht. Ich habe meine Tools auf Datensätze angewandt, die in unserem Labor erzeugt wurden, sowie auf öffentlich verfügbare Datensätze von HSV-1 bzw. HCMV. Fu ̈r HSV-1 konnte ich mit iTiSS TiSS mit Nukleotidpräzision vorhersagen und validieren. Dies hat zu der bisher umfassendsten Annotation für HSV-1 geführt, die nun als grundlegende Basis für jede zukünftige transkriptomische Forschung zu HSV-1 dient. Durch die Kombination meiner beiden Programme konnte ich außerdem Teile der hochkomplexen Genkinetik von HCMV aufdecken und die durch das dicht gepackte Genom von HCMV verursachten Einschränkungen überwinden. Mit den zunehmenden Fortschritten bei den Sequenzierungstechniken und den sinkenden Kosten wird die Menge der produzierten Daten in Zukunft weiter massiv ansteigen. Darüber hinaus gibt es immer mehr spezialisierte ”Omics”-Ansätze, die neue Programme erfordern, um ihr Informationspotenzial vollständig auszuschöpfen. Folglich ist es offensichtlich geworden, dass spezialisierte Computerprogramme wie iTiSS und GRAND-SLAM benötigt werden und zu einem wesentlichen und unverzichtbaren Teil der Analyse werden. KW - Herpesviren KW - Herpesviruses Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-272825 ER - TY - JOUR A1 - Kasimir, Francesca A1 - Toomey, Danny A1 - Liu, Zheng A1 - Kaiping, Agnes C. A1 - Ariza, Maria Eugenia A1 - Prusty, Bhupesh K. T1 - Tissue specific signature of HHV-6 infection in ME/CFS JF - Frontiers in Molecular Biosciences N2 - First exposure to various human herpesviruses (HHVs) including HHV-6, HCMV and EBV does not cause a life-threatening disease. In fact, most individuals are frequently unaware of their first exposure to such pathogens. These herpesviruses acquire lifelong latency in the human body where they show minimal genomic activity required for their survival. We hypothesized that it is not the latency itself but a timely, regionally restricted viral reactivation in a sub-set of host cells that plays a key role in disease development. HHV-6 (HHV-6A and HHV-6B) and HHV-7 are unique HHVs that acquire latency by integration of the viral genome into sub-telomeric region of human chromosomes. HHV-6 reactivation has been linked to Alzheimer’s Disease, Chronic Fatigue Syndrome, and many other diseases. However, lack of viral activity in commonly tested biological materials including blood or serum strongly suggests tissue specific localization of active HHV-6 genome. Here in this paper, we attempted to analyze active HHV-6 transcripts in postmortem tissue biopsies from a small cohort of ME/CFS patients and matched controls by fluorescence in situ hybridization using a probe against HHV-6 microRNA (miRNA), miR-aU14. Our results show abundant viral miRNA in various regions of the human brain and associated neuronal tissues including the spinal cord that is only detected in ME/CFS patients and not in controls. Our findings provide evidence of tissue-specific active HHV-6 and EBV infection in ME/CFS, which along with recent work demonstrating a possible relationship between herpesvirus infection and ME/CFS, provide grounds for renewed discussion on the role of herpesviruses in ME/CFS. KW - HHV-6 KW - ME/CFS KW - EBV KW - epstein-barr virus KW - herpesvirus KW - viral pathology Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-299433 SN - 2296-889X VL - 9 ER - TY - THES A1 - Uehlein, Sabrina T1 - Expression und Funktion von CD28 im Schwein T1 - Expression and function of CD28 in pigs N2 - Trotz zahlreicher Fortschritte im Verständnis der Funktionsweise des kostimulatorischen Rezeptors CD28 in Mensch, Maus, Ratte und Makake ist nach wie vor wenig hierüber in Bezug auf das Tiermodell Schwein bekannt. Die vorliegende Arbeit untersucht die Funktion und Expression von CD28 in Schweine-T-Zellen sowie die Regulierbarkeit der T-Zellaktivierung durch anti-pCD28 mAb. Die Ergebnisse zeigen, dass hierbei vor allem CD4+ und CD8+ T-Zellen differenziert betrachtet werden müssen. Grundsätzlich unterscheiden sich die beiden T-Zellpopulationen in der CD28 mRNA Expression, im Expressionsverhältnis zwischen CD28 mRNA und Protein, sowie im proliferativen Ansprechen auf anti-pCD28mAb. So reagierten CD4+ im Vergleich zu CD8+ T-Zellen auf die kostimulatorische Inkubation mit anti-pCD28 mAb des Klons 3D11 sensibler. In direkt stimulatorischen Ansätzen zeigte sich, dass CD4+ und CD8+ T-Zellen durch unterschiedliche anti-pCD28 mAb differentiell angesprochen werden können. Eine superagonistische Funktion konnte für CD4+ T-Zell aktivierende anti-pCD28 mAb in den bisherigen Versuchen noch nicht beobachtet werden. Letzteres ist hierbei vor allem für den Transfer von vielversprechenden Therapiestrategien vom Kleintier- zum Großtiermodell auf dem Weg zur Entwicklung neuer Therapieoptionen für Autoimmunerkrankungen, Erkrankungen mit starker proinflammatorischer Aktivität und dem Myokardinfarkt von Bedeutung. N2 - Even though tremendous progress has been made in clarifying the function of the costimulatory receptor CD28 in human, mouse, rat, and macaques, concerning pigs, an important large animal model, only little is still known about CD28 expression and function. Therefore, our work aimed at investigating the function and expression of CD28 in porcine T cells as well as the applicability of anti-pCD28 mAb as a tool to regulate T cell activation, specifically. Our results indicate that the two major T cell groups, CD4+ and CD8+, have to be considered separately. These cell populations differ in their level of pCD28 mRNA expression, their ratio of CD28 mRNA and protein expression as well as their proliferative responsiveness towards anti-pCD28 mAb. In costimulatory assays, CD4+ compared to CD8+ T cells showed higher sensitivity toward low concentrations of the anti-pCD28 mAb 3D11. Additionally, in direct stimulatory assays, CD4+ and CD8+ T cells can be specifically targeted by different anti-pCD28 mAb. With these assays, a superagonistic anti-pCD28 mAb could not been detected so far. With anti-pCD28 superagonist, promising therapeutic strategies developed in rodents could be tested in pigs as a large animal model, representing the next step on the way towards new therapeutic options for autoim-mune diseases, diseases with strong proinflammatory activity and myocardial infarction. KW - Antigen CD28 KW - Regulatorischer T-Lymphozyt KW - Monoklonaler Antikörper KW - T-Lymphozyt KW - Antigen CD3 KW - Kostimulation KW - CD4 T-Zellen KW - CD8 T-Zellen KW - Dynabeads KW - superagonistische Funktion Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-245512 ER - TY - THES A1 - Chithelen, Janice T1 - Targeting viral and host factors to optimize anti-measles virus therapy T1 - Zielgerichtete Hemmung von Virus- und Wirtsfaktoren zur Optimierung der Anti-Masern-Virus-Therapie N2 - Measles is an ancient disease with historical records as early as the 9th century. Extensive study as well as advances in scientific knowledge of virology have led to identification of the viral pathogen and subsequent development of an effective vaccine leading to global efforts towards measles elimination. In 2018, around 140,000 deaths were reported due to measles with incomplete vaccine coverage being one of the leading causes of resurgence. Measles is highly contagious and often regarded as a childhood illness. However, measles is associated with a number of complications and persistent infections like subacute sclerosing panencephalitis (SSPE), which have brought into focus the need for specific anti-viral therapies. The aim of this study was to target host and viral factors to optimize anti-measles virus therapy. Our approach was to test a panel of compounds known to inhibit host cell functions or viral factors for their antiviral effect on measles replication. Primary human lymphocytes, persistently infected NT2 cells and post-mitotic neurons were used as in vitro model systems of acute, persistent and neuronal infection respectively to test the inhibitors. Using the inhibitors Ceranib-2 and SKI-II to target the sphingolipid metabolism enzymes acid ceramidase and sphingosine kinase in infected human primary lymphocytes, we observed a decreased protein translational capacity mediated by mTORC1, EIF4E and ribosomal protein S6 phosphorylation that probably contributes to the antiviral effect. In the persistently infected neural NT2 cells and post-mitotic neurons derived from LUHMES cells, we observed effective infection inhibition and viral clearance upon treatment with a small non-nucleoside inhibitor (ERDRP-0519) specifically targeting the Morbillivirus large polymerase. Other inhibitors such as Ribavirin and Favipiravir were less effective. To conclude, 1) we identified a mTOR associated protein translation axis associated with the sphingolipid metabolism, which affects measles virus replication and 2) In vitro persistently infected neuronal and post-mitotic neuron models were successfully used as a rapid method to test antivirals against measles virus. N2 - Masern sind eine uralte Krankheit, die bereits im 9. Jahrhundert historisch belegt ist. Umfangreiche Studien und Fortschritte in der Virologie haben die Identifizierung des viralen Erregers und anschließende Entwicklung eines wirksamen Impfstoffs ermöglicht, was zu weltweiten Bemühungen um die Eliminierung der Masern geführt hat. Im Jahr 2018 wurden rund 140.000 Todesfälle aufgrund von Masern gemeldet, wobei die unvollständige Durchimpfungsrate eine der Hauptursachen für das Wiederauftreten der Krankheit ist. Masern sind hoch ansteckend und werden oft als Kinderkrankheit betrachtet. Die Erkrankung ist jedoch assoziiert mit einer Reihe Komplikationen und persistierenden Infektionen wie die subakute sklerosierende Panenzephalitis (SSPE), was den Bedarf nach spezifischen antiviralen Therapien in den Focus gebracht hat. Ziel dieser Studie war es, zelluläre und virale Faktoren ins Visier zu nehmen, um die Therapie gegen das Masernvirus zu optimieren. Unser Ansatz bestand darin, eine Reihe von Substanzen, die bekanntermaßen Wirtsfunktionen oder virale Faktoren hemmen, auf ihre antivirale Wirkung auf die Masernreplikation zu testen. Primäre menschliche Lymphozyten, persistierend infizierte NT2-Zellen und post-mitotische Neuronen wurden als in-vitro-Modellsysteme für akute, persistierende und neuronale Infektionen verwendet, um die Inhibitoren zu testen. Durch den Einsatz der Inhibitoren Ceranib-2 und SKI-II, die auf die Enzyme saure Ceramidase und Sphingosinkinase des Sphingolipid-Stoffwechsels abzielen, konnten wir in infizierten menschlichen primären Lymphozyten eine verringerte Protein-Translationskapazität vermittelt durch mTORC1, EIF4E und ribosomales Protein S6-Phosphorylierung beobachten, die wahrscheinlich zur antiviralen Wirkung beiträgt. In den persistierend infizierten neuronalen NT2-Zellen und aus LUHMES-Zellen differenzierten post-mitotischen Neuronen beobachteten wir eine effektive Elimination des Virus oder Infektionshemmung bei Behandlung mit einem nicht-nukleosidischen Inhibitor (ERDRP-0519), der spezifisch auf die Polymerase des Morbillivirus abzielt. Andere Inhibitoren wie Ribavirin und Favipiravir waren weniger effektiv. Zusammenfassend lässt sich sagen, dass wir 1) wir eine mTOR-assoziierte Protein-Translationsachse identifiziert haben, die mit dem Sphingolipid-Stoffwechsel in Verbindung steht und die Masernvirus-Replikation beeinflusst, und 2) In-vitro-Modelle für persistierend infizierte neuronale und post-mitotische Neuronen erfolgreich als schnelle Methode zum Testen von Virostatika gegen Masernvirus angewandt haben. KW - measles virus KW - sphingolipid Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-293059 ER - TY - JOUR A1 - Cyran, Laura A1 - Serfling, Julia A1 - Kirschner, Luisa A1 - Raifer, Hartmann A1 - Lohoff, Michael A1 - Hermanns, Heike M. A1 - Kerstan, Andreas A1 - Bodem, Jochen A1 - Lutz, Manfred B. T1 - Flt3L, LIF, and IL‐10 combination promotes the selective in vitro development of ESAM\(^{low}\) cDC2B from murine bone marrow JF - European Journal of Immunology N2 - The development of two conventional dendritic cells (DC) subsets (cDC1 and cDC2) and the plasmacytoid DC (pDC) in vivo and in cultures of bone marrow (BM) cells is mediated by the growth factor Flt3L. However, little is known about the factors that direct the development of the individual DC subsets. Here, we describe the selective in vitro generation of murine ESAM\(^{low}\) CD103\(^{-}\) XCR1\(^{-}\) CD172a\(^{+}\) CD11b\(^{+}\) cDC2 from BM by treatment with a combination of Flt3L, LIF, and IL‐10 (collectively named as FL10). FL10 promotes common dendritic cell progenitors (CDP) proliferation in the cultures, similar to Flt3L and CDP sorted and cultured in FL10 generate exclusively cDC2. These cDC2 express the transcription factors Irf4, Klf4, and Notch2, and their growth is reduced using BM from Irf4\(^{-/-}\) mice, but the expression of Batf3 and Tcf4 is low. Functionally they respond to TLR3, TLR4, and TLR9 signals by upregulation of the surface maturation markers MHC II, CD80, CD86, and CD40, while they poorly secrete proinflammatory cytokines. Peptide presentation to TCR transgenic OT‐II cells induced proliferation and IFN‐γ production that was similar to GM‐CSF‐generated BM‐DC and higher than Flt3L‐generated DC. Together, our data support that FL10 culture of BM cells selectively promotes CDP‐derived ESAM\(^{low}\) cDC2 (cDC2B) development and survival in vitro. KW - dendritic cells KW - cDC2 subset KW - Flt3L KW - LIF KW - IL‐10 Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-312448 VL - 52 IS - 12 SP - 1946 EP - 1960 ER - TY - THES A1 - Wiese, Teresa T1 - Pharmacological targeting of acid sphingomyelinase increases CD4\(^+\) Foxp3\(^+\) regulatory T cell subsets in patients with major depression T1 - Pharmakologische Hemmung der sauren Sphingomyelinase verstärkt CD4\(^+\) Foxp3\(^+\) regulatorische T-Zell-Subpopulationen bei Patienten mit Depression N2 - Lack of acid sphingomyelinase (ASM) activity, either through genetic deficiency or through pharmacological inhibition, is linked with increased activity and frequency of Foxp3+ regulatory T cells (Treg) among cluster of differentiation (CD) 4+ T cells in mice in vivo and in vitro1. Thus, pharmacological blockade of ASM activity, which catalyzes the cleavage of sphingomyelin to ceramide and phosphocholine, might be used as a new therapeutic mechanism to correct numeric and/ or functional Treg de-ficiencies in diseases like multiple sclerosis or major depression. In the present study, the effect of pharmacological inhibition of ASM in humans, in vitro and in vivo, was analyzed. In the in vitro experiments, peripheral blood mono-nuclear cells (PBMC) of healthy human blood donors were treated with two widely prescribed antidepressants with high (sertraline, Ser) or low (citalopram, Cit) capaci-ty to inhibit ASM activity. Similar to the findings in mice an increase in the frequency of Treg among human CD4+ T cells upon inhibition of ASM activity was observed. For the analysis in vivo, a prospective study of the composition of the CD4+ T cell com-partment of patients treated for major depression was done. The data show that pharmacological inhibition of ASM activity was superior to antidepressants with little or no ASM-inhibitory activity in increasing CD45RA- CD25high effector Treg (efTreg) frequencies among CD4+ T cells to normal levels. Independently of ASM inhibition, correlating the data with the clinical response, i.e. improvement of the Hamilton rat-ing scale for depression (HAMD) by at least 50 per cent (%) after four weeks of treatment, it was found that an increase in efTreg frequencies among CD4+ cells dur-ing the first week of treatment identified patients with a clinical response. Regarding the underlying mechanism, it could be found that the positive effect of ASM inhibition on Treg required CD28 co-stimulation suggesting that enhanced CD28 co-stimulation was the driver of the observed increase in the frequency of Treg among human CD4+ T cells. Inhibition of ASM activity was further associated with changes in the expression and shuttling of CTLA-4, a key inhibitory molecule ex-pressed by Treg, between cellular compartments but the suppressive activity of CTLA-4 through its transendocytosis activity was unaffected by the inhibition of ASM activity. In summary, the frequency of (effector) Treg among CD4+ T cells in mice and in hu-mans is increased after inhibition of ASM activity suggesting that ASM blockade might beneficially modulate autoimmune diseases and depression-promoting in-flammation. N2 - Ein Mangel an Aktivität der sauren Sphingomyelinase (ASM), entweder durch ge-netisches Defizit oder durch pharmakologische Hemmung, ist mit einer erhöhten Aktivität und Häufigkeit von Foxp3+ regulatorischen T-Zellen (Treg) innerhalb der CD4+ (cluster of differentation 4) T-Zellen in Mäusen in vivo und in vitro verbun-den1. Daher könnte die pharmakologische Blockade der ASM-Aktivität, die die Spaltung von Sphingomyelin in Ceramid und Phosphocholin katalysiert, als neuer therapeutischer Mechanismus zur Korrektur von numerischen und/oder funktionel-len Treg-Defiziten bei Erkrankungen wie Multipler Sklerose oder schwerer Depres-sion eingesetzt werden. In der vorliegenden Studie wurde die Wirkung der pharmakologischen Hemmung von ASM beim Menschen, in vitro und in vivo analysiert. In den In-vitro-Experimenten wurden die peripheren mononukleären Blutzellen (PBMC) gesunder menschlicher Blutspender mit zwei weithin verschriebenen Antidepressiva mit ho-her (Sertralin, Ser) oder niedriger (Citalopram, Cit) Fähigkeit zur Hemmung der ASM-Aktivität untersucht. Ähnlich wie bei Mäusen wurde bei Hemmung der ASM-Aktivität ein Anstieg der Häufigkeit von Treg innerhalb der menschlichen CD4+ T-Zellen festgestellt. Für die Analyse in vivo wurde eine prospektive Studie über die Zusammensetzung des CD4+ T-Zellkomplexes bei Patienten, die wegen einer De-pression im Krankenhaus behandelt wurden, durchgeführt. Die Daten zeigen, dass die pharmakologische Hemmung der ASM-Aktivität Antidepressiva mit ge-ringer oder keiner ASM-hemmenden Aktivität überlegen war, was die Vermehrung der CD45RA- CD25hoch-Effektor-Treg (efTreg)-Frequenzen innerhalb der CD4+ T-Zellen betraf. Unabhängig von der Untersuchung zur ASM-Aktivität beobachteten wir, dass die klinische Reaktion (d.h. der Verbesserung der Hamilton-Bewertungsskala für Depressionen (HAMD) um mindestens 50 Prozent (%) nach vierwöchiger Behandlung) mit einem frühen Anstieg der efTreg-Frequenzen unter CD4+-Zellen während der ersten Behandlungswoche positiv korrelierte. Hinsichtlich des zugrunde liegenden Mechanismus konnte festgestellt werden, dass die positive Wirkung der ASM-Hemmung auf Treg eine CD28-Kostimulation erforderte, was darauf hindeutet, dass eine verstärkte CD28-Kostimulation die Ur-sache für den beobachteten Anstieg der Frequenz von Treg innerhalb menschli-cher CD4+ T-Zellen war. Die Hemmung der ASM-Aktivität war darüber hinaus mit Veränderungen in der Expression und im zellulären Umsatz von CTLA-4, einem von Treg exprimierten inhibitorischen Schlüsselmolekül, verbunden. Die suppressi-ve Aktivität von CTLA-4 durch seine Transendozytose-Aktivität wurde jedoch durch die Hemmung der ASM-Aktivität nicht beeinflusst. Zusammenfassend lässt sich sagen, dass die Häufigkeit von (Effektor-)Treg unter-halb der CD4+ T-Zellen in Mäusen und beim Menschen nach Hemmung der ASM-Aktivität erhöht ist, was darauf hindeutet, dass eine ASM-Blockade Autoimmuner-krankungen und depressionsfördernde Entzündungen vorteilhaft modulieren könn-te. KW - Treg KW - CD28 KW - ASM KW - CTLA-4 KW - Major depression KW - Ceramid Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-233471 ER - TY - JOUR A1 - Lodha, Manivel A1 - Erhard, Florian A1 - Dölken, Lars A1 - Prusty, Bhupesh K. T1 - The hidden enemy within: non-canonical peptides in virus-induced autoimmunity JF - Frontiers in Microbiology N2 - Viruses play a key role in explaining the pathogenesis of various autoimmune disorders, whose underlying principle is defined by the activation of autoreactive T-cells. In many cases, T-cells escape self-tolerance due to the failure in encountering certain MHC-I self-peptide complexes at substantial levels, whose peptides remain invisible from the immune system. Over the years, contribution of unstable defective ribosomal products (DRiPs) in immunosurveillance has gained prominence. A class of unstable products emerge from non-canonical translation and processing of unannotated mammalian and viral ORFs and their peptides are cryptic in nature. Indeed, high throughput sequencing and proteomics have revealed that a substantial portion of our genomes comprise of non-canonical ORFs, whose generation is significantly modulated during disease. Many of these ORFs comprise short ORFs (sORFs) and upstream ORFs (uORFs) that resemble DRiPs and may hence be preferentially presented. Here, we discuss how such products, normally “hidden” from the immune system, become abundant in viral infections activating autoimmune T-cells, by discussing their emerging role in infection and disease. Finally, we provide a perspective on how these mechanisms can explain several autoimmune disorders in the wake of the COVID-19 pandemic. KW - viruses KW - cryptic peptides KW - autoimmunity KW - defective ribosomal products KW - non-canonical translation KW - COVID-19 Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-263053 SN - 1664-302X VL - 13 ER - TY - JOUR A1 - Dahlhoff, Julia A1 - Manz, Hannah A1 - Steinfatt, Tim A1 - Delgado-Tascon, Julia A1 - Seebacher, Elena A1 - Schneider, Theresa A1 - Wilnit, Amy A1 - Mokhtari, Zeinab A1 - Tabares, Paula A1 - Böckle, David A1 - Rasche, Leo A1 - Martin Kortüm, K. A1 - Lutz, Manfred B. A1 - Einsele, Hermann A1 - Brandl, Andreas A1 - Beilhack, Andreas T1 - Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression JF - Leukemia N2 - Multiple myeloma remains a largely incurable disease of clonally expanding malignant plasma cells. The bone marrow microenvironment harbors treatment-resistant myeloma cells, which eventually lead to disease relapse in patients. In the bone marrow, CD4\(^{+}\)FoxP3\(^{+}\) regulatory T cells (Tregs) are highly abundant amongst CD4\(^{+}\) T cells providing an immune protective niche for different long-living cell populations, e.g., hematopoietic stem cells. Here, we addressed the functional role of Tregs in multiple myeloma dissemination to bone marrow compartments and disease progression. To investigate the immune regulation of multiple myeloma, we utilized syngeneic immunocompetent murine multiple myeloma models in two different genetic backgrounds. Analyzing the spatial immune architecture of multiple myeloma revealed that the bone marrow Tregs accumulated in the vicinity of malignant plasma cells and displayed an activated phenotype. In vivo Treg depletion prevented multiple myeloma dissemination in both models. Importantly, short-term in vivo depletion of Tregs in mice with established multiple myeloma evoked a potent CD8 T cell- and NK cell-mediated immune response resulting in complete and stable remission. Conclusively, this preclinical in-vivo study suggests that Tregs are an attractive target for the treatment of multiple myeloma. KW - Multiple myeloma KW - transient regulatory T-cell targeting KW - immune control Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-271787 SN - 1476-5551 VL - 36 IS - 3 ER - TY - JOUR A1 - Prada, Juan Pablo A1 - Maag, Luca Estelle A1 - Siegmund, Laura A1 - Bencurova, Elena A1 - Liang, Chunguang A1 - Koutsilieri, Eleni A1 - Dandekar, Thomas A1 - Scheller, Carsten T1 - Estimation of R0 for the spread of SARS-CoV-2 in Germany from excess mortality JF - Scientific Reports N2 - For SARS-CoV-2, R0 calculations in the range of 2–3 dominate the literature, but much higher estimates have also been published. Because capacity for RT-PCR testing increased greatly in the early phase of the Covid-19 pandemic, R0 determinations based on these incidence values are subject to strong bias. We propose to use Covid-19-induced excess mortality to determine R0 regardless of RT-PCR testing capacity. We used data from the Robert Koch Institute (RKI) on the incidence of Covid cases, Covid-related deaths, number of RT-PCR tests performed, and excess mortality calculated from data from the Federal Statistical Office in Germany. We determined R0 using exponential growth estimates with a serial interval of 4.7 days. We used only datasets that were not yet under the influence of policy measures (e.g., lockdowns or school closures). The uncorrected R0 value for the spread of SARS-CoV-2 based on RT-PCR incidence data was 2.56 (95% CI 2.52–2.60) for Covid-19 cases and 2.03 (95% CI 1.96–2.10) for Covid-19-related deaths. However, because the number of RT-PCR tests increased by a growth factor of 1.381 during the same period, these R0 values must be corrected accordingly (R0corrected = R0uncorrected/1.381), yielding 1.86 for Covid-19 cases and 1.47 for Covid-19 deaths. The R0 value based on excess deaths was calculated to be 1.34 (95% CI 1.32–1.37). A sine-function-based adjustment for seasonal effects of 40% corresponds to a maximum value of R0January = 1.68 and a minimum value of R0July = 1.01. Our calculations show an R0 that is much lower than previously thought. This relatively low range of R0 fits very well with the observed seasonal pattern of infection across Europe in 2020 and 2021, including the emergence of more contagious escape variants such as delta or omicron. In general, our study shows that excess mortality can be used as a reliable surrogate to determine the R0 in pandemic situations. KW - SARS-CoV-2 KW - R0 KW - mortality Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-301415 VL - 12 IS - 1 ER - TY - THES A1 - Haas, Tobias Eberhard T1 - Analyse der RNA-Landschaft und Chromatinorganisation in lytischer HSV-1 Infektion und Stress T1 - Analysis of RNA landscape and chromatin organization in lytic HSV-1 infection and stress N2 - Zellstress in Form von lytischer Herpes-simplex-Virustyp-1-Infektion, Hitze und Salzstress führt dazu, dass die RNA-Polymerase II über das 3'-Ende von manchen Genen hinaus transkribiert. Dies geht bei Herpes-simplex-Virustyp-1-Infektion teilweise mit offenem Chromatin nach dem 3'-Ende einher. In dieser Arbeit wurden verschiedene Methoden getestet, um diese Effekte genomweit zu eruieren. Dabei wurden die Peak-Caller ATAC-seq-Pipeline, F-Seq, Hotspots und MACS2 getestet sowie mit der Hilfsgröße „downstream Open Chromatin Regions“ gearbeitet. Weiterhin wurde das R-Skript „Pipeline for ATAC-seq and 4sU-seq plotting“ entwickelt, mit dem sich die Dynamik der oben beschriebenen Effekte zeigen lässt: Die Offenheit des Chromatins ist bei Herpesinfektion zusätzlich zur Erhöhung nach dem 3'-Ende generell erhöht. Die Transkription der RNA-Polymerase II über das 3'-Ende hingegen nimmt nach 75k Basenpaaren rapide ab. Die Ergebnisse des R-Skripts im Bezug auf Salz und Hitzestress decken sich mit vorbeschriebener Literatur, in der gezeigt wurde, dass eine Erhöhung der Offenheit des Chromatins nach dem 3'-Ende nicht stattfindet. N2 - Cell stress in the form of lytic herpes simplex virus type 1 infection, heat, and salt stress causes RNA polymerase II to transcribe beyond the 3' end of some genes. This is sometimes associated with open chromatin beyond the 3' end in herpes simplex virus type 1 infection. In this work, several methods were tested to elicit these effects genome-wide. The peak caller ATAC-seq-Pipeline, F-Seq, hotspots, and MACS2 were tested, and the auxiliary variable "downstream open chromatin regions" was used. Furthermore, the R script "Pipeline for ATAC-seq and 4sU-seq plotting" was developed to show the dynamics of the effects described above: Chromatin openness is generally increased in herpes infection in addition to being increased after the 3' end. In contrast, RNA polymerase II transcription across the 3' end decreases rapidly after 75k base pairs. The results of the R-script in relation to salt and heat stress are consistent with pre-described literature showing that an increase in chromatin openness after the 3' end does not occur. KW - Herpes-simplex-Virus KW - Salzstress KW - Hitzestress KW - Chromatin KW - Peak Caller Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-283028 ER - TY - JOUR A1 - Sivarajan, Rinu A1 - Oberwinkler, Heike A1 - Roll, Valeria A1 - König, Eva-Maria A1 - Steinke, Maria A1 - Bodem, Jochen T1 - A defined anthocyanin mixture sourced from bilberry and black currant inhibits Measles virus and various herpesviruses JF - BMC Complementary Medicine and Therapies N2 - Background Anthocyanin-containing plant extracts and carotenoids, such as astaxanthin, have been well-known for their antiviral and anti-inflammatory activity, respectively. We hypothesised that a mixture of Ribes nigrum L. (Grossulariaceae) (common name black currant (BC)) and Vaccinium myrtillus L. (Ericaceae) (common name bilberry (BL)) extracts (BC/BL) with standardised anthocyanin content as well as single plant extracts interfered with the replication of Measles virus and Herpesviruses in vitro. Methods We treated cell cultures with BC/BL or defined single plant extracts, purified anthocyanins and astaxanthin in different concentrations and subsequently infected the cultures with the Measles virus (wild-type or vaccine strain Edmonston), Herpesvirus 1 or 8, or murine Cytomegalovirus. Then, we analysed the number of infected cells and viral infectivity and compared the data to non-treated controls. Results The BC/BL extract inhibited wild-type Measles virus replication, syncytia formation and cell-to-cell spread. This suppression was dependent on the wild-type virus-receptor-interaction since the Measles vaccine strain was unaffected by BC/BL treatment. Furthermore, the evidence was provided that the delphinidin-3-rutinoside chloride, a component of BC/BL, and purified astaxanthin, were effective anti-Measles virus compounds. Human Herpesvirus 1 and murine Cytomegalovirus replication was inhibited by BC/BL, single bilberry or black currant extracts, and the BC/BL component delphinidin-3-glucoside chloride. Additionally, we observed that BC/BL seemed to act synergistically with aciclovir. Moreover, BC/BL, the single bilberry and black currant extracts, and the BC/BL components delphinidin-3-glucoside chloride, cyanidin-3-glucoside, delphinidin-3-rutinoside chloride, and petunidin-3-galactoside inhibited human Herpesvirus 8 replication. Conclusions Our data indicate that Measles viruses and Herpesviruses are differentially susceptible to a specific BC/BL mixture, single plant extracts, purified anthocyanins and astaxanthin. These compounds might be used in the prevention of viral diseases and in addition to direct-acting antivirals, such as aciclovir. KW - anthocyanin KW - astaxanthin KW - bilberry KW - black currant KW - herpesvirus KW - measels virus Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-301423 VL - 22 ER - TY - JOUR A1 - Karikari, Akua A. A1 - McFleder, Rhonda L. A1 - Ribechini, Eliana A1 - Blum, Robert A1 - Bruttel, Valentin A1 - Knorr, Susanne A1 - Gehmeyr, Mona A1 - Volkmann, Jens A1 - Brotchie, Jonathan M. A1 - Ahsan, Fadhil A1 - Haack, Beatrice A1 - Monoranu, Camelia-Maria A1 - Keber, Ursula A1 - Yeghiazaryan, Rima A1 - Pagenstecher, Axel A1 - Heckel, Tobias A1 - Bischler, Thorsten A1 - Wischhusen, Jörg A1 - Koprich, James B. A1 - Lutz, Manfred B. A1 - Ip, Chi Wang T1 - Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson’s disease mice JF - Brain, Behavior, and Immunity N2 - Background Antigen-specific neuroinflammation and neurodegeneration are characteristic for neuroimmunological diseases. In Parkinson’s disease (PD) pathogenesis, α-synuclein is a known culprit. Evidence for α-synuclein-specific T cell responses was recently obtained in PD. Still, a causative link between these α-synuclein responses and dopaminergic neurodegeneration had been lacking. We thus addressed the functional relevance of α-synuclein-specific immune responses in PD in a mouse model. Methods We utilized a mouse model of PD in which an Adeno-associated Vector 1/2 serotype (AAV1/2) expressing human mutated A53T-α-Synuclein was stereotactically injected into the substantia nigra (SN) of either wildtype C57BL/6 or Recombination-activating gene 1 (RAG1)\(^{-/-}\) mice. Brain, spleen, and lymph node tissues from different time points following injection were then analyzed via FACS, cytokine bead assay, immunohistochemistry and RNA-sequencing to determine the role of T cells and inflammation in this model. Bone marrow transfer from either CD4\(^{+}\)/CD8\(^{-}\), CD4\(^{-}\)/CD8\(^{+}\), or CD4\(^{+}\)/CD8\(^{+}\) (JHD\(^{-/-}\)) mice into the RAG-1\(^{-/-}\) mice was also employed. In addition to the in vivo studies, a newly developed A53T-α-synuclein-expressing neuronal cell culture/immune cell assay was utilized. Results AAV-based overexpression of pathogenic human A53T-α-synuclein in dopaminergic neurons of the SN stimulated T cell infiltration. RNA-sequencing of immune cells from PD mouse brains confirmed a pro-inflammatory gene profile. T cell responses were directed against A53T-α-synuclein-peptides in the vicinity of position 53 (68–78) and surrounding the pathogenically relevant S129 (120–134). T cells were required for α-synuclein-induced neurodegeneration in vivo and in vitro, while B cell deficiency did not protect from dopaminergic neurodegeneration. Conclusions Using T cell and/or B cell deficient mice and a newly developed A53T-α-synuclein-expressing neuronal cell culture/immune cell assay, we confirmed in vivo and in vitro that pathogenic α-synuclein peptide-specific T cell responses can cause dopaminergic neurodegeneration and thereby contribute to PD-like pathology. KW - Parkinson’s disease KW - α-synuclein-specific T cells KW - neurodegeneration Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-300600 VL - 101 SP - 194 EP - 210 ER - TY - JOUR A1 - Chithelen, Janice A1 - Franke, Hannah A1 - Länder, Nora A1 - Grafen, Anika A1 - Schneider-Schaulies, Jürgen T1 - The sphingolipid inhibitors ceranib-2 and SKI-II reduce measles virus replication in primary human lymphocytes: effects on mTORC1 downstream signaling JF - Frontiers in Physiology N2 - The bioactive sphingolipids ceramide and sphingosine-1-phosphate (S1P) are involved in the regulation of cell homeostasis and activity ranging from apoptosis to proliferation. We recently described that the two compounds ceranib-2 (inhibiting acid ceramidase) and SKI-II [inhibiting the sphingosine kinases 1 and − 2 (SphK1/2)] reduce mTORC1 activity and measles virus (MV) replication in human primary peripheral blood lymphocytes (PBL) by about one log step. We now further investigated whether mTORC1 downstream signaling and viral protein expression may be affected by ceranib-2 and/or SKI-II. Western blot analyses showed that in uninfected cells the phosphorylation of the eukaryotic initiation factor 4E (eIF4E) was reduced by both inhibitors. Interestingly, MV infection led to an increase of rpS6 protein levels and phosphorylation of eIF4E. Treatment with both inhibitors reduced the rpS6 protein expression, and in addition, SKI-II reduced rpS6 phosphorylation. The phosphorylation of eIF4E was slightly reduced by both inhibitors. In addition, SKI-II led to reduced levels of IKK in MV-infected cells. Both inhibitors reduced the expression of viral proteins and the titers of newly synthesized MV by approximately one log step. As expected, SKI-II and rapamycin reduced also the virally encoded GFP expression; however, ceranib-2 astonishingly led to increased levels of GFP fluorescence. Our findings suggest that the inhibitors ceranib-2 and SKI-II act via differential mechanisms on MV replication. The observed effects on mTORC1 downstream signaling, predominantly the reduction of rpS6 levels by both inhibitors, may affect the translational capacity of the cells and contribute to the antiviral effect in human primary PBL. KW - acid ceramidase inhibitor ceranib-2 KW - sphingosine kinase inhibitor SKI-II KW - mTORC1 KW - translation KW - measles virus Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-265988 SN - 1664-042X VL - 13 ER - TY - JOUR A1 - Herrmann, Thomas A1 - Karunakaran, Mohindar M. T1 - Butyrophilins: γδ T cell receptor ligands, immunomodulators and more JF - Frontiers in Immunology N2 - Butyrophilins (BTN) are relatives of the B7 family (e.g., CD80, PD-L1). They fulfill a wide range of functions including immunomodulation and bind to various receptors such as the γδ T cell receptor (γδTCR) and small molecules. One intensively studied molecule is BTN3A1, which binds via its cytoplasmic B30.2 domain, metabolites of isoprenoid synthesis, designated as phosphoantigen (PAg), The enrichment of PAgs in tumors or infected cells is sensed by Vγ9Vδ2 T cells, leading to the proliferation and execution of effector functions to remove these cells. This article discusses the contribution of BTNs, the related BTNL molecules and SKINT1 to the development, activation, and homeostasis of γδ T cells and their immunomodulatory potential, which makes them interesting targets for therapeutic intervention. KW - butyrophilin KW - immune therapy KW - T cell receptor KW - γδ T cell KW - BTN3A1 KW - BTN2A1 KW - phosphoantigen KW - tumor Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-265944 SN - 1664-3224 VL - 13 ER - TY - JOUR A1 - Vogel, Patrick A1 - Rückert, Martin Andreas A1 - Friedrich, Bernhard A1 - Tietze, Rainer A1 - Lyer, Stefan A1 - Kampf, Thomas A1 - Hennig, Thomas A1 - Dölken, Lars A1 - Alexiou, Christoph A1 - Behr, Volker Christian T1 - Critical Offset Magnetic PArticle SpectroScopy for rapid and highly sensitive medical point-of-care diagnostics JF - Nature Communications N2 - Magnetic nanoparticles (MNPs) have been adapted for many applications, e.g., bioassays for the detection of biomarkers such as antibodies, by controlled engineering of specific surface properties. Specific measurement of such binding states is of high interest but currently limited to highly sensitive techniques such as ELISA or flow cytometry, which are relatively inflexible, difficult to handle, expensive and time-consuming. Here we report a method named COMPASS (Critical-Offset-Magnetic-Particle-SpectroScopy), which is based on a critical offset magnetic field, enabling sensitive detection to minimal changes in mobility of MNP ensembles, e.g., resulting from SARS-CoV-2 antibodies binding to the S antigen on the surface of functionalized MNPs. With a sensitivity of 0.33 fmole/50 µl (≙7 pM) for SARS-CoV-2-S1 antibodies, measured with a low-cost portable COMPASS device, the proposed technique is competitive with respect to sensitivity while providing flexibility, robustness, and a measurement time of seconds per sample. In addition, initial results with blood serum demonstrate high specificity. KW - biochemical assays KW - characterization and analytical techniques KW - magnetic properties and materials KW - nanoparticles Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-300893 VL - 13 ER - TY - JOUR A1 - Geiger, Nina A1 - König, Eva-Maria A1 - Oberwinkler, Heike A1 - Roll, Valeria A1 - Diesendorf, Viktoria A1 - Fähr, Sofie A1 - Obernolte, Helena A1 - Sewald, Katherina A1 - Wronski, Sabine A1 - Steinke, Maria A1 - Bodem, Jochen T1 - Acetylsalicylic acid and salicylic acid inhibit SARS-CoV-2 replication in precision-cut lung slices JF - Vaccines N2 - Aspirin, with its active compound acetylsalicylic acid (ASA), shows antiviral activity against rhino- and influenza viruses at high concentrations. We sought to investigate whether ASA and its metabolite salicylic acid (SA) inhibit SARS-CoV-2 since it might use similar pathways to influenza viruses. The compound-treated cells were infected with SARS-CoV-2. Viral replication was analysed by RTqPCR. The compounds suppressed SARS-CoV-2 replication in cell culture cells and a patient-near replication system using human precision-cut lung slices by two orders of magnitude. While the compounds did not interfere with viral entry, it led to lower viral RNA expression after 24 h, indicating that post-entry pathways were inhibited by the compounds. KW - acetylsalicylic acid KW - salicylic acid KW - antiviral activity KW - aspirin KW - SARS-CoV-2 KW - precision-cut lung slices Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-289885 SN - 2076-393X VL - 10 IS - 10 ER - TY - JOUR A1 - Traub, Jan A1 - Grondey, Katja A1 - Gassenmaier, Tobias A1 - Schmitt, Dominik A1 - Fette, Georg A1 - Frantz, Stefan A1 - Boivin-Jahns, Valérie A1 - Jahns, Roland A1 - Störk, Stefan A1 - Stoll, Guido A1 - Reiter, Theresa A1 - Hofmann, Ulrich A1 - Weber, Martin S. A1 - Frey, Anna T1 - Sustained increase in serum glial fibrillary acidic protein after first ST-elevation myocardial infarction JF - International Journal of Molecular Sciences N2 - Acute ischemic cardiac injury predisposes one to cognitive impairment, dementia, and depression. Pathophysiologically, recent positron emission tomography data suggest astroglial activation after experimental myocardial infarction (MI). We analyzed peripheral surrogate markers of glial (and neuronal) damage serially within 12 months after the first ST-elevation MI (STEMI). Serum levels of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were quantified using ultra-sensitive molecular immunoassays. Sufficient biomaterial was available from 45 STEMI patients (aged 28 to 78 years, median 56 years, 11% female). The median (quartiles) of GFAP was 63.8 (47.0, 89.9) pg/mL and of NfL 10.6 (7.2, 14.8) pg/mL at study entry 0–4 days after STEMI. GFAP after STEMI increased in the first 3 months, with a median change of +7.8 (0.4, 19.4) pg/mL (p = 0.007). It remained elevated without further relevant increases after 6 months (+11.7 (0.6, 23.5) pg/mL; p = 0.015), and 12 months (+10.3 (1.5, 22.7) pg/mL; p = 0.010) compared to the baseline. Larger relative infarction size was associated with a higher increase in GFAP (ρ = 0.41; p = 0.009). In contrast, NfL remained unaltered in the course of one year. Our findings support the idea of central nervous system involvement after MI, with GFAP as a potential peripheral biomarker of chronic glial damage as one pathophysiologic pathway. KW - myocardial infarction KW - STEMI KW - glial fibrillary acidic protein KW - GFAP KW - neurofilament light chain KW - NfL KW - glial damage KW - cardiac magnetic resonance imaging KW - MRI KW - infarction size Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-288261 SN - 1422-0067 VL - 23 IS - 18 ER - TY - JOUR A1 - Eder, Sascha A1 - Hollmann, Claudia A1 - Mandasari, Putri A1 - Wittmann, Pia A1 - Schumacher, Fabian A1 - Kleuser, Burkhard A1 - Fink, Julian A1 - Seibel, Jürgen A1 - Schneider-Schaulies, Jürgen A1 - Stigloher, Christian A1 - Beyersdorf, Niklas A1 - Dembski, Sofia T1 - Synthesis and characterization of ceramide-containing liposomes as membrane models for different T cell subpopulations JF - Journal of Functional Biomaterials N2 - A fine balance of regulatory (T\(_{reg}\)) and conventional CD4\(^+\) T cells (T\(_{conv}\)) is required to prevent harmful immune responses, while at the same time ensuring the development of protective immunity against pathogens. As for many cellular processes, sphingolipid metabolism also crucially modulates the T\(_{reg}\)/T\(_{conv}\) balance. However, our understanding of how sphingolipid metabolism is involved in T cell biology is still evolving and a better characterization of the tools at hand is required to advance the field. Therefore, we established a reductionist liposomal membrane model system to imitate the plasma membrane of mouse T\(_{reg}\) and T\(_{conv}\) with regards to their ceramide content. We found that the capacity of membranes to incorporate externally added azide-functionalized ceramide positively correlated with the ceramide content of the liposomes. Moreover, we studied the impact of the different liposomal preparations on primary mouse splenocytes in vitro. The addition of liposomes to resting, but not activated, splenocytes maintained viability with liposomes containing high amounts of C\(_{16}\)-ceramide being most efficient. Our data thus suggest that differences in ceramide post-incorporation into T\(_{reg}\) and T\(_{conv}\) reflect differences in the ceramide content of cellular membranes. KW - liposome KW - ceramide KW - cell membrane model Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-286130 SN - 2079-4983 VL - 13 IS - 3 ER - TY - JOUR A1 - Geiger, Nina A1 - Kersting, Louise A1 - Schlegel, Jan A1 - Stelz, Linda A1 - Fähr, Sofie A1 - Diesendorf, Viktoria A1 - Roll, Valeria A1 - Sostmann, Marie A1 - König, Eva-Maria A1 - Reinhard, Sebastian A1 - Brenner, Daniela A1 - Schneider-Schaulies, Sibylle A1 - Sauer, Markus A1 - Seibel, Jürgen A1 - Bodem, Jochen T1 - The acid ceramidase is a SARS-CoV-2 host factor JF - Cells N2 - SARS-CoV-2 variants such as the delta or omicron variants, with higher transmission rates, accelerated the global COVID-19 pandemic. Thus, novel therapeutic strategies need to be deployed. The inhibition of acid sphingomyelinase (ASM), interfering with viral entry by fluoxetine was reported. Here, we described the acid ceramidase as an additional target of fluoxetine. To discover these effects, we synthesized an ASM-independent fluoxetine derivative, AKS466. High-resolution SARS-CoV-2–RNA FISH and RTqPCR analyses demonstrate that AKS466 down-regulates viral gene expression. It is shown that SARS-CoV-2 deacidifies the lysosomal pH using the ORF3 protein. However, treatment with AKS488 or fluoxetine lowers the lysosomal pH. Our biochemical results show that AKS466 localizes to the endo-lysosomal replication compartments of infected cells, and demonstrate the enrichment of the viral genomic, minus-stranded RNA and mRNAs there. Both fluoxetine and AKS466 inhibit the acid ceramidase activity, cause endo-lysosomal ceramide elevation, and interfere with viral replication. Furthermore, Ceranib-2, a specific acid ceramidase inhibitor, reduces SARS-CoV-2 replication and, most importantly, the exogenous supplementation of C6-ceramide interferes with viral replication. These results support the hypotheses that the acid ceramidase is a SARS-CoV-2 host factor. KW - SARS-CoV-2 KW - ceramides KW - ceramidase KW - fluoxetine KW - acid sphingomyelinase Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-286105 SN - 2073-4409 VL - 11 IS - 16 ER - TY - JOUR A1 - Gschmack, Eva A1 - Monoranu, Camelia-Maria A1 - Marouf, Hecham A1 - Meyer, Sarah A1 - Lessel, Lena A1 - Idris, Raja A1 - Berg, Daniela A1 - Maetzler, Walter A1 - Steigerwald, Frank A1 - Volkmann, Jens A1 - Gerlach, Manfred A1 - Riederer, Peter A1 - Koutsilieri, Eleni A1 - Scheller, Carsten T1 - Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson’s disease JF - Journal of Neural Transmission N2 - Idiopathic Parkinson’s disease (PD) is characterized by a progredient degeneration of the brain, starting at deep subcortical areas such as the dorsal motor nucleus of the glossopharyngeal and vagal nerves (DM) (stage 1), followed by the coeruleus–subcoeruleus complex; (stage 2), the substantia nigra (SN) (stage 3), the anteromedial temporal mesocortex (MC) (stage 4), high-order sensory association areas and prefrontal fields (HC) (stage 5) and finally first-order sensory association areas, premotor areas, as well as primary sensory and motor field (FC) (stage 6). Autoimmunity might play a role in PD pathogenesis. Here we analyzed whether anti-brain autoantibodies differentially recognize different human brain areas and identified autoantigens that correlate with the above-described dissemination of PD pathology in the brain. Brain tissue was obtained from deceased individuals with no history of neurological or psychiatric disease and no neuropathological abnormalities. Tissue homogenates from different brain regions (DM, SN, MC, HC, FC) were subjected to SDS-PAGE and Western blot. Blots were incubated with plasma samples from 30 PD patients and 30 control subjects and stained with anti-IgG antibodies to detect anti-brain autoantibodies. Signals were quantified. Prominent autoantigens were identified by 2D-gel-coupled mass spectrometry sequencing. Anti-brain autoantibodies are frequent and occur both in healthy controls and individuals with PD. Glial fibrillary acidic protein (GFAP) was identified as a prominent autoantigen recognized in all plasma samples. GFAP immunoreactivity was highest in DM areas and lowest in FC areas with no significant differences in anti-GFAP autoantibody titers between healthy controls and individuals with PD. The anti-GFAP autoimmunoreactivity of different brain areas correlates with the dissemination of histopathological neurodegeneration in PD. We hypothesize that GFAP autoantibodies are physiological but might be involved as a cofactor in PD pathogenesis secondary to a leakage of the blood–brain barrier. KW - Parkinson KW - GFAP KW - autoantibodies KW - Braak Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-325161 VL - 129 IS - 5-6 ER - TY - THES A1 - Adenugba, Akinbami Raphael T1 - Functional analysis of the gene organization of the pneumoviral attachment protein G T1 - Funktionelle Analyse der Genorganisation des pneumoviralen Attachment-Protein G N2 - The putative attachment protein G of pneumonia virus of mice (PVM), a member of the Pneumoviruses, is an important virulence factor with so far ambiguous function in a virus-cell as well as in virus-host context. The sequence of the corresponding G gene is characterized by significant heterogeneity between and even within strains, affecting the gene and possibly the protein structure. This accounts in particular for the PVM strain J3666 for which two differing G gene organizations have been described: a polymorphism in nucleotide 65 of the G gene results in the presence of an upstream open reading frame (uORF) that precedes the main ORF in frame (GJ366665A) or extension of the major G ORF for 18 codons (GJ366665U). Therefore, this study was designed to analyse the impact of the sequence variations in the respective G genes of PVM strains J3666 and the reference strain 15 on protein expression, replication and virulence. First, the controversy regarding the consensus sequence of PVM J3666 was resolved. The analysis of 45 distinct cloned fragments showed that the strain separated into two distinct virus populations defined by the sequence and structure of the G gene. This division was further supported by nucleotide polymorphisms in the neighbouring M and SH genes. Sequential passage of this mixed strain in the cell line standardly used for propagation of virus stocks resulted in selection for the GJ366665A-containing population in one of two experiments pointing towards a moderate replicative advantage. The replacement of the G gene of the recombinant PVM 15 with GJ366665A or GJ366665U, respectively, using a reverse genetic approach indicated that the presence of uORF within the GJ366665A significantly reduced the expression of the main G ORF on translational level while the potential extension of the ORF in GJ366665U increased G protein expression. In comparison, the effect of the G gene-structure on virus replication was inconsistent and dependent on cell line and type. While the presence of uORF correlated with a replication advantage in the standardly used BHK-21 cells and primary murine embryonic fibroblasts, replication in the murine macrophage cell line RAW 264.7 did not. In comparison, the GJ366665U variant was not associated with any effect on replication in cultured cells at all. Nonetheless, in-vivo analysis of the recombinant viruses associated the GJ366665U gene variant, and hence an increased G expression, with higher virulence whereas the GJ366665A gene, and therefore an impaired G expression, conferred an attenuated phenotype to the virus. To extend the study to other G gene organizations, a recombinant PVM expressing a G protein without the cytoplasmic domain and for comparison a G-deletion mutant, both known to be attenuated in vivo, were studied. Not noticed before, this structure of the G gene was associated with a 75% reduction in G protein expression and a significant attenuation of replication in macrophage-like cells. This attenuation was even more prominent for the virus lacking G. Taking into consideration the higher reduction in G protein levels compared to the GJ366665A variant indicates that a threshold amount of G is required for efficient replication in these cells. In conclusion, the results gathered indicated that the expression levels of the G protein were modulated by the sequence of the 5’ untranslated region of the gene. At the same time the G protein levels modulated the virulence of PVM. N2 - Das mutmaßliche „attachment“ Protein G des Pneumonievirus der Maus (PVM), einem Mitglied des Genus Pneumovirus, ist ein bedeutender Virulenzfaktor, mit allerdings noch nicht vollständig verstandener Funktion. Dabei zeichnet sich die Sequenz des G-Gens durch Nukleotid-Polymorphismen und damit verbundenen Variationen in der Genorganisation und möglicherweise der Proteinstruktur sowohl zwischen als auch innerhalb von PVM-Stämmen aus. Insbesondere für den PVM-Stamm J3666 wurden zwei verschiedene Organisationen des G-Gens beschrieben: ein Polymorphismus des Nukleotids 65 des G-Genes erzeugt einen neuen „upstream Open reading frame“ (uORF), der dem eigentlichen G-ORF vorausgeht (GJ366665A), oder führt zu einer Verlängerung des eigentlichen G-ORF von G um 18 Kodons (GJ366665U). Ziel dieser Studie war es deshalb, die Auswirkung dieser Sequenzvariabilitäten der für PVM J3666 beschriebenen G-Gene im Vergleich zu dem des Referenzstamms PVM 15 bezüglich Proteinexpression, der Virusreplikation und der Virulenz zu untersuchen. Als erstes wurden die beschriebenen Sequenzunterschiede bezüglich des PVM-Stamms J3666 untersucht. Die Analyse von 45 verschiedenen klonierten Fragmenten von PVM J3666 zeigte, dass es sich bei diesem Stamm eigentlich um zwei separate Viruspopulationen handelt, die sich durch die Sequenz und Struktur des G-Genes definieren lassen. Diese Unterscheidung wird durch weitere Nukleotid-Polymorphismen in den benachbarten Genen, M und SH, gestärkt. Sequenzielle Passagierung dieses gemischten Stammes in der standardmäßig zur Virusanzucht verwendeten BHK-21-Zelllinie resultierte in einem von zwei Experimenten in der Selektion der GJ366665A-Population, das ein Hinweis auf einen moderaten Replikationsvorteil darstellt. Der Austausch des G-Gens des Referenzstamms PVM 15 durch GJ366665A oder GJ366665U mithilfe der Reversen Genetik, zeigte, dass der uORF innerhalb von GJ366665A zu einer deutlich reduzierten Expression des eigentlichen G-ORF führt. Andererseits führte die potenzielle Verlängerung des ORF in GJ366665U zu einer im gleichen Maße erhöhten Expression des G-Proteins. Dagegen war der Einfluss der G-Genorganisation auf die Virusvermehrung in Zellkultur in Abhängigkeit von Zelllinie und Zelltyp inkonsistent. Während ein uORF mit einem Replikationsvorteil in BHK-21-Zellen und primären murinen embryonen Fibroblasten korrelierte, war dies in der murinen Makrophagen-Zelllinie RAW 264.7 nicht zu beobachten. Im Vergleich dazu konnte die GJ366665U-Variante nicht mit einem Einfluss auf die Virusvermehrung in Verbindung gebracht werden. Nichtsdestotrotz, konnte die GJ366665U-Variante, und damit eine erhöhte Expression von G, mit einer gesteigerten Virulenz assoziiert werden, während die GJ366665A-Variante, d. h. eine verringerte G-Expression zur Attenuierung des Virus führte. Die Untersuchungen wurden auf weitere G-Genstrukturen, d.h. ein rekombinantes PVM, rPVM-Gt, das ein N-terminal verkürztes G-Protein exprimiert, ausgeweitet. Zum Vergleich wurde eine Deletionsmutante des kompletten G-Gens, rPVM-ΔG, mit einbezogen. Von beiden Viren war bereits bekannt, dass sie in vivo attenuiert sind. Die Organisation des Gt-Gens war mit einer um 75 % verringerten Expression des entsprechenden Proteins assoziiert, was zuvor nicht beobachtet worden war. Zugleich zeigte rPVM-Gt eine deutliche Attenuierung der Replikation in RAW 264.7-Zellen und primären Mausmakrophagen, die von der G-Deletionsmutante noch übertroffen wurde. Die im Vergleich zu der GJ366665A-Variante deutlich höhere Reduktion der G-Expression dieser beiden G-Mutanten in Betracht ziehend, scheint dies darauf hinzuweisen, dass eine bestimmte Mindestexpression von G für eine effiziente Virusvermehrung in diesen Zellen benötigt wird. Zusammenfassend deuten die erhaltenen Ergebnisse darauf hin, dass die Expression des G-Proteins durch die jeweiligen 5’ nicht-translatierte Region des Gens moduliert wird, was einen neuen Mechanismus für Negativstrang-RNA-Viren darstellt. Zugleich moduliert die Expressionsrate von G die Virulenz von PVM. KW - G glycoprotein KW - protein regulation and expression KW - Pneumoviruses KW - regulation KW - expression KW - replication KW - virulence KW - 5`-UTR KW - PVM KW - RSV Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-128146 ER - TY - THES A1 - Heidrich [geb. Englert], Johanna T1 - Bestimmung der Prävalenz medikamentenresistenter HIV-Infektionen bei therapienaiven Patienten in der Viktoriasee-Region in Tansania T1 - Determining the prevalence of drug-resistant HIV infections in treatment-naive patients in the Lake Victoria region of Tanzania N2 - Bestimmung der Prävalenz medikamentenresistenter HIV-Infektionen bei therapienaiven Patienten in der Viktoriasee-Region in Tansania Seitdem HIV im Jahr 1983 als Ursache des „acquired immundeficiency syndrome“ (AIDS) isoliert wurde, hat sich viel in der Therapie dieser Infektion getan. Trotzdem handelt es sich um eine Erkrankung, welche bisher nicht geheilt werden kann. Da der weitaus größere Anteil der betroffenen Menschen in strukturschwachen Ländern lebt, ist die größte Herausforderung, eine flächendeckende Therapie weltweit zu etablieren und diese für jeden zugänglich zu machen. Aufgrund der hohen Mutationsrate des HI-Virus, kommt es zur schnellen Resistenzentwicklung. In strukturschwachen Ländern wie Tansania ist eine Resistenztestung vor Therapiebeginn aktuell aufgrund fehlender Infrastruktur sowie geringer finanzieller Mittel nicht denkbar. Deshalb wird nach WHO-Empfehlung eine standardisierte Dreifachkombination, in der Regel Tenofovir, Lamivudin und Efavirenz, angewendet, ohne vorher eine Resistenztestung vorzunehmen. In regelmäßigen Nachuntersuchungen wird anhand von Viruslast und CD4-Zahl der Erfolg der begonnenen Therapie gemessen und nur bei einem Versagen dieser eine Umstellung vorgenommen. Bereits im Jahr 2011 wurde von unserer Arbeitsgruppe (Kasang, Kalluvya et al.) nachgewiesen, dass eine deutlich höhere Prävalenz für Primärresistenzen von HI-Viren gegenüber antiretroviraler Therapie bestand, als zuvor angenommen. Betrachtet wurden dabei alle Patienten, welche neu als HIV-positiv getestet wurden und nun therapiert werden sollten. Neu war, dass auch ältere Patienten (>25 Jahre) mit einbezogen wurden. Aufgrund der hohen Prävalenz an Primärresistenzen (19%) nahm man an, dass durch antiretrovirale Therapie entstandene resistente Viren zwischen Partnern direkt übertragen werden können. In der vorliegenden Arbeit sollte durch die Untersuchung einer größeren Patientengruppe dieser These nachgegangen werden. Untersucht wurde das Plasma von 114 Patienten (> 25 Jahre), welche unmittelbar vor dem Start einer antiretroviralen Therapie standen und bisher therapienaiv waren. Zur Bestimmung von möglicherweise vorliegenden Resistenzen erfolgte im S3-Labor zunächst die Isolierung der Virus-RNA aus dem Plasma. Diese wurde anschließend in DNA umschrieben, amplifiziert, aufgereinigt und sequenziert. Die Sequenzen wurden online durch die „HIV DRUG RESISTANCE DATABASE“ der Stanford University im Hinblick auf den Subtyp der reversen Transkriptase (RT), der Protease sowie auf Resistenzen gegenüber den gängigen aniretroviralen Medikamenten analysiert mit folgenden Ergebnissen: 1. Die Prävalenz für eine Primärresistenz gegenüber antiretroviralen Medikamenten betrug 21,5 % 2. Die Medikamente der Triple-Therapie waren in der untersuchten Gruppe mit einer Prävalenz von 10,53 % betroffen. 3. Diese Ergebnisse sind besorgniserregend und bestätigen die von Kasang, Kalluvya et al. aufgestellte These Für den weitaus größeren Teil der untersuchten Patienten wäre jedoch die Triple-Therapie ohne kostspielige und aufwendige Resistenztestung ausreichend gewesen. Vorderstes Ziel bleibt somit die finanziellen Ressourcen weiterhin Zugänglichkeit der medikamentösen Behandlung zu nutzen, da dies die beste Methode ist, die Ausbreitung dieser Pandemie einzudämmen. Dennoch werden in den nächsten Jahren weiterhin Untersuchungen mit noch größeren Patientenzahlen nötig sein, um die Wirksamkeit des aktuellen Therapieregimes ständig zu überprüfen und gegebenenfalls eine Anpassung vorzunehmen. N2 - Determining the prevalence of drug-resistant HIV infections in treatment-naive patients in the Lake Victoria region of Tanzania Since HIV was identified as the cause of AIDS, there has been significant progress on the therapy of this disease although there is no cure. Most frequently those affected live in economically underdeveloped countries. Against this backdrop, the challenge is to establish a comprehensive therapy worldwide and make it available for everyone. Due to the high mutation rate of the HI virus, resistance develops quickly. In structurally weak countries such as Tanzania, resistance testing before the start of therapy is currently inconceivable due to the lack of infrastructure and low financial resources. Therefore, according to WHO recommendations, a standardised triple combination, usually tenofovir, lamivudine and efavirenz, is used without prior resistance testing. In regular follow-up examinations, the success of the therapy started is measured on the basis of viral load and CD4 count, and a change is only made if this fails. As early as 2011, our research group (Kasang, Kalluvya et al.) demonstrated that there was a significantly higher prevalence of primary resistance of HI viruses to antiretroviral therapy than previously assumed. All patients who were newly tested as HIV-positive, and were now to be treated, were considered. What was new was that older patients (>25 years) were also included. Due to the high prevalence of primary resistance (19%), it was assumed that resistant viruses resulting from antiretroviral therapy can be transmitted directly between partners. In the present study, this hypothesis was investigated by examining a larger group of patients. The plasma of 114 patients (> 25 years) who were about to start antiretroviral therapy and who had been therapy-naive so far was examined. To determine the possible presence of resistance, the virus RNA was first isolated from the plasma in the S3 laboratory. This was then transcribed into DNA, amplified, purified and sequenced. The sequences were analysed online by the "HIV DRUG RESISTANCE DATABASE" of Stanford University with regard to the subtype of the reverse transcriptase (RT), the protease and resistance to the common antiretroviral drugs with the following results: 1. The prevalence for primary resistance to antiretroviral drugs was 21.5 %. 2. Triple therapy drugs were affected with a prevalence of 10.53% in the group studied. 3. These results are worrying and confirm the thesis put forward by Kasang, Kalluvya et al. However, for the vast majority of patients studied, triple therapy would have been sufficient without costly and time-consuming resistance testing. The primary goal therefore remains to continue to use the financial resources for accessibility of drug treatment, as this is the best method to contain the spread of this pandemic. Nevertheless, further studies with even larger numbers of patients will be necessary in the coming years in order to constantly monitor the effectiveness of the current treatment regime and make adjustments if necessary. KW - HIV KW - HIV-Infektion KW - Tansania KW - HAART KW - Resistenz KW - Primärresistenz KW - Viktoriaseeregion Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-222931 ER - TY - THES A1 - Jonas, Franziska T1 - CNS1-dependency of \(in\) \(vivo\) peptide-induced CD4\(^+\)Foxp3\(^+\) regulatory T cells T1 - CNS1-Abhängigkeit von \(in\) \(vivo\) Peptid-induzierten CD4\(^+\)Foxp3\(^+\) regulatorischen T-Zellen N2 - CD4+Foxp3+ Tregs can be induced in vitro by TGF-b stimulation. Here, CNS1 deficient CD4+ T cells were found to show compromised Foxp3 upregulation in vitro compared to CNS1 WT CD4+ T cells. Moreover, we could demonstrate that antigen-specific CD4+Foxp3+ Tregs can be induced in vivo by tolerogenic antigen stimulation. Parenteral application of agonist BDC2.5 mimetope induced Foxp3 expression in CD4+ BDC2.5 tg cells. We could show that induction of Foxp3 expression by tolerogenic peptide stimulation is impaired in CNS1 deficient CD4+ BDC2.5 tg cells compared to CNS1 WT CD4+ BDC2.5 tg controls. These results indeed indicate that in vivo induced Tregs share mechanistic characteristics with naturally occurring pTregs. Additional in vivo experiments with blocking monoclonal anti-TGF-b demonstrated that high dosage TGF-b blockade abrogated peptide-induced Foxp3 expression in CNS1 WT BDC2.5 tg CD4+ cells, akin to what is seen for impaired Foxp3 upregulation in peptide-stimulated CNS1 KO BDC2.5 tg CD4+ cells without anti-TGF-b-treatment. Adoptive transfer of CD4+CD25- T cells in T cell deficient recipients dramatically increased CD4+Foxp3+ Treg frequencies in both CNS1 WT CD4+ and CNS1 KO CD4+ donor cells. Despite an initially lower increase in Foxp3 expression in CNS1 KO donor cells compared to CNS1 WT donor cells early after transfer, in this setting impaired Treg induction in CNS1 deficient cells was not preserved over time. Consequently, diabetes onset and progression were indistinguishable between mice that received CNS1 WT or CNS1 KO donor cells. Additional Foxp3 induction by peptide stimulation of immunodeficient recipients after transfer of CNS1 WT BDC2.5. tg or CNS1 KO BDC2.5 tg donor cells was not detectable. N2 - CD4+Foxp3+ Tregs können in vitro mittels TGF-b-Stimulation induziert werden. Im Rahmen dieses Projekts konnte bestätigt werden, dass CNS1-defiziente CD4+ T-Zellen im Vergleich zu CD4+ CNS1 WT-Zellen in vitro eine eingeschränkte Foxp3-Hochregulation zeigen. Des Weiteren konnten wir Antigen-spezifische CD4+Foxp3+ Tregs mittels tolerogener Antigenstimulation in vivo induzieren. Parenteral appliziertes BDC2.5-Mimetop induzierte die Foxp3 Expression in CD4+ BDC2.5 transgenen T-Zellen. Hierbei zeigten CNS1 KO BDC2.5 transgene CD4+ T-Zellen im Vergleich zu CNS1 WT BDC2.5 transgenen CD4+ T-Zell-Kontrollen eine eingeschränkte Hochregulation der Foxp3 Expression nach Mimetop-Stimulation. Peptid-induzierte CD4+Foxp3+ Tregs verhalten sich somit ähnlich wie natürlich vorkommende pTregs. Unter Verwendung höherer Dosen von anti-TGF-b zeigte sich bei Mimetop-Stimulation im in vivo Experiment eine eingeschränkte Foxp3-Hochregulation der CNS1 WT CD4+ BDC2.5 transgenen T-Zellen, ähnlich wie es bei CNS1 KO CD4+ BDC2.5 transgenen T-Zellen ohne anti-TGF-b-Behandlung zu beobachten war. ... KW - Treg KW - Regulatorischer T-Lymphozyt KW - Diabetes mellitus Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-243887 ER - TY - THES A1 - Hühne, Tom T1 - Untersuchungen zur selektiven Induktion von Zelltod in CD4+ Foxp3- konventionellen T-Zellen der Maus durch Hemmung der sauren Sphingomyelinase \(in\) \(vitro\) T1 - Analysis of the selective induction of cell death in murine CD4+ Foxp3- conventional T cells by inhibition of acid sphingomyelinase \(in\) \(vitro\) N2 - Die saure Sphingomyelinase (Asm) ist ein lysosomales Enzym, das sezerniert werden kann und die Reaktion von Sphingomyelin zu Ceramid und Phosphocholin katalysiert. Seine Funktion ist bedeutsam für die Aufrechterhaltung des zellulären Lipidstoffwechsels und für die Integrität der Plasmamembran. Enzymdefekte sind an der Pathogenese von Infektionen und zahlreichen Stoffwechselerkrankungen wie z.B. der Niemann-Pick-Krankheit, Diabetes mellitus Typ II und auch an der Entstehung psychischer Erkrankungen beteiligt. Immunologisch bedeutsam ist, dass durch Hemmung der Asm mit trizyklischen Antidepressiva (TZA) oder Serotonin-Wiederaufnahme-Inhibitoren (SSRI) die Frequenz CD4+ CD25+ Foxp3+ regulatorischer T-Zellen (Treg) der Maus erhöht wird. Grund für die Frequenzerhöhung ist jedoch nicht die Erhöhung der absoluten Treg-Zellzahl, sondern das selektive Sterben CD4+ CD25- Foxp3- konventioneller T-Zellen (Tconv). Erstaunlicherweise führt die Behandlung mit dem kompetitiven Asm-Inhibitor ARC39, einem Bisphosphonat, nicht zu diesem Effekt. Es konnte gezeigt werden, dass IL-2 die regulatorischen T-Zellen vor dem durch Asm-Hemmung induziertem Zelltod schützt. In Abwesenheit von IL-2 gehen auch Treg-Zellen durch die Asm-Inhibition zugrunde. Treg-Zellen exprimieren konstitutiv CD25, den IL-2-Rezeptor, dessen α-Kette die Bindungsstelle von Interleukin-2 bildet. Die β- und γ-Kette des Rezeptors sind an der Bindung des Transkriptionsfaktors STAT5 beteiligt, das wiederum die Gentranskription von antiapoptotischen Proteinen wie bcl-2 und bcl-x sowie CD25 fördert. Dahingehend wurde versucht, den verantwortlichen Faktor für den Schutz von Treg-Zellen vor dem Zelltod in der IL-2-Signaltransduktion zu identifizieren. Der Transkriptionsfaktor STAT5 konnte hierbei ausgeschlossen werden. Weder die genetische Überexpression noch die Defizienz von STAT5 hatten Einfluss auf das T-Zell-Gleichgewicht. Die genauen molekularen Mechanismen der Treg-spezifischen IL-2-Protektion bleiben daher ungeklärt. Zu diskutieren sind der Einfluss von Zn2+-Ionen, Januskinasen und Mitgliedern der FoxO-Familie. Die zugrundeliegende Hypothese, dass das spezifische Sterben konventioneller T-Zellen auf einer Erhöhung der lysosomalen Membranpermeabilität (LMP) besteht, woraufhin proapoptotisch wirksame Cathepsine ins Zytosol freigesetzt werden und Caspasen zur Auslösung von Apoptose führen, konnte nicht abschließend bestätigt werden. Jedoch wurde nachgewiesen, dass durch Inhibition von Cathepsinen das Sterben konventioneller T-Zellen in Abwesenheit von IL-2 verlangsamt wird. Eine Protektion der Tconv-Zellen durch Caspase-Inhibitoren kann nur bei hohen 60 Konzentrationen des Inhibitors ZVAD bei gleichzeitig geringer Asm-Inhibitor-Konzentration erreicht werden. In Zusammenschau der Ergebnisse müssen weitere Formen des Zelltods neben der Apoptose, etwa eine durch Asm-Inhibition induzierte Ferroptose, in Erwägung gezogen werden. Neben dem durch Asm-Inhibition erzeugten Lipidstress begünstigt das Vorliegen von hypoxischen Bedingungen die Induktion von Zelltod. Schon das alleinige Auftreten von Hypoxie ohne den Einfluss von Asm-Inhibitoren führt zu einer Treg-Frequenzerhöhung. Der Hypoxie-induzierte Faktor HIF-1α induziert die Expression von Foxp3, wodurch die Differenzierung und Suppressivität von CD4+ CD25+ Foxp3+ Treg-Zellen gefördert wird. Der Einfluss von Hypoxie spielt womöglich vor allem in der Tumortherapie eine entscheidende Rolle. HIF-1α regt hypoxische, nicht-vaskularisierte Tumorareale zur Neovaskularisation an und bremst durch die Frequenzerhöhung regulatorischer T-Zellen die eigene Immunabwehr. Ein Abbau des Transkriptionsfaktors HIF-1α stellt somit eine therapeutische Option in der Therapie solider Tumoren dar. Abschließend lässt sich also festhalten, dass die relative Frequenzerhöhung regulatorischer T-Zellen durch Asm-Inhibition nicht durch Apoptose erklärt werden kann, sondern alternative Erklärungsmodelle wie z.B. die Ferroptose in Betracht gezogen werden müssen. Die Protektion CD25+ regulatorischer T-Zellen beruht auf der Wirkung von IL-2 und wird durch Hypoxie positiv beeinflusst. Eine genaue Identifizierung der für den Zelltod relevanten Mechanismen ist erforderlich, um sichere therapeutische Maßnahmen im Rahmen von Infektionen und Autoimmunkrankheiten zu etablieren. N2 - The acid sphingomyelinase (Asm) is a lysosomal enzyme that can be secreted and catalyses the cleavage of sphingomyelin to ceramide and phosphocholine. Its function is important for the maintenance of cellular lipid metabolism and for the integrity of the plasma membrane. Enzyme defects are involved in the pathogenesis of infections and numerous metabolic diseases such as Niemann-Pick disease, diabetes mellitus type II and also in the development of mental illness. It is of immunological importance that the inhibition of the Asm with tricyclic antidepressants (TCA) or serotonin reuptake inhibitors (SSRI) leads to an increase of the frequency of CD4+ CD25+ Foxp3+ regulatory T cells (Treg) in the mouse. The reason for this frequency increase is not an increase in the absolute Treg cell count, but rather due to the selective death of CD4+ CD25- Foxp3- conventional T cells (Tconv) Surprisingly, treatment with the competitive Asm-inhibitor ARC39, a bisphosphonate, does not lead to this effect. It could be demonstrated that IL-2 protects regulatory T cells from cell death induced by Asm inhibition. In the absence of IL-2, Treg cells also die due to Asm inhibition. Treg cells constitutively express CD25, the IL-2 receptor, whose α-chain forms the binding site of interleukin-2. The β- and γ-chain of the receptor are involved in the binding of the transcription factor STAT5, which itself promotes gene transcription of anti-apoptotic proteins such as bcl-2 and bcl-x as well as CD25. Therefore, we tried to identify the responsible factor responsible for protecting Treg cells from cell death in IL-2 signal transduction. The transcription factor STAT5 was excluded. Neither the genetic over-expression nor the deficiency of STAT5 had any influence on the T-cell balance. The exact molecular mechanisms of Treg specific IL-2 protection remain unexplained. The influence of Zn2+ ions, Janus kinases and FoxO-family members will be discussed. The underlying hypothesis that the specific death of conventional T cells is based on an increase in lysosomal membrane permeability (LMP), whereupon proapoptotic cathepsins are released into the cytosol and caspases lead to the induction of apoptosis could not be conclusively confirmed. However, it has been shown that inhibition of cathepsins slows down the death of conventional T cells in the absence of IL-2. A protection of Tconv cells by caspase inhibitors can only be achieved at high concentrations of the inhibitor ZVAD with simultaneously low Asm inhibitor concentrations. In summary, other forms of cell death besides apoptosis, such as ferroptosis induced by Asm inhibition, need to be considered. 62 Besides lipid stress induced by Asm inhibition, the presence of hypoxic conditions favors the induction of cell death. Even the mere occurrence of hypoxia without the influence of Asm inhibitors leads to an increase in Treg frequency. Hypoxia-induced factor HIF-1α induces Foxp3 expression, promoting differentiation and suppressiveness of CD4+ CD25+ Foxp3+ Treg cells. The influence of hypoxia possibly plays a decisive role especially in tumor therapy. HIF-1α stimulates hypoxic, non-vascularized tumor areas to neovascularize and slows down the own immune defense by increasing the frequency of regulatory T cells. A degradation of the transcription factor HIF-1α is therefore a therapeutic option in the therapy of solid tumors. In conclusion, it can be stated that the relative frequency increase of regulatory T cells by Asm inhibition cannot be explained by apoptosis, but alternative explanation models such as ferroptosis must be considered. The protection of CD25+ regulatory T cells is based on the effect of IL-2 and is positively influenced by hypoxia. A precise identification of the mechanisms relevant for cell death is necessary to establish safe therapeutic measures in the context of infections and autoimmune diseases. KW - Sphingomyelinphosphodiesterase KW - Desipramin KW - Regulatorischer T-Lymphozyt KW - Sphingomyelinase KW - Desipramin KW - T-Zelle KW - Regulatorische T-Lymphozyt Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-248351 ER - TY - JOUR A1 - Hennig, Thomas A1 - Djakovic, Lara A1 - Dölken, Lars A1 - Whisnant, Adam W. T1 - A Review of the Multipronged Attack of Herpes Simplex Virus 1 on the Host Transcriptional Machinery JF - Viruses N2 - During lytic infection, herpes simplex virus (HSV) 1 induces a rapid shutoff of host RNA synthesis while redirecting transcriptional machinery to viral genes. In addition to being a major human pathogen, there is burgeoning clinical interest in HSV as a vector in gene delivery and oncolytic therapies, necessitating research into transcriptional control. This review summarizes the array of impacts that HSV has on RNA Polymerase (Pol) II, which transcribes all mRNA in infected cells. We discuss alterations in Pol II holoenzymes, post-translational modifications, and how viral proteins regulate specific activities such as promoter-proximal pausing, splicing, histone repositioning, and termination with respect to host genes. Recent technological innovations that have reshaped our understanding of previous observations are summarized in detail, along with specific research directions and technical considerations for future studies. KW - herpes simplex virus KW - RNA polymerase II KW - transcription KW - host shutoff KW - promoter-proximal pausing KW - C-terminal domain KW - polyadenylation KW - splicing Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-246165 SN - 1999-4915 VL - 13 IS - 9 ER - TY - THES A1 - Averbeck, Nadja Mirjam T1 - Der Einfluss von niedrig-dosiertem Prednisolon auf die T-Zell-Aktivierung bei Patienten mit HIV-Infektion T1 - Influence of prednisolone therapy on t-cell activation in HIV-infected patients N2 - Hintergrund: Die HIV-Infektion wird von einer allgemeinen Hyperimmunaktivierung begleitet, die wahrscheinlich eine treibende Kraft in der Pathogenese der Entwicklung von AIDS darstellt. Im Rahmen einer 24-monatigen, Placebo-kontrollierten, randomisierten Doppelblindstudie wurde in unserer Arbeitsgruppe der Einfluss von gering-dosiertem Prednisolon (5 mg/Tag) auf die Progression der Erkrankung untersucht (ProCort-Studie, clinicaltrials.gov NCT01299948). Es konnte gezeigt werden, dass gering-dosiertes Prednisolon bei weiblichen Studienteilnehmerinnen zu einer signifikant verlangsamten Progression hin zum Studienendpunkt AIDS geführt hat. Die immunologischen Grundlagen dieses Effektes sind noch nicht ausreichend verstanden. Es ist bekannt, dass die HIV-Infektion zu einer Zunahme der aktivierten T-Zellen im Blut führt und dass der Anteil dieser aktivierten T-Zellen mit der Krankheitsprogression korreliert. Diese T-Zell Hyperaktivierung wird unter antiretroviraler Behandlung wieder normalisiert. In der vorliegenden Arbeit sollte der Einfluss der Prednisolon-Behandlung auf die T-Zell-Aktivierung untersucht werden, um zu verstehen, ob die Prenisolon-Behandlung ähnliche positive Effekte auf das Immunsystem hat, wie die antiretrovirale Therapie. Methoden: In dieser Studie wurden insgesamt 154 PBMC-Proben (77 Placebo, 77 Prednisolon) des Studienzeitpunktes 12 Monate untersucht. Die PBMC wurden mit Fluorochrom-markierten Antikörpern gegen CD3 (PerCP-Cy 5.5), CD8 (FITC), CD38 (PE) und HLA-DR (APC) gefärbt und durchflusszytometrisch analysiert. Folgende Populationen wurden definiert: T-Zellen (CD3+), CD8-positive T Zellen (CD3+/CD8+), CD4-positive T Zellen (CD3+/CD8-), aktivierte T Zellen (CD38+/HLA-DR+). Eine statistische Analyse der Daten erfolgte mit Hilfe der GraphPad Prism Software. Ergebnisse: Patienten mit Prednisolon-Behandlung zeigten im Vergleich zu Patienten mit Placebo-Behandlung eine geringere Aktivierung der CD8+ T Zellen (median 8.04 % [CI95% 8.158-11.54]) vs. median 9.74 % [CI95% 9.71-13.05] sowie der CD4+ T Zellen (median 6.910% [CI95% 6.862-8.721] vs. median 8.185 % [CI95% 8.088-10.49]). Die Unterschiede sind jedoch statistisch nicht signifikant (p=0.1250 bzw. p=0.1032, U test). Bei einer Stratifizierung der Daten nach Geschlecht erreichten die festgestellten Unterschiede zwischen Placebo- und Prednisolonbehandlung bei weiblichen Studienteilnehmern statistische Signifikanz (CD8+ Aktivierung: median 7.3 % [CI95% 7.413-10.26] vs. median 10.3 % [CI95% 9.927-13.69], p = 0.0248, U-test), sowie der CD4+ T Zellen (median 6.735% [CI95% 6.448-8.476] vs. (median 8.36% [CI95% 8.274-10.72], p = 0.0158, U-test), während bei männlichen Studienteilnehmern kein Unterschied auftrat. Die Lymphozytenaktivierung zeigte eine positive Korrelation zur HIV-Viruslast (p = 0.0521 für CD8+ und p = 0.0078 für CD4+, lineare Regression) und zum Immunaktivierungsmarker sCD14 (p = 0.0075 für CD8+ und p < 0.0085 für CD4+, lineare Regression) und zum Aktivierungsmarker supar (p = 0.0261 für CD8+ und p < 0.0001 für CD4+, lineare Regression). Aktivierte CD4+ Zellen zeigten eine positive, aktivierte CD8+ Zellen eine negative Korrelation zum Anteil an memory-B-Zellen (p = 0.0080 für CD8+ und p < 0.0001 für CD4+, lineare Regression). In einer Kaplan-Meyer-Analyse innerhalb des Placebo-Arms zeigten Patienten mit einer höherne Immunaktivierung bei CD8+ T-Lymphozyten (Quartilen Q1 und Q2) eine signifikant schnellere Progression zu AIDS als Patienten mit einer niedrigen Immunaktivierung (Quartilen Q3 und G4, p = 0.0176). Diskussion: In dieser Arbeit konnte gezeigt werden, dass Studienteilnehmerinnen mit Prednisolon-Behandlung zum Zeitpunkt 12 Monate eine signifikant niedrigere Lymphozytenaktivierung zeigen als Studienteilnehmerinnen mit Placebo-Behandlung. Die Prednisolon-vermittelte Reduktion der Immunaktivierung korrelierte mit verlangsamter Krankheitsprogression. Die HIV-induzierte Immunaktivierung ist damit ein treibender Faktor in der Progression der Erkrankung. Immunmodulatorische Therapien bei Patienten mit ungenügender Immunrekonstitution unter antiretroviraler Behandlung könnten daher möglicherweise einen positiven Behandlungseffekt erzielen. Zielsetzung dieser Arbeit ist die Bestimmung der Aktivierung von CD8+ und CD4+ T-Lymphozyten bei Teilnehmern eines RCT, in dem der Effekt von niedrig-dosiertem Prednisolon auf die Progression der HIV-Infektion untersucht werden sollte. Die Ergebnisse sollten mit der Art der Behandlung (Placebo oder Prednisolon), weiteren Markern der Immunaktivierung sowie der Viruslast korreliert werden und der Effekt auf die Krankheitsprogression untersucht werden. Aus diesen Ergebnissen sollten Rückschlüsse auf die Effekte von Prednisolon auf das Immunsystem, sowie ein besseres Verständnis der Immunpathogenese der Infektion gewonnen werden. N2 - HIV-infection comes along with chronic immune activation, which is most likely a driving force in the progression to AIDS. During a 24-month, placebo-controlled, randomized, double-blind study called the Pro-Cort trial, our work group investigated the impact of low dose prednisolone (5mg/day) on the progression of the HIV-infection. In this dissertation t-cell-activation was analyzed by the positive expression of CD3/ CD8 and CD38/HLADR markers. It showed a positive correlation to the viral load in HIV-infection. The t-cell-activation correlates also positive with known biomarkers of immune activation as sCD14 and supar. In a correlation to memory B-cells, activated CD4-t-cells correlated positively to memory B-cells, while activated CD8-t-cells correlated negatively to them. In a Kaplan-meyer-analysis in the placebo arm patients with high immune activation of CD8 positive t-cells showed a significant faster progression to AIDS than patients with a low immune activation of CD8 positive t-cells. Furthermore especially in female participants the treatment with prednisolone leaded to a significant lower immune activation. In summary positive immune modulating effects of prednisolone therapy were seen on HIV-infected individuals. KW - HIV-Infektion KW - Prednisolon KW - Immunaktivierung KW - T-Zell-Aktivierung KW - HIV-infection KW - immune activation Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-224866 ER - TY - THES A1 - Mann, Benedikt T1 - Einfluss einer Prednisolon-Behandlung auf B-Zell-Populationen bei Patienten mit HIV-Infektion T1 - Influence of prednisolone therapy on b-cell-populations in HIV-infected patients N2 - Die HIV-Infektion wird von einer Hyperimmunaktivierung begleitet, die vermutlich eine treibende Kraft in der Pathogenese der Entwicklung von AIDS darstellt. Die Rolle der B-Zellen im Rahmen dieser Veränderungen und dem Einfluss einer Prednisolontherapie wird durch die ProCort-Studie genauer beschrieben. Diese stellt eine zweijährige, Placebo-kontrollierte, randomisierte Doppelblindstudie dar, bei der die Patienten 5mg Prednisolon täglich einnahmen. Mittels durchflusszytometrischen Messungen wurden bestimmte B-Zellpopulationen differenziert und quantifiziert. Die resultierenden Ergebnisse wurden weiterhin mit bekannten Immunaktivierungsmarkern korreliert. In der Arbeit konnte gezeigt werden, dass Studienteilnehmerinnen durch eine Prednisolontherapie signifikant mehr Memory-B-Zellen bzw. resting Memory-B-Zellen im Vergleich zur Placebogruppe aufweisen. Ferner konnte die Bedeutung der B-Zellen als prognostischer Marker der HIV-Infektion dadurch unterstützt werden, dass die genannten B-Zellreihen signifikant negative Korrelationen zu anderen, bereits etablierten Progressionsmarkern (CD4/CD8-Ratio, CD8/CD38/HLADR-Aktivierung, suPAR, sCD14) vorlagen. Zusammenfassend zeigt die Arbeit, dass die Veränderungen im B-Zellkompartment Teil des Immunaktiverungsprozesses im Rahmen der HIV- Infektion sind und Prednisolon modulierende Einflüsse darauf hat. N2 - The HIV-infection goes along with a chronic immune activation, which is considered as the driving force of progression to AIDS. As part of the ProCort trial, which is a double-blind, randomized, placebo-controlled clinical trial over two years, HIV-infected patients got 5 mg prednisolone per day for two years. In this dissertation specific b-cell-populations were measured and correlated with known biomarkers of immune activation (CD38+/HLADR+ t-cells, suPAR, sCD14). As result higher counts of memory-b-cells and resting-memory-b-cells especially in the female subgroup were found. Furthermore these cell-populations showed a negative correlation with biomarkers of immune activation. In summary the prednisolone therapy had positive immune modulating effects on b-cells and biomarkers of immune activation. KW - HIV-Infektion KW - Lymphozyt KW - Immunsystem KW - Biomarker KW - Prednisolon KW - Immunaktivierung KW - chronic immune activation KW - Progression zu AIDS KW - progression to AIDS KW - ProCort KW - Memory-B-Zellen KW - memory b cell KW - Immunpathogenese KW - immune pathogenesis Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-225558 ER - TY - JOUR A1 - Wiese, Teresa A1 - Dennstädt, Fabio A1 - Hollmann, Claudia A1 - Stonawski, Saskia A1 - Wurst, Catherina A1 - Fink, Julian A1 - Gorte, Erika A1 - Mandasari, Putri A1 - Domschke, Katharina A1 - Hommers, Leif A1 - Vanhove, Bernard A1 - Schumacher, Fabian A1 - Kleuser, Burkard A1 - Seibel, Jürgen A1 - Rohr, Jan A1 - Buttmann, Mathias A1 - Menke, Andreas A1 - Schneider-Schaulies, Jürgen A1 - Beyersdorf, Niklas T1 - Inhibition of acid sphingomyelinase increases regulatory T cells in humans JF - Brain Communications N2 - Genetic deficiency for acid sphingomyelinase or its pharmacological inhibition has been shown to increase Foxp3\(^+\) regulatory T-cell frequencies among CD4\(^+\) T cells in mice. We now investigated whether pharmacological targeting of the acid sphingomyelinase, which catalyzes the cleavage of sphingomyelin to ceramide and phosphorylcholine, also allows to manipulate relative CD4\(^+\) Foxp3\(^+\) regulatory T-cell frequencies in humans. Pharmacological acid sphingomyelinase inhibition with antidepressants like sertraline, but not those without an inhibitory effect on acid sphingomyelinase activity like citalopram, increased the frequency of Foxp3\(^+\) regulatory T cell among human CD4\(^+\) T cells in vitro. In an observational prospective clinical study with patients suffering from major depression, we observed that acid sphingomyelinase-inhibiting antidepressants induced a stronger relative increase in the frequency of CD4\(^+\) Foxp3\(^+\) regulatory T cells in peripheral blood than acid sphingomyelinase-non- or weakly inhibiting antidepressants. This was particularly true for CD45RA\(^-\) CD25\(^{high}\) effector CD4\(^+\) Foxp3\(^+\) regulatory T cells. Mechanistically, our data indicate that the positive effect of acid sphingomyelinase inhibition on CD4\(^+\) Foxp3\(^+\) regulatory T cells required CD28 co-stimulation, suggesting that enhanced CD28 co-stimulation was the driver of the observed increase in the frequency of Foxp3+ regulatory T cells among human CD4\(^+\) T cells. In summary, the widely induced pharmacological inhibition of acid sphingomyelinase activity in patients leads to an increase in Foxp3+ regulatory T-cell frequencies among CD4\(^+\) T cells in humans both in vivo and in vitro. KW - acid sphingomyelinase KW - antidepressants KW - major depression KW - regulatory T cells KW - sphingolipids Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-259868 VL - 3 IS - 2 ER - TY - JOUR A1 - Dölken, Lars A1 - Stich, August A1 - Spinner, Christoph D. T1 - Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset — Lessons Learned JF - Viruses N2 - After more than one year of the COVID-19 pandemic, antiviral treatment options against SARS-CoV-2 are still severely limited. High hopes that had initially been placed on antiviral drugs like remdesivir have so far not been fulfilled. While individual case reports provide striking evidence for the clinical efficacy of remdesivir in the right clinical settings, major trials failed to demonstrate this. Here, we highlight and discuss the key findings of these studies and underlying reasons for their failure. We elaborate on how such shortcomings should be prevented in future clinical trials and pandemics. We suggest in conclusion that any novel antiviral agent that enters human trials should first be tested in a post-exposure setting to provide rapid and solid evidence for its clinical efficacy before initiating further time-consuming and costly clinical trials for more advanced disease. In the COVID-19 pandemic this might have established remdesivir early on as an efficient antiviral agent at a more suitable disease stage which would have saved many lives, in particular in large outbreaks within residential care homes. KW - COVID-19 KW - SARS-CoV-2 KW - antiviral treatment KW - remdesivir Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-239648 SN - 1999-4915 VL - 13 IS - 6 ER - TY - JOUR A1 - Batool, Farwa A1 - Saeed, Muhammad A1 - Saleem, Hafiza Nosheen A1 - Kirschner, Luisa A1 - Bodem, Jochen T1 - Facile synthesis and in vitro activity of N-substituted 1,2-benzisothiazol-3(2H)-ones against dengue virus NS2BNS3 protease JF - Pathogens N2 - Several new N-substituted 1,2-benzisothiazol-3(2H)-ones (BITs) were synthesised through a facile synthetic route for testing their anti-dengue protease inhibition. Contrary to the conventional multistep synthesis, we achieved structurally diverse BITs with excellent yields using a two-step, one-pot reaction strategy. All the synthesised compounds were prescreened for drug-like properties using the online Swiss Absorption, Distribution, Metabolism and Elimination (SwissADME) model, indicating their favourable pharmaceutical properties. Thus, the synthesised BITs were tested for inhibitory activity against the recombinant dengue virus serotype-2 (DENV-2) NS2BNS3 protease. Dose–response experiments and computational docking analyses revealed that several BITs bind to the protease in the vicinity of the catalytic triad with IC\(_{50}\) values in the micromolar range. The DENV2 infection assay showed that two BITs, 2-(2-chlorophenyl)benzo[d]isothiazol-3(2H)-one and 2-(2,6-dichlorophenyl)benzo[d]isothiazol-3(2H)-one, could suppress DENV replication and virus infectivity. These results indicate the potential of BITs for developing new anti-dengue therapeutics. KW - dengue virus KW - direct-acting antivirals KW - 1,2-benzisothiazolinone KW - drug discovery KW - infectivity assays Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-236605 SN - 2076-0817 VL - 10 IS - 4 ER - TY - JOUR A1 - Ickrath, Pascal A1 - Sprügel, Lisa A1 - Beyersdorf, Niklas A1 - Scherzad, Agmal A1 - Hagen, Rudolf A1 - Hackenberg, Stephan T1 - Detection of Candida albicans-Specific CD4+ and CD8+ T Cells in the Blood and Nasal Mucosa of Patients with Chronic Rhinosinusitis JF - Journal of Fungi N2 - Candida albicans is ubiquitously present, and colonization in the nose and oral cavity is common. In healthy patients, it usually does not act as a pathogen, but in some cases can cause diseases. The influence of C. albicans as a trigger of T cell activation on the pathogenesis of chronic rhinosinusitis (CRS) is controversial, and its exact role is not clear to date. The aim of the present study was to detect and characterize C. albicans-specific CD4+ and CD8+ T cells in patients with CRS, with and without nasal polyps. Tissue and blood samples were collected from patients suffering from chronic rhinosinusitis with (CRSwNP) and without nasal polyps (CRSsNP), and from healthy controls. A peptide pool derived from C. albicans antigen was added to tissue and blood samples. After 6 days, lymphocytes were analyzed by multicolor flow cytometry. Activation was assessed by the intracellular marker Ki-67, and the cytokine secretion was measured. Tissue CD8+ T cells of CRSsNP patients showed a significantly higher proportion of Ki-67+ cells after activation with C. albicans antigen compared to peripheral blood CD8+ T cells. Cytokine secretion in response to C. albicans antigen was similar for all study groups. In this study, C. albicans-specific CD4+ and CD8+ T cells were detected in peripheral blood and mucosal tissue in all study groups. In patients suffering from CRSsNP, C. albicans-specific CD8+ T cells were relatively enriched in the nasal mucosa, suggesting that they might play a role in the pathogenesis of CRSsNP. KW - Candida albicans KW - chronic rhinosinusitis KW - T cell activation KW - nasal polyps Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-239671 SN - 2309-608X VL - 7 IS - 6 ER - TY - JOUR A1 - Goettsch, Winfried A1 - Beerenwinkel, Niko A1 - Deng, Li A1 - Dölken, Lars A1 - Dutilh, Bas E. A1 - Erhard, Florian A1 - Kaderali, Lars A1 - Kleist, Max von A1 - Marquet, Roland A1 - Matthijnssens, Jelle A1 - McCallin, Shawna A1 - McMahon, Dino A1 - Rattei, Thomas A1 - Van Rij, Ronald P. A1 - Robertson, David L. A1 - Schwemmle, Martin A1 - Stern-Ginossar, Noam A1 - Marz, Manja T1 - ITN—VIROINF: Understanding (harmful) virus-host interactions by linking virology and bioinformatics JF - Viruses N2 - Many recent studies highlight the fundamental importance of viruses. Besides their important role as human and animal pathogens, their beneficial, commensal or harmful functions are poorly understood. By developing and applying tailored bioinformatical tools in important virological models, the Marie Skłodowska-Curie Initiative International Training Network VIROINF will provide a better understanding of viruses and the interaction with their hosts. This will open the door to validate methods of improving viral growth, morphogenesis and development, as well as to control strategies against unwanted microorganisms. The key feature of VIROINF is its interdisciplinary nature, which brings together virologists and bioinformaticians to achieve common goals. KW - bioinformatic KW - virus KW - virology KW - virus host interaction Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-236687 SN - 1999-4915 VL - 13 IS - 5 ER - TY - JOUR A1 - Eckert, Ina N. A1 - Ribechini, Eliana A1 - Jarick, Katja J. A1 - Strozniak, Sandra A1 - Potter, Sarah J. A1 - Beilhack, Andreas A1 - Lutz, Manfred B. T1 - VLA-1 Binding to Collagen IV Controls Effector T Cell Suppression by Myeloid-Derived Suppressor Cells in the Splenic Red Pulp JF - Frontiers in Immunology N2 - Myeloid-derived suppressor cells (MDSCs) represent a major population controlling T cell immune responses. However, little is known about their molecular requirements for homing and T cell interaction to mediate suppression. Here, we investigated the functional role of the homing and collagen IV receptor VLA-1 (α1β1-integrin) on in vitro GM-CSF generated murine MDSCs from wild-type (WT) and CD49a/α1-integrin (Itga1\(^{−/−}\)) gene-deficient mice. Here, we found that effector (Teff) but not naive (Tn) CD4\(^+\) T cells express VLA-1 and monocytes further up-regulated their expression after culture in GM-CSF when they differentiated into the monocytic subset of resting MDSCs (R-MDSCs). Subsequent activation of R-MDSCs by LPS+IFN-γ (A-MDSCs) showed increased in vitro suppressor potential, which was independent of VLA-1. Surprisingly, VLA-1 deficiency did not influence A-MDSC motility or migration on collagen IV in vitro. However, interaction times of Itga1\(^{−/−}\) A-MDSCs with Teff were shorter than with WT A-MDSCs on collagen IV but not on fibronectin substrate in vitro. After injection, A-MDSCs homed to the splenic red pulp where they co-localized with Teff and showed immediate suppression already after 6 h as shown by inhibition of T cell proliferation and induction of apoptosis. Injection of A-MDSCs from Itga1\(^{−/−}\) mice showed equivalent homing into the spleen but a reduced suppressive effect. Interaction studies of A-MDSCs with Teff in the subcapsular red pulp with intravital two-photon microscopy revealed also here that MDSC motility and migration parameters were not altered by VLA-1 deficiency, but the interaction times with Teff were reduced. Together, our data point to a new role of VLA-1 adhesion to collagen IV as a prerequisite for extended contact times with Teff required for suppression. KW - myeloid-derived suppressor cells (MDSCs) KW - T cells KW - VLA-1 KW - homing KW - spleen Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-222671 SN - 1664-3224 VL - 11 ER - TY - INPR A1 - Hennig, Thomas A1 - Prusty, Archana B. A1 - Kaufer, Benedikt A1 - Whisnant, Adam W. A1 - Lodha, Manivel A1 - Enders, Antje A1 - Thomas, Julius A1 - Kasimir, Francesca A1 - Grothey, Arnhild A1 - Herb, Stefanie A1 - Jürges, Christopher A1 - Meister, Gunter A1 - Erhard, Florian A1 - Dölken, Lars A1 - Prusty, Bhupesh K. T1 - Selective inhibition of microRNA processing by a herpesvirus-encoded microRNA triggers virus reactivation from latency N2 - Herpesviruses have mastered host cell modulation and immune evasion to augment productive infection, life-long latency and reactivation thereof 1,2. A long appreciated, yet elusively defined relationship exists between the lytic-latent switch and viral non-coding RNAs 3,4. Here, we identify miRNA-mediated inhibition of miRNA processing as a novel cellular mechanism that human herpesvirus 6A (HHV-6A) exploits to disrupt mitochondrial architecture, evade intrinsic host defense and drive the latent-lytic switch. We demonstrate that virus-encoded miR-aU14 selectively inhibits the processing of multiple miR-30 family members by direct interaction with the respective pri-miRNA hairpin loops. Subsequent loss of miR-30 and activation of miR-30/p53/Drp1 axis triggers a profound disruption of mitochondrial architecture, which impairs induction of type I interferons and is necessary for both productive infection and virus reactivation. Ectopic expression of miR-aU14 was sufficient to trigger virus reactivation from latency thereby identifying it as a readily drugable master regulator of the herpesvirus latent-lytic switch. Our results show that miRNA-mediated inhibition of miRNA processing represents a generalized cellular mechanism that can be exploited to selectively target individual members of miRNA families. We anticipate that targeting miR-aU14 provides exciting therapeutic options for preventing herpesvirus reactivations in HHV-6-associated disorders like myalgic encephalitis/chronic fatigue syndrome (ME/CFS) and Long-COVID. KW - Herpesvirus KW - HHV-6 KW - miRNA processing KW - miR-30 KW - mitochondria KW - fusion and fission KW - type I interferon KW - latency KW - virus reactivation Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-267858 UR - https://doi.org/10.21203/rs.3.rs-820696/v1 ET - submitted version ER - TY - THES A1 - Gasparyan [geb. Düver], Franziska T1 - Virale Reaktivierungen nach allogener Stammzelltransplantation bei Kindern T1 - Viral reactivations following hematopoietic stem cell transplantation in pediatric patients N2 - Virale Reaktivierungen treten im Rahmen der Immundefizienz und Immunsuppression nach allogener Stammzelltransplantation häufig auf und können zu schwerwiegenden Komplikationen führen. Ziel dieser retrospektiven Studie war die Charakterisierung von viralen Reaktivierungen im ersten Jahr nach allogener Stammzelltransplantation, die Identifikation von Risikofaktoren sowie die Untersuchung des Einflusses viraler Reaktivierungen auf das Transplantationsoutcome. 107 pädiatrische allogene Stammzelltransplantationen im Zeitrahmen von Januar 2005 bis Dezember 2015 wurden in diesem Zusammenhang auf Infektionen mit dem Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), Humanen Herpesvirus 6 (HHV 6), Herpes simplex Virus (HSV), Varicella zoster Virus (VZV) und Adenovirus (ADV) untersucht. N2 - Viral reactivation occurs frequently in the context of immunodeficiency and immunosuppression after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and can cause severe complications. The aim of this single-center retrospective analysis was to characterize viral infections in the first year after HSCT, to investigate risk factors and to study the impact of viral infections on transplantation outcome. 107 pediatric allo-HSCT from January 2005 through December 2015 were analyzed for infections with Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpesvirus 6 (HHV 6), herpes simplex virus (HSV), varicella zoster virus (VZV) and adenovirus (ADV). KW - Stammzelltransplantation KW - Pädiatrie KW - Reaktivierung KW - Virusinfektion KW - EBV KW - CMV KW - HHV 6 KW - Adenoviren KW - Herpes simplex KW - Varicella zoster Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-243537 ER - TY - JOUR A1 - Haack, Stephanie A1 - Baiker, Sarah A1 - Schlegel, Jan A1 - Sauer, Markus A1 - Sparwasser, Tim A1 - Langenhorst, Daniela A1 - Beyersdorf, Niklas T1 - Superagonistic CD28 stimulation induces IFN‐γ release from mouse T helper 1 cells in vitro and in vivo JF - European Journal of Immunology N2 - Like human Th1 cells, mouse Th1 cells also secrete IFN‐γ upon stimulation with a superagonistic anti‐CD28 monoclonal antibody (CD28‐SA). Crosslinking of the CD28‐SA via FcR and CD40‐CD40L interactions greatly increased IFN‐γ release. Our data stress the utility of the mouse as a model organism for immune responses in humans. KW - CD28 KW - Th1 cells KW - cytokine release KW - interferon γ KW - Superagonistic antibody Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-239028 VL - 51 IS - 3 SP - 738 EP - 741 ER - TY - JOUR A1 - Morbach, Caroline A1 - Beyersdorf, Niklas A1 - Kerkau, Thomas A1 - Ramos, Gustavo A1 - Sahiti, Floran A1 - Albert, Judith A1 - Jahns, Roland A1 - Ertl, Georg A1 - Angermann, Christiane E. A1 - Frantz, Stefan A1 - Hofmann, Ulrich A1 - Störk, Stefan T1 - Adaptive anti-myocardial immune response following hospitalization for acute heart failure JF - ESC Heart Failure N2 - Aims It has been hypothesized that cardiac decompensation accompanying acute heart failure (AHF) episodes generates a pro-inflammatory environment boosting an adaptive immune response against myocardial antigens, thus contributing to progression of heart failure (HF) and poor prognosis. We assessed the prevalence of anti-myocardial autoantibodies (AMyA) as biomarkers reflecting adaptive immune responses in patients admitted to the hospital for AHF, followed the change in AMyA titres for 6 months after discharge, and evaluated their prognostic utility. Methods and results AMyA were determined in n = 47 patients, median age 71 (quartiles 60; 80) years, 23 (49%) female, and 24 (51%) with HF with preserved ejection fraction, from blood collected at baseline (time point of hospitalization) and at 6 month follow-up (visit F6). Patients were followed for 18 months (visit F18). The prevalence of AMyA increased from baseline (n = 21, 45%) to F6 (n = 36, 77%; P < 0.001). At F6, the prevalence of AMyA was higher in patients with HF with preserved ejection fraction (n = 21, 88%) compared with patients with reduced ejection fraction (n = 14, 61%; P = 0.036). During the subsequent 12 months after F6, that is up to F18, patients with newly developed AMyA at F6 had a higher risk for the combined endpoint of death or rehospitalization for HF (hazard ratio 4.79, 95% confidence interval 1.13–20.21; P = 0.033) compared with patients with persistent or without AMyA at F6. Conclusions Our results support the hypothesis that AHF may induce patterns of adaptive immune responses. More studies in larger populations and well-defined patient subgroups are needed to further clarify the role of the adaptive immune system in HF progression. KW - adaptive immune response KW - acute heart failure KW - anti-myocardial KW - autoantibody KW - inflammation Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-258907 VL - 8 IS - 4 ER - TY - JOUR A1 - Liu, Fengming A1 - Han, Kun A1 - Blair, Robert A1 - Kenst, Kornelia A1 - Qin, Zhongnan A1 - Upcin, Berin A1 - Wörsdörfer, Philipp A1 - Midkiff, Cecily C. A1 - Mudd, Joseph A1 - Belyaeva, Elizaveta A1 - Milligan, Nicholas S. A1 - Rorison, Tyler D. A1 - Wagner, Nicole A1 - Bodem, Jochen A1 - Dölken, Lars A1 - Aktas, Bertal H. A1 - Vander Heide, Richard S. A1 - Yin, Xiao-Ming A1 - Kolls, Jay K. A1 - Roy, Chad J. A1 - Rappaport, Jay A1 - Ergün, Süleyman A1 - Qin, Xuebin T1 - SARS-CoV-2 Infects Endothelial Cells In Vivo and In Vitro JF - Frontiers in Cellular and Infection Microbiology N2 - SARS-CoV-2 infection can cause fatal inflammatory lung pathology, including thrombosis and increased pulmonary vascular permeability leading to edema and hemorrhage. In addition to the lung, cytokine storm-induced inflammatory cascade also affects other organs. SARS-CoV-2 infection-related vascular inflammation is characterized by endotheliopathy in the lung and other organs. Whether SARS-CoV-2 causes endotheliopathy by directly infecting endothelial cells is not known and is the focus of the present study. We observed 1) the co-localization of SARS-CoV-2 with the endothelial cell marker CD31 in the lungs of SARS-CoV-2-infected mice expressing hACE2 in the lung by intranasal delivery of adenovirus 5-hACE2 (Ad5-hACE2 mice) and non-human primates at both the protein and RNA levels, and 2) SARS-CoV-2 proteins in endothelial cells by immunogold labeling and electron microscopic analysis. We also detected the co-localization of SARS-CoV-2 with CD31 in autopsied lung tissue obtained from patients who died from severe COVID-19. Comparative analysis of RNA sequencing data of the lungs of infected Ad5-hACE2 and Ad5-empty (control) mice revealed upregulated KRAS signaling pathway, a well-known pathway for cellular activation and dysfunction. Further, we showed that SARS-CoV-2 directly infects mature mouse aortic endothelial cells (AoECs) that were activated by performing an aortic sprouting assay prior to exposure to SARS-CoV-2. This was demonstrated by co-localization of SARS-CoV-2 and CD34 by immunostaining and detection of viral particles in electron microscopic studies. Moreover, the activated AoECs became positive for ACE-2 but not quiescent AoECs. Together, our results indicate that in addition to pneumocytes, SARS-CoV-2 also directly infects mature vascular endothelial cells in vivo and ex vivo, which may contribute to cardiovascular complications in SARS-CoV-2 infection, including multipleorgan failure. KW - endothelial cell infection KW - animal models KW - SARS-CoV-2 KW - aorta ring KW - hACE2 Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-241948 SN - 2235-2988 VL - 11 ER - TY - JOUR A1 - Schneider-Schaulies, Sibylle A1 - Schumacher, Fabian A1 - Wigger, Dominik A1 - Schöl, Marie A1 - Waghmare, Trushnal A1 - Schlegel, Jan A1 - Seibel, Jürgen A1 - Kleuser, Burkhard T1 - Sphingolipids: effectors and Achilles heals in viral infections? JF - Cells N2 - As viruses are obligatory intracellular parasites, any step during their life cycle strictly depends on successful interaction with their particular host cells. In particular, their interaction with cellular membranes is of crucial importance for most steps in the viral replication cycle. Such interactions are initiated by uptake of viral particles and subsequent trafficking to intracellular compartments to access their replication compartments which provide a spatially confined environment concentrating viral and cellular components, and subsequently, employ cellular membranes for assembly and exit of viral progeny. The ability of viruses to actively modulate lipid composition such as sphingolipids (SLs) is essential for successful completion of the viral life cycle. In addition to their structural and biophysical properties of cellular membranes, some sphingolipid (SL) species are bioactive and as such, take part in cellular signaling processes involved in regulating viral replication. It is especially due to the progress made in tools to study accumulation and dynamics of SLs, which visualize their compartmentalization and identify interaction partners at a cellular level, as well as the availability of genetic knockout systems, that the role of particular SL species in the viral replication process can be analyzed and, most importantly, be explored as targets for therapeutic intervention. KW - glycosphingolipids KW - ceramides KW - sphingosine 1-phosphate KW - sphingomyelinase KW - HIV KW - SARS-CoV-2 KW - measles Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-245151 SN - 2073-4409 VL - 10 IS - 9 ER - TY - THES A1 - Haack, Stephanie T1 - A novel mouse model for systemic cytokine release upon treatment with a superagonistic anti-CD28 antibody T1 - Ein neues Mausmodell zur Untersuchung der Zytokinfreisetzung nach Behandlung mit einem superagonistischen anti-CD28 Antikörper N2 - The adaptive immune system is known to provide highly specific and effective immunity against a broad variety of pathogens due to different effector cells. The most prominent are CD4+ T-cells which differentiate after activation into distinct subsets of effector and memory cells, amongst others T helper 1 (Th1) cells. We have recently shown that mouse as well as human Th1 cells depend on T cell receptor (TCR) signals concomitant with CD28 costimulation in order to secrete interferon  (IFN) which is considered as their main effector function. Moreover, there is a class of anti-CD28 monoclonal antibodies that is able to induce T cell (re-)activation without concomitant TCR ligation. These so-called CD28-superagonists (CD28-SA) have been shown to preferentially activate and expand CD4+ Foxp3+ regulatory T (Treg) cells and thereby efficaciously conferring protection e.g. against autoimmune responses in rodents and non-human primates. Considering this beneficial effect, CD28-SA were thought to be of great impact for immunotherapeutic approaches and a humanized CD28-SA was subjected to clinical testing starting with a first-in-man trial in London in 2006. Unexpectedly, the volunteers experienced life-threatening side effects due to a cytokine release syndrome (CRS) that was unpredicted by the preclinical studies prior to the trial. Retrospectively, CD4+ memory T cells within the tissues were identified as source of pro-inflammatory cytokines released upon CD28-SA administration. This was not predicted by the preclinical testing indicating a need for more reliable and predictive animal models. Whether mouse CD4+ T cells are generally irresponsive to CD28-SA stimulation or rather the lack of a bona fide memory T cell compartment in cleanly housed specific-pathogen-free (SPF) mice is the reason why the rodent models failed to predict the risk for a CRS remained unclear. To provide SPF mice with a true pool of memory/effector T cells, we transferred in vitro differentiated TCR-transgenic OT-II Th1 cells into untreated recipient mice. Given that Treg cells suppress T cell activation after CD28- SA injection in vivo, recipients were either Treg-competent or Treg-deficient, wild type or DEREG mice, respectively. Subsequent CD28-SA administration resulted in induction of systemic pro-inflammatory cytokine release, dominated by IFN, that was observed to be much more pronounced and robust in Treg-deficient recipients. Employing a newly established in vitro system mirroring the in vivo responses to CD28-SA stimulation of Th1 cells revealed that antigen-presenting cells (APCs) amplify CD28-SAinduced IFN release by Th1 cells due to CD40/CD40L-interactions. Thus, these data are the first to show that mouse Th1 cells are indeed sensitive to CD28-SA stimulation in vivo and in vitro responding with strong IFN release accompanied by secretion of further pro-inflammatory cytokines, which is compatible with a CRS. In conclusion, this study will facilitate preclinical testing of immunomodulatory agents providing a mouse model constituting more “human-like” conditions allowing a higher degree of reliability and translationability. N2 - Das adaptive Immunsystem ermöglicht mittels hocheffektiver, antigen-spezifischer Mechanismen und unterschiedlicher Effektorzellen den Schutz vor einer nahezu unbegrenzten Vielfalt von Pathogenen. Die Hauptakteure stellen hierbei CD4+ T-Zellen dar, welche nach Aktivierung distinkte Effektorpopulationen, unter anderem Th1 Zellen, bilden. Wir zeigten kürzlich, dass sowohl für Maus- als auch humane Th1-Zellen CD28-Kostimulation mit zeitgleicher T-Zellrezeptor (TZR)-Aktivierung essentiell für die Sekretion von Interferon  (IFN), deren Haupteffektorfunktion, ist. Allerdings sind monoklonale anti-CD28 Anti-körper bekannt, die auch ohne TZR-Signal T-Zellen aktivieren können. Diese sogenannten CD28 Supera-gonisten (CD28-SA) aktivieren und expandieren vorrangig CD4+ Foxp3+ regulatorische T-Zellen (Treg) und vermitteln wirksamen Schutz vor z.B. Autoimmunreaktionen in Nagern und Primaten. Um diesen erfolgversprechenden Effekt für immuntherapeutische Ansätze nutzen zu können, wurde 2006 in Lon-don eine erste klinische Erprobung eines humanisierten CD28-SA begonnen. Unerwarteterweise zeigten sich bei den Probanden lebensbedrohliche Nebenwirkungen, die Ausdruck eines Zytokin-Ausschüttungs-Syndroms (Cytokine Release Syndrome, CRS) waren, welches durch die vorangegangenen präklinischen Studien nicht vorhersagbar war. Rückblickend konnte die Sekretion pro-inflammatorischer Zytokine auf CD4+ Gedächtnis-T-Zellen im Gewebe zurückgeführt werden, die so auf die Gabe des CD28-SA reagier-ten. Die unvorhersehbare Reaktion im Menschen zeigt deutlich, dass verlässlichere und prädiktivere Tiermodelle unverzichtbar sind. Ob Maus CD4+-T-Zellen möglicherweise nicht durch CD28-SA stimulier-bar sind oder dieser fehlgeleiteten Einschätzung über das mögliche Risiko eines CRS eher das Fehlen eines echten CD4+ Gedächtnis-T-Zellen-Kompartiments in sauber gehaltenen spezifischen-Pathogen-freien (SPF) Mäusen zugrunde liegt, ist bisher ungeklärt. Um in SPF-Mäusen ein Gedächtnis-T-Zell-Kompartiment zu etablieren, wurden in vitro-differenzierte Th1 Zellen, die TZR-transgenen OT-II-Mäusen entstammen, in unbehandelte Empfängermäuse transferiert. Da bekannt ist, dass Treg-Zellen die Aktivierung von T-Zellen nach Anwendung von CD28-SA in vivo supprimieren, wurden Treg-kompetente (wildtypische) oder -defiziente (DEREG) Empfänger verwendet. Die anschließend erfolgte Injektion von CD28-SA löste die systemische Sekretion pro-inflammatorischer Zytokine aus, wobei eine stark erhöhter IFN-Konzentration im Serum zu beobachten war, welche deutlich ausgeprägter und robuster bei den Treg-defizienten Empfängern ausfiel. Ein neu etabliertes in vitro-System, welches die in vivo Antwort der Th1-Zellen auf CD28-SA-Stimulation widerspiegelt, identifizierte Antigen-präsentierende Zellen (APZs) als essentiellen Faktor für die erhöhte IFN-Sekretion der Th1-Zellen nach CD28-SA-Stimulation in Abhängigkeit von CD40/CD40L-Interaktionen. Zusammenfassend zeigt diese Thesis zum ersten Mal, dass Maus Th1 Zellen sowohl in vivo als auch in vitro durch CD28 SA stimulierbar sind, wodurch eine starke IFN-Sekretion induziert wird, die von der gesteigerten Ausschüttung anderer pro-inflammatorischer Zytokine begleitet wird und in Abwesenheit von Treg einem CRS gleicht. Folglich kann diese Erkenntnis die präklinische Forschung bei der Erprobung neuer immuntherapeutischer Ansät-ze durch ein neues Mausmodell voranbringen, das dem menschlichen erfahreneren Immunsystem mehr als bisherige Modelle entspricht und somit verlässlichere Vorhersagen erlaubt und eine verbesserte Übertragbarkeit von Maus zu Mensch ermöglicht. KW - CD28 KW - CD28-SA KW - cytokine release syndrome Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-237757 ER - TY - JOUR A1 - Krüger, Sören A1 - Leskien, Miriam A1 - Schuller, Patricia A1 - Prifert, Christiane A1 - Weißbrich, Benedikt A1 - Vogel, Ulrich A1 - Krone, Manuel T1 - Performance and feasibility of universal PCR admission screening for SARS‐CoV‐2 in a German tertiary care hospital JF - Journal of Medical Virology N2 - Anamnestic screening of symptoms and contact history is applied to identify coronavirus disease 2019 (COVID‐19) patients on admission. However, asymptomatic and presymptomatic patients remain undetected although the viral load may be high. In this retrospective cohort study, all hospitalized patients who received polymerase chain reaction (PCR) admission testing from March 26th until May 24th, 2020 were included. Data on COVID‐19‐specific symptoms and contact history to COVID‐19 cases were retrospectively extracted from patient files and from contact tracing notes. The compliance to the universal testing protocol was high with 90%. Out of 6940 tested patients, 27 new severe acute respiratory syndrome coronavirus‐2 infections (0.4%) were detected. Seven of those COVID‐19 cases (26% of all new cases) were asymptomatic and had no positive contact history, but were identified through a positive PCR test. The number needed to identify an asymptomatic patient was 425 in the first wave of the epidemic, 1218 in the low incidence phase. The specificity of the method was above 99.9%. Universal PCR testing was highly accepted by staff as demonstrated by high compliance. The costs to detect one asymptomatic case in future studies need to be traded off against the costs and damage caused by potential outbreaks of COVID‐19. KW - admission screening KW - COVID‐19 KW - infection control KW - SARS‐CoV‐2 KW - testing strategy Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-238971 VL - 93 IS - 5 SP - 2890 EP - 2898 ER - TY - JOUR A1 - Thomann, Anna Sophie A1 - Schneider, Theresa A1 - Cyran, Laura A1 - Eckert, Ina Nathalie A1 - Kerstan, Andreas A1 - Lutz, Manfred B. T1 - Conversion of Anergic T Cells Into Foxp3\(^-\) IL-10\(^+\) Regulatory T Cells by a Second Antigen Stimulus In Vivo JF - Frontiers in Immunology N2 - T cell anergy is a common mechanism of T cell tolerance. However, although anergic T cells are retained for longer time periods in their hosts, they remain functionally passive. Here, we describe the induction of anergic CD4\(^+\) T cells in vivo by intravenous application of high doses of antigen and their subsequent conversion into suppressive Foxp3\(^-\) IL-10\(^+\) Tr1 cells but not Foxp3\(^+\) Tregs. We describe the kinetics of up-regulation of several memory-, anergy- and suppression-related markers such as CD44, CD73, FR4, CD25, CD28, PD-1, Egr-2, Foxp3 and CTLA-4 in this process. The conversion into suppressive Tr1 cells correlates with the transient intracellular CTLA-4 expression and required the restimulation of anergic cells in a short-term time window. Restimulation after longer time periods, when CTLA-4 is down-regulated again retains the anergic state but does not lead to the induction of suppressor function. Our data require further functional investigations but at this stage may suggest a role for anergic T cells as a circulating pool of passive cells that may be re-activated into Tr1 cells upon short-term restimulation with high and systemic doses of antigen. It is tentative to speculate that such a scenario may represent cases of allergen responses in non-allergic individuals. KW - T cells KW - anergy KW - Tr1 KW - conversion KW - in vivo Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-241429 SN - 1664-3224 VL - 12 ER - TY - JOUR A1 - Liang, Chunguang A1 - Bencurova, Elena A1 - Psota, Eric A1 - Neurgaonkar, Priya A1 - Prelog, Martina A1 - Scheller, Carsten A1 - Dandekar, Thomas T1 - Population-predicted MHC class II epitope presentation of SARS-CoV-2 structural proteins correlates to the case fatality rates of COVID-19 in different countries JF - International Journal of Molecular Sciences N2 - We observed substantial differences in predicted Major Histocompatibility Complex II (MHCII) epitope presentation of SARS-CoV-2 proteins for different populations but only minor differences in predicted MHCI epitope presentation. A comparison of this predicted epitope MHC-coverage revealed for the early phase of infection spread (till day 15 after reaching 128 observed infection cases) highly significant negative correlations with the case fatality rate. Specifically, this was observed in different populations for MHC class II presentation of the viral spike protein (p-value: 0.0733 for linear regression), the envelope protein (p-value: 0.023), and the membrane protein (p-value: 0.00053), indicating that the high case fatality rates of COVID-19 observed in some countries seem to be related with poor MHC class II presentation and hence weak adaptive immune response against these viral envelope proteins. Our results highlight the general importance of the SARS-CoV-2 structural proteins in immunological control in early infection spread looking at a global census in various countries and taking case fatality rate into account. Other factors such as health system and control measures become more important after the early spread. Our study should encourage further studies on MHCII alleles as potential risk factors in COVID-19 including assessment of local populations and specific allele distributions. KW - COVID-19 KW - population coverage KW - MHC II KW - MHC I KW - B-cell KW - T-cell KW - epitope mapping KW - lethality rate KW - infection spread KW - SARS-CoV-2 Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-258936 SN - 1422-0067 VL - 22 IS - 5 ER - TY - JOUR A1 - Avota, Elita A1 - Bodem, Jochen A1 - Chithelen, Janice A1 - Mandasari, Putri A1 - Beyersdorf, Niklas A1 - Schneider-Schaulies, Jürgen T1 - The Manifold Roles of Sphingolipids in Viral Infections JF - Frontiers in Physiology N2 - Sphingolipids are essential components of eukaryotic cells. In this review, we want to exemplarily illustrate what is known about the interactions of sphingolipids with various viruses at different steps of their replication cycles. This includes structural interactions during entry at the plasma membrane or endosomal membranes, early interactions leading to sphingolipid-mediated signal transduction, interactions with internal membranes and lipids during replication, and interactions during virus assembly and budding. Targeted interventions in sphingolipid metabolism – as far as they can be tolerated by cells and organisms – may open novel possibilities to support antiviral therapies. Human immunodeficiency virus type 1 (HIV-1) infections have intensively been studied, but for other viral infections, such as influenza A virus (IAV), measles virus (MV), hepatitis C virus (HCV), dengue virus, Ebola virus, and severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), investigations are still in their beginnings. As many inhibitors of sphingolipid metabolism are already in clinical use against other diseases, repurposing studies for applications in some viral infections appear to be a promising approach. KW - sphingolipid KW - ceramide KW - sphingosine-1-phosphate KW - plasma membrane KW - virus entry KW - virus replication KW - virus budding Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-246975 SN - 1664-042X VL - 12 ER - TY - JOUR A1 - Zimniak, Melissa A1 - Kirschner, Luisa A1 - Hilpert, Helen A1 - Geiger, Nina A1 - Danov, Olga A1 - Oberwinkler, Heike A1 - Steinke, Maria A1 - Sewald, Katherina A1 - Seibel, Jürgen A1 - Bodem, Jochen T1 - The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue JF - Scientific Reports N2 - To circumvent time-consuming clinical trials, testing whether existing drugs are effective inhibitors of SARS-CoV-2, has led to the discovery of Remdesivir. We decided to follow this path and screened approved medications "off-label" against SARS-CoV-2. Fluoxetine inhibited SARS-CoV-2 at a concentration of 0.8 mu g/ml significantly in these screenings, and the EC50 was determined with 387 ng/ml. Furthermore, Fluoxetine reduced viral infectivity in precision-cut human lung slices showing its activity in relevant human tissue targeted in severe infections. Fluoxetine treatment resulted in a decrease in viral protein expression. Fluoxetine is a racemate consisting of both stereoisomers, while the S-form is the dominant serotonin reuptake inhibitor. We found that both isomers show similar activity on the virus, indicating that the R-form might specifically be used for SARS-CoV-2 treatment. Fluoxetine inhibited neither Rabies virus, human respiratory syncytial virus replication nor the Human Herpesvirus 8 or Herpes simplex virus type 1 gene expression, indicating that it acts virus-specific. Moreover, since it is known that Fluoxetine inhibits cytokine release, we see the role of Fluoxetine in the treatment of SARS-CoV-2 infected patients of risk groups. KW - SARS-CoV-2 KW - viral epidemiology KW - viral infection Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-259820 VL - 11 ER - TY - THES A1 - Lehnert, Jonathan T1 - Einfluss von Osteopontin auf Foxp3-negative konventionelle und Foxp3-positive regulatorische CD4-positive T-Zellen der Maus T1 - Effect of Osteopontin on CD4+ CD25+ Foxp3+ regulatory T-cells and CD4+ CD25- Foxp3- conventional T-cells N2 - In dieser Arbeit wurde der Einfluss des Zytokins OPN speziell auf CD4+ CD25+ Foxp3+- regulatorische bzw. CD4+ CD25- Foxp3-- konventionelle T-Zellen mithilfe v.a. durchflusszytometrischer Daten untersucht. Es konnte gezeigt werden, dass rekombinantes OPN die Supprimierbarkeit von konventionellen T-Zellen aus OPN-Knock-out-Tieren durch regulatorische T-Zellen aus Wildtyp- oder OPN-KO-Tieren erhöht. Die Supprimierbarkeit von wildtypischen Tconv-Zellen wird durch OPN jedoch nicht beeinflusst. N2 - The effect of OPN on CD4+ CD25+ Foxp3+- Trag and CD4+ CD25- Foxp3- Tconv-cells was analyzed through FACS-analysis. It could be shown that OPN increases the suppression of Tconv from OPN-knock-out mice through Treg from WT or knock-out mice. KW - OPN KW - T-cells KW - Osteopontin KW - Treg KW - Tconv KW - T-Zellen Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-199460 ER - TY - THES A1 - Dennstädt, Fabio Stefan T1 - Modulation CD4+ humaner Treg- und Tconv-Zellen durch Inhibition der sauren Sphingomyelinase in vitro T1 - Modulation of CD4+ human Treg and Tconv cells by inhibition of the acid sphingomyelinase in vitro N2 - Die saure Sphingomyelinase (ASM) stellt durch die Umwandlung von Sphingomyelin in Ceramid und Phosphorylcholin ein zentrales, fein reguliertes Enzym im Sphingolipidmetabolismus dar. Dadurch nimmt es Einfluss auf verschiedene zelluläre Mechanismen wie Signalvermittlung, Endo- und Exozytose und Zellaktivierung. Dementsprechend weitreichend ist auch die Bedeutung der ASM bei verschiedenen Krankheiten wie Arteriosklerose, Depression oder Neoplasien. Auch auf das Immunsystem, insbesondere auf die Signalvermittlung durch T-Zellen innerhalb des adaptiven Immunsystems, nimmt die saure Sphingomyelinase Einfluss. Aufbauend auf früheren Forschungsarbeiten zur pharmakologischen und genetischen Hemmung der ASM im Mausmodell untersuchten wir, welche Auswirkungen die Hemmung dieses Enzyms in humanen Zellkulturen auf die Population regulatorischer und konventioneller T-Zellen haben. Hierzu verwendeten wir die beiden selektiven Serotonin-Wiederaufnahmehemmer Sertralin und Citalopram; zwei antidepressiv wirksame Medikamente, die durch eine Verdrängung der ASM von der lysosomalen Membran eine hemmende Wirkung ausüben. Wir konnten zeigen, dass diese beiden Substanzen sowohl in Maus-T-Zellen, als auch in humanen T-Zellen, in der Lage sind, die Aktivität der sauren Sphingomyelinase zu inhibieren. Durch Kultivierung von Immunzellen der Maus zusammen mit den Inhibitoren konnte darüber hinaus eine Erhöhung der Treg-Zellfrequenz erreicht werden. Verschiedene Zellkulturexperimente mit humanen PBMCs zeigten weiterhin, dass unter gewissen Umständen so auch eine Vermehrung regulatorischer T-Zellen im Menschen möglich ist, und dass dies mutmaßlich durch Einbindung der ASM im CD3/CD28-Signalweg bedingt ist. In mit AntiCD3-Antikörper stimulierten experimentellen Ansätzen kam es jedoch nur bei einzelnen Individuen, die als Responder identifiziert werden konnten, zu einer Treg-Zellvermehrung. Umgekehrt kam es durch externe Zugabe von C6-Ceramid zu einer Verringerung des Anteils an regulatorischen T-Zellen. Des Weiteren wurden verschiedene Veränderungen im Expressionsverhalten von Treg- und Tconv-Zellen bezüglich CD25, CD69 und CTLA-4 in Anwesenheit der ASMInhibitoren beobachtet. Weiterhin bestätigte sich, dass die pharmakologische Hemmung der sauren Sphingomyelinase auch Auswirkungen auf die Effektorfunktion von T-Zellen hat. Während die Proliferation der Zellen weitgehend unbeeinträchtigt blieb, kam es zu einer verringerten Sekretion der Zytokine IFN-gamma, TNF, IL-5 und IL-10. In ihrer Gesamtheit sprechen diese Ergebnisse dafür, dass Inhibitoren der sauren Sphingomyelinase begünstigend auf Krankheitsgeschehen mit überschießender oder dysregulierter Aktivität des Immunsystems einwirken könnten. Immunmodulatorischen Wirkungen durch Inhibition der ASM erklären möglicherweise auch Einflüsse auf das Immunsystem, die für verschiedene Antidepressiva beschrieben wurden. Insgesamt ist die Bedeutung der sauren Sphingomyelinase innerhalb der Regulation des adaptiven Immunsystems jedoch noch ein weitgehend ungeklärtes Thema mit vielen offenen Fragen. Daher ist auch in Zukunft weitere klinische und experimentelle Forschung erforderlich, um zu klären, welchen Einfluss dieses Enzyms auf Immunzellen hat und wie sich dieser auch klinisch anwenden lässt. N2 - By catalyzing the transformation of sphingomyeline into ceramide and phosphocholine, the acid sphingomyelinase (ASM) plays a central role in the metabolism of sphingolipids and is tightly regulated. Therefore it takes essential influence upon different cellular mechanisms like signal transduction, endo-/exocytosis and cell activation. Accordingly complex is the importance of the ASM in different diseases like atherosclerosis, depression or neoplastic diseases. The acid sphingomyelinase also greatly influences the signal mediation of T cells within the adaptive immune system. Based on previous research about the pharmacological and genetic inhibition of the ASM in mice we investigated, which impact an inhibition of this enzyme in human cell cultures may have on the populations of regulatory and conventional T cells. Therefore we mostly used the two selective serotonin reuptake inhibitors sertraline and citalopram. These two antidepressive drugs detach the ASM from the lysosomal membrane and thereby inhibit the enzyme. Here we show, that these two substances efficiently inhibit the ASM mice T cells as well as human T cells. Cultivating immune cells of mice together with the inhibitors led to an essential increase in the frequency of regulatory T cells. Various cell culture experiments with human PBMCs showed that under certain circumstances an increase in regulatory T cells is also possible in the human, most likely due to the involvement of the ASM in the CD3/CD28 signal pathway. Experimental approaches using � CD3-antibodies showed an increase in Treg cells in a fraction of the tested individuals. External addition of C6-ceramide led to a decrease in the frequency of regulatory T cells. In addition to that, we were able to observe diverse effects regarding the expression of CD25, CD69 and CTLA-4 in Treg and Tconv cells in the presence of the ASM-inhibitors. We were also able to confirm that the pharmacological inhibition of the acid sphingomyelinase has an impact on the effector functions of T cells. While there was no effect on cell proliferation, we observed a decreased secretion of the cytokines IFN-gamma, TNF, IL-5 and IL-10. Alltogether these results indicate that inhibitors of the acid sphingomyelinase might have positive effects in pathologies of overshooting or dysregulated activity of the immune system. Immunomodulatory effects after inhibition of the ASM might also explain observations of an influence of antidepressants on the immune system that have been described in the literature. Overall the importance of the acid sphingomyelinase within the regulation of the adaptive immune system is a new field of research with many open questions. Therefore further clinical and experimental research is needed to clarify, which impact this enzyme has on immune cells and how this impact might be used therapeutically. KW - T-Lymphozyt KW - Regulatorischer T-Lymphozyt KW - Serotonin-Reuptake-Hemmer KW - Sphingolipide KW - Sphingomyelinphosphodiesterase KW - Saure Sphingomyelinase KW - ASM-Inhibition KW - Regulatorische T-Zellen KW - Serotonin-Wiederaufnahmehemmer KW - Sphingolipidstoffwechsel KW - Ceramid KW - Sphingomyelin KW - Sertralin KW - Citalopram Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-205420 ER - TY - THES A1 - Börner, Kevin T1 - How CLEC16A modifies the function of thymic epithelial cells T1 - Wie CLEC16A die Funktion von Thymus-Epithelzellen beeinflusst N2 - Genomweite Assoziationsstudien haben CLEC16A als ein Suszeptibilitätsgen für Typ 1 Diabetes und weitere Autoimmunerkrankungen identifiziert. Die genaue Funktion von CLEC16A bleibt jedoch ungeklärt. Studien zeigten, dass sowohl das Drosophila Ortholog ema als auch das murine Clec16a eine Rolle in Autophagie spielen. Autophagie trägt zur Beladung der MHC-Klasse-II Moleküle und somit der Antigenpräsentation bei. Darüber hinaus konnten Studien belegen, dass Autophagie zur Antigenpräsentation während der T-Zell Selektion in Thymus-Epithelzellen benötigt wird. Dies schlägt eine mögliche Funktion von CLEC16A in Thymus-Epithelzellen während der T-Zell Selektion vor. Außerdem berichteten Arbeiten, dass CLEC16A als quantitativer Trait Locus für seine Nachbargene fungiert und dass Clec16a KD in Langerhans Inseln im Pankreas die Insulinsekretion und den Glukosestoffwechsel beeinträchtigt. Dieser Arbeit vorausgehend hatten Schuster et al. eine Clec16a KD NOD Maus generiert, welche vor spontanem autoimmunem Diabetes geschützt war. Für diese Arbeit wurde vermutet, dass CLEC16A als Suszeptibilitätsgen für Typ 1 Diabetes den Prozess der Autophagie in Thymus-Epithelzellen beeinträchtigt und somit Antigenpräsentation und das T-Zell Repertoire beeinflusst. Um auf der Vorarbeit von Schuster et al. aufzubauen und diese zu ergänzen, zielte diese Arbeit darauf ab, den Einfluss von CLEC16A auf Thymus-Epithelzellen zu untersuchen. Hierfür wurde ein CLEC16A KD in menschlichen Zellen mittels RNA Interferenz erzeugt und Autophagie durch Immunoblotting untersucht. Zusätzlich wurde die Entzündung im Pankreasgewebe von Clec16a KD NOD Mäusen mittels H.E. Färbung beurteilt und bewertet. Thymus-Transplanationen wurden durchgeführt, um zu sehen, ob der Einfluss von Clec16a KD T-Zell intrinsisch ist. Außerdem wurden intraperitoneale Glukosetoleranztests durchgeführt, um den Blutzuckerstoffwechsel in Clec16a KD Mäusen zu beurteilen. Schließlich wurden mittels qPCR Expressionslevel der benachbarten Gene, wie zum Beispiel Dexi und Socs1, erhoben, um die Eigenschaften von CLEC16A als quantitativer Trait Locus einzuordnen. Gemeinsam mit den Ergebnissen von Schuster et al. kann diese Arbeit aufzeigen, dass Clec16a KD die Ausprägung von Insulitis im Pankreas reduziert und Clec16a KD NOD Mäuse vor spontanem Autoimmundiabetes schützt. Dieser Schutz vor Erkrankung wird durch beeinträchtigte Autophagie in Thymus-Epithelzellen hervorgerufen, welche die T-Zell Selektion beeinflusst und die Reaktivität von T-Zellen reduziert. Der Einfluss des Clec16a KD ist innerhalb des Thymus wirksam. Der Blutzuckerstoffwechsel in Clec16a KD NOD Mäusen bleibt unverändert und kann deshalb als Ursache für den Schutz vor Type 1 Diabetes ausgeschlossen werden. Clec16a und Dexi zeigen ähnliche Expressionslevel auf, dennoch benötigt es weitere detaillierte Studien, um eine Beziehung zwischen den beiden Genen etablieren zu können. Letztlich konnte die Beeinträchtigung von Autophagie in menschlichen CLEC16A KD Zellen nachgewiesen werden, was bedeutet, dass die Funktion von CLEC16A evolutionär konserviert ist und ein möglicher Zusammenhang zwischen CLEC16A Polymorphismen und einem erhöhten Risiko für Typ 1 Diabetes im Menschen besteht. N2 - Genome-wide association studies revealed CLEC16A as a candidate gene for Type 1 Diabetes and multiple other autoimmune disorders. The function of CLEC16A remains unknown. However, previous work showed that the CLEC16A ortholog ema and the murine Clec16a were both implicated in autophagy, a process partially required for MHC class II loading and antigen presentation. Furthermore, studies could show that autophagy was required in thymic epithelial cells for antigen presentation during T cell selection, suggesting a possible role of CLEC16A in T cell selection in the thymus. Additionally, it was postulated that CLEC16A may function as an expression quantitative trait locus for its neighboring genes and that Clec16a KD was involved in pancreatic islet function and impaired insulin secretion and glucose homeostasis. Prior to this work, Schuster et al. had created a Clec16a KD NOD mouse, which was protected from spontaneous autoimmune diabetes. For this work it was hypothesized that CLEC16A variation serves as a Type 1 Diabetes risk gene by affecting autophagy in thymic epithelial cells, which modulates antigen presentation and shapes the T cell repertoire. To expand and complement previous findings by Schuster et al., this thesis aimed to investigate how CLEC16A modifies the function of thymic epithelial cells. For this purpose, CLEC16A KD was induced in human cells via RNA interference and autophagy was studied through immunoblotting. Additionally, inflammation of pancreatic tissue in Clec16a KD NOD mice was scored using H.E. stained pancreatic sections. Thymic transplantation experiments were conducted to test whether the effects of Clec16a KD were T cell intrinsic. Also, intraperitoneal glucose tolerance tests were performed to study glucose homeostasis in Clec16a KD NOD animals. Finally, using qPCR, gene expression levels of neighboring genes such as Dexi and Socs1 were measured to study Clec16a as an expression quantitative trait locus. In combination with the findings of Schuster et al., this thesis demonstrates that Clec16a KD reduces the severity of insulitis and protects from onset of spontaneous diabetes in the NOD mouse. Disease protection is conveyed by impaired autophagy in TEC, which leads to altered T cell selection and hyporeactive CD4+ T cells. The effects of Clec16a KD in the NOD mouse are thymus intrinsic. Glucose homeostasis remains unchanged in the Clec16a KD NOD mouse and plays no role in disease protection. Clec16a and Dexi presented similar expression levels, but further studies are required to investigate a clear link between these two genes. Finally, impaired autophagy could be replicated in human CLEC16A KD cells, which demonstrates a conserved function of CLEC16A and suggests a possible link between CLEC16A variation and risk of autoimmune disease in human. KW - Thymus KW - Toleranz KW - Autoimmunität KW - Diabetes mellitus Typ 1 KW - Epithelzelle KW - CLEC16A KW - T cell selection KW - Antigen presentation KW - Autophagy KW - Autoimmunity KW - T Zell Selektion KW - Antigenpräsentation KW - Autophagie Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-200230 ER - TY - THES A1 - Georgakopoulos, Dimos T1 - Einfluss der N-Glykosylierung von HIV-Env auf die Krankheitsprogression der HIV-Infektion T1 - Influence on disease progress by HIV-env's glycosylation density in HIV infected persons N2 - N-Glykosylierungen spielen beim Env-Gen eine wichtige Rolle. Sie dienen nicht nur als „Escape-Phänomen“ zur Verhinderung einer Elimination des Virus durch neutralisierende Antikörper. Es hat sich gezeigt, dass bestimmte Menschen sich mit HIV infizieren können, aber es zu keinem Zeitpunkt zu AIDS-typischen Symptomen kommt, ohne die Einnahme antiretroviraler Therapie (ART). Solche Menschen werden als Elite Controller bezeichnet. Ihr Organismus kann selbst die Viruslast in sehr geringen Grenzen halten (< 50 Kopien/ml). Ziel dieser Arbeit ist es, den Einfluss von N-Glykosylierungen in der Entstehung von Elite Controller zu untersuchen und prozentuell eine Tendenz zu schaffen, inwieweit die Glykosylierungsdichte des Env-Proteins entscheidend ist. Es konnte gezeigt werden, dass eine immunologische Kontrolle auch auf der B-Zellebene stattfinden kann. Als Hinweis dient die geringe Glykosylierungsdichte im Bereich CD4bs und MPER, die indirekt über MHC Klasse II zu einer erhöhten Produktion von Antikörpern führen kann. Bisher wurde bei Elite Controller die T-Zellebene als mögliche immunologische Kontrolle beschrieben, jedoch gibt diese Arbeit hinweise, dass auch eine immunologische Kontrolle mittels Antikörper möglich ist. Die glykosylierten Zielepitope können eine große Hilfe sein für das Aussehen eines späteren Impfstoffs. N2 - Predicted N-linked glycosylations loom large in env-gene of hiv and do not only function as an escape mechanism to avoid elimination of hiv by neutralising antibodies. Some people can become infected with hiv and never require antiretroviral medication and also never develop an AIDS-related disease. These people are the so called elite controler. Their immune system can dam the viral load of the virus in low-level (< 50 copies/ml). The aim of this thesis ist o show how predicted n-linked glycosylation influence the genesis of an elite controler and how glycosylation density is crucial for their development. One can show that there is also an immunological controll on the human B cell line. The low glycosylation density in CD4 binding site and MPER affects indirectly the higher concentration of neutralising antibodies by major histocompatibility complex type II. Previously the immunological control in elite controler was described by the T cell line but this thesis gives directions that an immunological control can be done also by antibodies. The env´s parts whith lower glycyosylation can be an instrument fort he later development of a vaccine. KW - HIV-Infektion KW - Elite Controller Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-217023 N1 - Aus datenschutzrechtlichen Gründen wurde der Zugriff auf den Volltext zu diesem Dokument gesperrt. Eine inhaltlich identische neue Version ist erhältlich unter: https://doi.org/10.25972/OPUS-30362 ER - TY - THES A1 - Pilgram, Lisa T1 - Produktion und pathophysiologische Bedeutung von Sphingosin-1-Phosphat in humanen dendritischen Zellen T1 - Production and pathophysiological significance of sphingosine-1-phosphate in human dendritic cells N2 - Dendritische Zellen (DCs) sind als Zielzellen des MV für dessen Pathogenese von zentraler Bedeutung und fördern sowohl Dissemination und Transmission des Virus. Auf zellulärer Ebene findet sich eine Modulation des Sphingolipidmetabolismus in MV-infizierten DC-Kulturen. S1P selbst ist ein bioaktives Sphingolipid, das über auto- und parakrine S1P-Rezeptorstimulation Funktion, Migration und Positionierung von Immunzellen, aber auch als intrazellulärer Botenstoff Calcium-Haushalt, Apoptose und Proliferation reguliert. Über die an der Vermittlung der intrazellulären S1P-Effekte beteiligten Strukturen ist bisher weniger bekannt und der S1P-Metabolismus einzelner Zellen trotz Kompartiment-abhängiger Schwankungen der S1P-Konzentrationen kaum adressiert. Für murine DCs konnte eine kontinuierliche S1P-Produktion und Sekretion nachgewiesen werden. Ob dies auch auf humane DCs zutrifft und pathophysiologisch im Rahmen einer MV-Infektion moduliert wird, ist bisher nicht bekannt. In dieser Arbeit wurde das Vorkommen S1Ps sowie dessen Metabolismus in humanen DCs quantitativ erfasst, und der Einfluss inflammatorischer, bakterieller und viraler (MV) Stimuli einbezogen. In Anbetracht der bekannten chemoattraktiven Potenz wurde nachfolgend der Beitrag S1Ps für die DC-induzierte T-Zellmigration untersucht. Es konnte gezeigt werden, dass beide SphK Isoenzyme und auch die irreversibel degradierende SPL in humanen unreifen DCs (iDCs) auf mRNA-Ebene exprimiert werden. S1P konnte intrazellulär nachgewiesen werden, eine mit Erythroyzten vergleichbare Speicherkapazität ist nicht anzunehmen. Unter bakteriell oder inflammatorisch vermittelter Ausreifung (mDCs) wurde eine Reduktion des S1P Gehalts in DCs beobachtet. Abweichend davon behielten insbesondere stark MV infizierte DC-Kulturen die hohen S1P-Spiegel unreifer DCs bei, was möglicherweise neben der modulierten Chemokinsynthese und Oberflächenexpression ko-stimulatorischer Moleküle einen weiteren Parameter ihrer inkompletten Reifung nach MV Infektion reflektiert. Da die Veränderungen zwischen MV-infizierten DCs und mDCs nur für S1P, nicht aber für andere Sphingolipidmetaboliten messbar waren, liegt ihnen wohl eine Regulation der Sphingosinkinasen oder S1P degradierender Enzyme zugrunde. Bei unveränderter Akkumulation der hierfür spezifischen mRNAs müsste dies auf Ebene der Translation, Stabilität oder Aktivität der Enzyme beruhen. Die indirekte Messung des extrazellulären S1Ps anhand der gegenläufigen S1P1-Dichte ließ vermuten, dass in DCs synthetisiertes S1P extrazellulär wirken konnte. Es kann dabei autokrin auf DCs wirken, beispielsweise deren Motilität oder Genexpression regulieren, ist aber auch Voraussetzung zum Aufbau eines S1P-Gradienten und damit parakriner Regulation lymphozytärer Migrationsvorgänge. Einen Beitrag S1Ps zur mDCs-induzierten T Zellchemotaxis konnte durch die erhobenen Daten mit hoher Wahrscheinlichkeit ausgeschlossen werden. Bezüglich der durch iDCs oder MV infizierte DCs induzierten T Zellchemotaxis konnte aufgrund experimenteller Limitationen keine abschließende Aussage zur Beteiligung S1Ps getroffen werden. Die T-Zellmigration auf DCs erwies sich im 2 D-System als gerichtete Bewegung. Weder Ausreifung noch MV-Infektion der DCs hatten Auswirkungen auf die Quantität der T-Zellmigration. Differentielle Expressionsmuster von Chemokinen in iDCs, mDCs und MV infizierten DCs sind jedoch bekannt und legen Variationen der Subset-Komposition innerhalb der migrierenden T Zellen nahe. Diese sollten gezielt in nachfolgenden Arbeiten untersucht werden. Zusammenfassend weist die vorliegende Arbeit eine kontinuierliche Synthese S1Ps in DCs mit Stimulus-abhängiger Fluktuation nach. Eine MV Infektion löst dabei einen zu inflammatorischen und bakteriellen Stimuli divergenten Effekt auf den S1P-Gehalt aus mit möglichen pathophysiologischen Konsequenzen. Eine Modulation der T Zellchemotaxis und damit der DC-T-Zell-Interaktion wäre im Rahmen inflammatorischer, bakterieller oder viraler Szenarien denkbar. Unter inflammatorischen und bakteriellen Bedingungen trug S1P jedoch nicht zur T-Zellchemotaxis bei, für MV blieb dies unklar. Dahingegen zeigten weitere Experimente der Arbeitsgruppe einen autokrin vermittelten Beitrag des intrazellulär produzierten S1Ps zur Migration MV-infizierter DCs im respiratorischen Epithel und identifizierten damit einen bisher unbekannten Einflussfaktor einer erfolgreichen MV-Transmission. N2 - As target for measles virus (MV) infection, dendritic cells (DCs) are central in MV pathogenesis also including viral dissemination and transmission. In this context, changes in sphingolipid metabolism and function of MV-infected DCs are described. Sphingosin-1-Phosphat (S1P) as a potent bioactive sphingolipid has pleiotropic functions in immunological processes. It regulates immune cell trafficking via autocrine or paracrine secretion and calcium homeostasis, apoptosis and proliferation via so far poorly defined intracellular signaling. Though compartment dependent S1P variations have been described, cell specific S1P metabolism remains mostly unclear. Little information is available in this regard for human DCs, especially under inflammatory, bacterial and viral (MV) conditions, while murine DCs were identified to continuously produce and secrete S1P. In this study, the S1P pool in human DCs, its metabolism as well as its fluctuation in maturation and MV-infection were investigated. Considering its function as a chemoattractant, resulting consequences in T cell chemotaxis induced by DCs were addressed. Sphingosinkinases (SphK1, SphK2), which generate, and S1P-Lyase (SPL), which irreversibly degrades S1P, were found to be expressed at the mRNA level in human immature DCs. Intracellular S1P was readily detected in immature DCs (iDCs), though they are unlikely to serve as S1P sores as described for erythrocytes. S1P concentrations decreased upon maturation triggered by cytokines (TNF α) or bacterial components (LPS). In contrast, S1P levels corresponding to those measured in iDCs were retained in MV-infected DC culture. In addition to the modulation of chemokine synthesis and surface expression of co-stimulatory molecules, retention of S1P levels may also reflect incomplete DC maturation induced by this virus. As fluctuations of the sphingolipid pool between maturing (mDCs) and infected DCs only affected levels of S1P but not its precursors, differential regulation of sphingosine kinases or degrading enzymes are most likely important in elevated S1P levels. As accumulation of mRNAs specific for SphK1, SphK2 and SPL was unaffected in MV-infected DC-cultures, regulation of the enzymes at translational, stability and/or activity level are likely to be operative. Due to its S1P dependent internalization, S1P1 serves as a surrogate marker of extracellular S1P level. The decreased intracellular S1P concentrations in mDCs were paralleled by upregulated S1P1 expression making decreased S1P secretion likely. In MV infected DC culture secretion seems to be maintained at a level comparable to iDCs. Presuming continuous secretion of S1P, the detected S1P in DCs might contribute to S1P gradients among and within tissues, thus regulating lymphocyte migration. Findings obtained within this work do not support a role of S1P in T cell chemotaxis induced by mDCs. Experimental limitations precluded a final statement on a potential role of S1P in T cell chemotaxis induced by iDCs or MV-infected DCs. T cell chemotaxis induced by mDCs was highly directional in a two-dimensional system. At an overall quantitative basis, T cell chemotaxis induced by iDCs, mDCs or MV-infected DCs did not differ. As DCs are known to vary their chemokine expression depending on their differentiation status, it is, however, quite possible that the subset composition of the migrating T cell compartment differs; which has not been directly addressed in this work. Altogether, this work revealed continuous production of S1P by human DCs with differentiation-dependent fluctuations. While intracellular S1P pools decreased with maturation induced by inflammatory conditions or LPS, these were fully retained upon MV infection. At a functional level, effects on T cell chemotaxis followed by differential interaction with DCs might be of pathogenetic advantage in inflammatory, bacterial or viral settings. However, S1P did not take part in T cell attraction by mDCs. Its contribution to T cell chemotaxis induced by MV infected DCs remains unsettled. However, further experiments in this research group revealed its importance in promoting migration in MV infected DCs by autocrine signaling, thus enabling efficient virus transmission. KW - Dendritische Zelle KW - Sphingolipide KW - Chemotaxis KW - Entzündung KW - Masernvirus KW - Sphingosin-1-Phosphat KW - T-Zellmigration KW - sphingosine-1-phosphate KW - T-cell migration Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-210214 ER - TY - THES A1 - Brado, Dominik Alexander T1 - Genetic diversity and baseline drug resistance of South African HIV-1 Integrase sequences prior to the availability of Integrase strand-transfer inhibitors T1 - Genetische Variabilität und medikamentöse Resistenz südafrikanischer HIV-1 Integrase Sequenzen vor der Verfügbarkeit von Integrase Strang-Transfer Inhibitoren N2 - Background: Integrase strand transfer inhibitors (INSTIs) are the latest addition to the array of antiretroviral compounds used to treat an infection with Human Immunodeficiency Virus (HIV). Due to their high efficacy and increased tolerability, INSTIs have become an integral part of first-line therapy in most high-income countries over the past years. However, little is known about HIV-1’s genetic inter- and intra-subtype diversity on the Integrase (IN)-gene and its impact on the emergence of INSTI-resistance. In the absence of a functional cure, long-term efficacy of first-line compounds remains paramount for reducing virological failure and curbing on-going HIV transmissions. South Africa, harbouring more than 20% of the global HIV burden (7.7 / 37.9 million people), requires international attention in order to globally pursue UNAIDS’ (Joint United Nations Programme on HIV/AIDS) 90-90-90 goals and the road to ending the HIV/AIDS (Acquired immunodeficiency syndrome) pandemic by 2030. Methods: In this study, the prevalence of INSTI-resistance associated mutations (RAM) was investigated in a cohort of 169 archived drug-naïve blood samples from multiple collection sites around Cape Town, South Africa. Viral RNA was isolated from plasma samples, the integrase fragment amplified by RT-PCR and subsequently sequenced by Sanger-sequencing. Additionally, all publicly available drug-naïve, South African IN sequences, isolated before the availability of the first INSTIs in 2007, were retrieved from the Los Alamos HIV sequence database (n=284). All sequences were analysed for RAMs using the Stanford HIV Drug resistance database. The identification of polymorphism in the South African subtype C IN consensus sequence allowed for comparative analyses with global subtype B, as well as subtype C sequences, from countries other than South Africa. Results: The IN gene could be amplified and sequenced in 95/169 samples (56%). Phylogenetic inference revealed close homology between three sequence-pairs, warranting the exclusion of 3/95 sequences from further analyses. Of the 92 samples used for mutational analyses, 86/92 (93.5%) belonged to subtype C, 5/92 (5.4%) to subtype B and 1/92 (1.1%) to subtype A. The prevalence of major and accessory INSTI RAMs was 0/92 (0%) and 1/91 (1.1%), respectively, similar to the observed rates of 8/284 (2.8%) and 8/284 (2.8%) in the database sequences (p = 0.2076 and p = 0.6944, Fisher’s exact test). Compared to subtype B IN sequences, 15 polymorphisms were significantly enriched in South African subtype C sequences (corrected p<0.0015. Fisher’s exact test, Bonferroni post-hoc procedure). Compared to subtype C IN sequences isolated outside South Africa, four polymorphisms were significantly enriched in this study cohort (corrected p<0.0014, Fisher’s exact test, Bonferroni post-hoc procedure). The highest prevalence margin was observed for the polymorphism Met50Ile being present in 60.1% of South African subtype C sequences, compared to 37% in non-South African subtype C sequences. Conclusions: The low prevalence of major and minor RAMs in all South African Integrase sequences predicts a high susceptibility to INSTIs, however, the presence of natural polymorphisms, in particular Met50Ile, in the majority of sequences warrants further monitoring under therapeutic pressure, as their role in mutational pathways leading to INSTI- resistance is yet to be determined. Additionally, this study revealed the presence of substantial inter- and intra-subtype diversity within the HIV-1 Subtype C IN-gene. These results implicate the need for more research on a regional, potentially patient-specific level, as mutational insights from other diverse backgrounds may not accurately represent the South African context. The implementation of a national pre-treatment INSTI-resistance screening program may provide necessary insights into the development of mutational pathways leading to INSTI-resistance under therapeutic pressure for the South African context and thereby bring South Africa one step closer to achieving UNAIDS 90-90-90 goals and ending the AIDS epidemic by 2030. N2 - Hintergrund: Integrase Strang-Transfer Inhibitoren (INSTIs) sind die neuste medikamentöse Ergänzung in der Therapie einer HIV-Infektion. Auf Grund ihrer starken Wirksamkeit und eines guten Nebenwirkungsprofils sind INSTIs in den letzten Jahren ein integraler Bestandteil von Erstlinien-Therapieregimen in den meisten wirtschaftlich starken Ländern geworden. Allerdings ist wenig bekannt über die genetische Variabilität des IN-gens und über ihren Einfluss auf die Entwicklung von INSTI-Resistenzen. Mit einem Anteil von über 20% der globalen HIV-Last (7,7 / 37,9 Millionen Menschen) benötigt Südafrika einen internationalen Fokus, um die von UNAIDS formulierten 90-90-90 Ziele und das mögliche Ende der HIV/AIDS Pandemie bis 2030 auf globaler Ebene zu verfolgen. Methoden: In dieser Arbeit wurde die Prävalenz von INSTI RAMs in einer Kohorte von 169 archivierten, therapie-naiven Blutproben von mehreren Sammelstellen um Kapstadt, Südafrika, untersucht. Virale RNA wurde aus Plasmaproben isoliert, das Integrase-Fragment mittels RT-PCR amplifiziert und anschließend Sanger-sequenziert. Zusätzlich wurden alle in der Los Alamos HIV Sequenz Datenbank verfügbaren, therapie-naive, südafrikanische IN Sequenzen, die vor der Verfügbarkeit von INSTIs im Jahr 2007 isoliert wurden, der Analyse dieser Arbeit hinzugefügt (n=284). Die Interpretation der gefundenen Mutationen erfolgte mittels der HIV Therapie-Resistenz Datenbank der Stanford Universität. Durch Generierung eines südafrikanischen IN Subtyp C Consensus-Stranges und nachfolgendem Vergleich mit öffentlich verfügbaren Subtyp B und Subtyp C Sequenzen, die außerhalb Südafrikas isoliert wurden, erfolgte die Analyse von natürlich vorkommenden Polymorphismen. Ergebnisse: Das IN-Fragment konnte in 95/169 Plasmaproben (56%) erfolgreich amplifiziert und sequenziert werden. Phylogenetische Analysen zeigten eine enge Homologie zwischen drei Sequenz-Paaren, woraufhin 3/95 Sequenzen von weiteren Analysen ausgeschlossen wurden. Von den übrigen 92 Sequenzen gehörten 86/92 (93,5%) zu dem Subtyp C, 5/92 (5,4%) zu dem Subtyp B und 1/91 (1,1%) zu dem Subtyp A. Die Prävalenz von Haupt- und Nebenresistenz-Mutationen lag bei jeweils 0/92 (0%) und 1/92 (1,1%). Ähnliche Raten hierfür von 8/284 (2,8%) und 8/284 (2,8%) konnten in den Datenbank-Sequenzen beobachtet werden (p = 0,2076 und p = 0,6944, Fisher’s exact test). Im Vergleich zu Subtyp B IN Sequenzen waren 15 Polymorphismen signifikant erhöht in südafrikanischen Subtype C IN Sequenzen (korrigiertes p<0,0015, Fisher’s exact test, Bonferroni post-hoc Korrektur). Im Vergleich zu nicht-südafrikanischen Subtyp C Sequenzen zeigten sich vier Polymorphismen signifikant erhöht (korrigiertes p<0,0014, Fisher’s exact test, Bonferroni post-hoc Korrektur). Der größte Prävalenzunterschied konnte für den Polymorphismus Met50Ile beobachtet werden. Dieser war vorhanden in 217/361 (60,1%) der südafrikanischen Subtyp C Sequenzen, verglichen zu 203/548 (37.0%) der nicht-südafrikanischen Subtyp C Sequenzen. Schlussfolgerung: Die niedrige Prävalenz von Haupt- und Neben-RAMs in südafrikanischen IN-Sequenzen verspricht ein gutes Ansprechen von INSTIs in diesem Kontext. Allerdings bedingt das Vorhandensein von natürlichen Polymorphismen, insbesondere der Polymorphismus Met50Ile das weitere Beobachten dieser Mutationen unter dem Einfluss von therapeutischem Druck, da deren Bedeutung in der Entwicklung von INSTI-Resistenzen noch nicht abschließend geklärt werden konnte. Zudem impliziert die in dieser Arbeit gezeigte inter- und intra-subtyp Diversität auf dem IN-Gen, die Notwendigkeit von weiterer Forschung auf regionaler Ebene, da Beobachtungen, die auf verschiedenen polymorphistischen Kontexten beruhen, nicht notwendigerweise auf den südafrikanischen Kontext übertragen werden können. Mit der Einführung eines nationalen, prä-therapeutischen Screening- Programms für das Vorhandensein von INSTI-Resistenzen könnte Südafrika wichtige Einblicke in die Entwicklung von INSTI-Resistenzen gewinnen und somit den 90-90-90 Zielen und der Möglichkeit die AIDS-Pandemie bis zum Jahr 2030 zu beenden, einen Schritt näher sein. KW - HIV KW - Sequenzanalyse KW - HIV Drug resistance KW - HIV South Africa KW - Integrase inhibitor KW - Dolutegravir Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-216562 ER - TY - THES A1 - Gleich, Melanie T1 - Effekte einer Lithium-Therapie bei HIV-Patienten mit HAND auf neurochemische und immunologische Marker der Krankheitsprogression: Analyse einer randomisierten, doppelt-verblindeten, kontrollierten klinischen Studie in Südafrika T1 - Effects of lithium therapy in HIV patients with HAND on neurochemical and immunological markers of disease progression: Analysis of a randomized, double-blinded and controlled clinical trial in South Africa N2 - Patienten mit einer HIV-Infektion werden mit antiretroviralen Medikamenten therapiert, um die Krankheitsprogression zu verhindern, die HIV-Replikation zu hemmen und klinische HIV-induzierte Symptome zu verbessern. Für HIV-assoziierte neurokognitive Störungen (HAND) als Folge einer Infektion mit HIV gibt es jedoch noch keine ausreichende Therapie. In dieser Arbeit wurden PBMC, Serum- und Liquorproben von Teilnehmern einer placebokontrollierten klinischen Studie analysiert, in der die Wirksamkeit einer Lithium-Therapie bei HIV-Patienten mit HAND untersucht wurde. Die Studienteilnehmer erhielten für sechs Monate zusätzlich zu ihrer antiretroviralen Medikation Lithiumcarbonat bzw. ein Placebo. Die Einschlusskriterien waren eine mindestens sechs Monaten bestehende antiretrovirale Therapie bei unterdrückter Viruslast und eine mittelschwere bis schwere Manifestation der HIV-assoziierten neurokognitiven Störung. Die Studie wurde in Primary Care Kliniken des öffentlichen Sektors in Kapstadt, Südafrika, durchgeführt. Als primärer Wirksamkeitsendpunkt wurde die Veränderung des Global Deficit Scores (GDS) von Beginn der Studie bis zum Ende der 24. Woche festgelegt. Es hatten insgesamt 66 Patienten an der Studie teilgenommen, davon bekamen 32 Patienten das Medikament Lithiumcarbonat und 34 Patienten ein Placebo. Den Patienten wurden zu den Zeitpunkten Baseline (V3) und 24. Woche (V12) Blut- und CSF-Proben entnommen. In der vorliegenden Arbeit wurden die Proben mittles Durchflusszytometrie und ELISA untersucht. Die Daten wurden mit dem GDS sowie weiteren Progressionsmarkern der HIV-Infektion wie Viruslast und CD4+ Zellzahl korreliert. Von den 66 Teilnehmern, die die Studie begonnen haben, schlossen insgesamt 61 Teilnehmer ab, darunter hatten 30 Patienten Lithiumcarbonat und 31 Patienten ein Placebo eingenommen. Das Durchschnittsalter lag bei 40 Jahren und die mittlere CD4+ T-Zellzahl umfasste 500 Zellen pro ml. Es traten sechs schwerwiegende unerwünschte Ereignisse auf, aber keines wurde in Zusammenhang mit dem Studienmedikament betrachtet. Die Patienten mit HAND, die zusätzlich zu einer antiretroviralen Therapie eine medikamentöse Behandlung mit Lithium erhielten, haben dieses klinisch gut vertragen. Jedoch konnte keine Verbesserung in Bezug auf neurokognitive Beeinträchtigungen für die Studienteilnehmer beobachtet werden. In der vorliegenden Arbeit konnte gezeigt werden, dass im zeitlichen Verlauf von V3 zu V12 ein signifikante Verbesserung des GDS innerhalb der Placebo-, sowie innerhalb der Lithium-Gruppe beobachtet werden konnte, wohingegen bei den Gruppen untereinander, Lithium versus Placebo, zu den jeweiligen Zeitpunkten V3 sowie V12, ähnliche Werte gemessen werden konnten und sich daher die Lithium-, und die Placebo-Gruppe nicht signifikant voneinander unterschieden. Aus den in dieser Arbeit gewonnenen Ergebnissen ließ sich zudem ableiten, dass ein signifikanter Abfall der BDNF Konzentration im Plasma zu verzeichnen war. Insgesamt war ein Trend erkennbar, dass Patienten mit blip eine höhere Immunaktivierung zeigten, als Patienten ohne blip. Jedoch hatte die Behandlung mit Lithium keinen Einfluss auf die Immunaktivierung der CD8+ T-Zellen. Des Weiteren zeigte sich unter der Lithium-Therapie ein signifikanter Abfall der CD4+ Zellzahlen. N2 - Patients with HIV infection are treated with antiretroviral drugs to prevent a progression of the disease, to inhibit HIV replication and improve clinical HIV-induced symptoms. However, there is still no effective therapy available. In this work, PBMC, serum and CSF samples from participants in a placebo-controlled clinical study were analyzed to evaluate the efficacy of lithium therapy in HIV patients with HIV-associated-neurocognitive-disorders (HAND). The study participants received lithium carbonate or placebo for 24 weeks in addition to their antiretroviral medication. Inclusion criteria were at least six months of antiretroviral therapy with suppressed viral load and a moderately severe to severe manifestation of HIV-associated neurocognitive disorder (HAND). The study was conducted in public sector primary care clinics in Cape Town, South Africa. The primary efficacy endpoint was defined as the change in the Global Deficit Score (GDS) from baseline to the end of week 24. A total of 66 patients participated in the study: 32 patients received lithium carbonate and 34 patients received a placebo. Blood and CSF samples were collected from the patients at baseline (V3) and week 24 (V12). In the present study, the samples were analyzed by flow cytometry and ELISA. The data were correlated with GDS and other HIV infection progression markers, such as viral load and CD4+ cell count. Of the 66 participants who started the study, a total of 61 participants completed the study, including 30 patients on lithium carbonate and 31 patients on placebo. The mean age was 40 years and the mean CD4+ T cell count was 500 cells per ml. Six serious adverse events occurred, but none were considered related to the study drug. Patients with HAND who received lithium medication in addition to antiretroviral therapy tolerated it well clinically. However, no improvement was observed in terms of neurocognitive impairment for the study participants. In the present study, it was shown that a significant decrease in GDS was observed over time from V3 to V12 in both the placebo and lithium groups, whereas the lithium versus placebo groups showed similar values at V3 and V12 and therefore the lithium and placebo groups did not differ significantly. From the results obtained in this study it was also concluded that there was a significant decrease in plasma BDNF concentration. Overall, there was a trend that patients with blip showed higher immune activation than patients without blip. However, treatment with lithium had no effect on the immune activation of CD8+ T cells. Furthermore, a significant decrease in CD4+ cell counts was observed under lithium therapy. KW - AIDS KW - HIV-assoziierte neurokognitive Störung KW - GDS KW - Lithiumtherapie Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-218873 ER - TY - JOUR A1 - De Lira, Maria Nathalia A1 - Raman, Sudha Janaki A1 - Schulze, Almut A1 - Schneider-Schaulies, Sibylle A1 - Avota, Elita T1 - Neutral Sphingomyelinase-2 (NSM 2) Controls T Cell Metabolic Homeostasis and Reprogramming During Activation JF - Frontiers in Molecular Biosciences N2 - Neutral sphingomyelinase-2 (NSM2) is a member of a superfamily of enzymes responsible for conversion of sphingomyelin into phosphocholine and ceramide at the cytosolic leaflet of the plasma membrane. Upon specific ablation of NSM2, T cells proved to be hyper-responsive to CD3/CD28 co-stimulation, indicating that the enzyme acts to dampen early overshooting activation of these cells. It remained unclear whether hyper-reactivity of NSM2-deficient T cells is supported by a deregulated metabolic activity in these cells. Here, we demonstrate that ablation of NSM2 activity affects metabolism of the quiescent CD4\(^+\) T cells which accumulate ATP in mitochondria and increase basal glycolytic activity. This supports enhanced production of total ATP and metabolic switch early after TCR/CD28 stimulation. Most interestingly, increased metabolic activity in resting NSM2-deficient T cells does not support sustained response upon stimulation. While elevated under steady-state conditions in NSM2-deficient CD4\(^+\) T cells, the mTORC1 pathway regulating mitochondria size, oxidative phosphorylation, and ATP production is impaired after 24 h of stimulation. Taken together, the absence of NSM2 promotes a hyperactive metabolic state in unstimulated CD4\(^+\) T cells yet fails to support sustained T cell responses upon antigenic stimulation. KW - neutral sphingomyelinase-2 KW - T cell receptor KW - Seahorse XF KW - oxidative phosphorylation KW - ATP-adenosine triphosphate KW - Mitochondria Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-211311 SN - 2296-889X VL - 7 ER - TY - JOUR A1 - Steinhardt, M. J. A1 - Wiercinska, E. A1 - Pham, M. A1 - Grigoleit, G. U. A1 - Mazzoni, A. A1 - Da-Via, M. A1 - Zhou, X. A1 - Meckel, K. A1 - Nickel, K. A1 - Duell, J. A1 - Krummenast, F. C. A1 - Kraus, S. A1 - Hopkinson, C. A1 - Weissbrich, B. A1 - Müllges, W. A1 - Stoll, G. A1 - Kortüm, K. M. A1 - Einsele, H. A1 - Bonig, H. A1 - Rasche, L. T1 - Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes JF - Journal of Translational Medicine N2 - Background Progressive multifocal leukoencephalopathy is a demyelinating CNS disorder. Reactivation of John Cunningham virus leads to oligodendrocyte infection with lysis and consequent axonal loss due to demyelination. Patients usually present with confusion and seizures. Late diagnosis and lack of adequate therapy options persistently result in permanent impairment of brain functions. Due to profound T cell depletion, impairment of T-cell function and potent immunosuppressive factors, allogeneic hematopoietic cell transplantation recipients are at high risk for JCV reactivation. To date, PML is almost universally fatal when occurring after allo-HCT. Methods To optimize therapy specificity, we enriched JCV specific T-cells out of the donor T-cell repertoire from the HLA-identical, anti-JCV-antibody positive family stem cell donor by unstimulated peripheral apheresis [1]. For this, we selected T cells responsive to five JCV peptide libraries via the Cytokine Capture System technology. It enables the enrichment of JCV specific T cells via identification of stimulus-induced interferon gamma secretion. Results Despite low frequencies of responsive T cells, we succeeded in generating a product containing 20 000 JCV reactive T cells ready for patient infusion. The adoptive cell transfer was performed without complication. Consequently, the clinical course stabilized and the patient slowly went into remission of PML with JCV negative CSF and containment of PML lesion expansion. Conclusion We report for the first time feasibility of generating T cells with possible anti-JCV activity from a seropositive family donor, a variation of virus specific T-cell therapies suitable for the post allo transplant setting. We also present the unusual case for successful treatment of PML after allo-HCT via virus specific T-cell therapy. KW - Myeloma KW - JCV KW - Prodigy KW - CCS KW - PML KW - Donor lymphocytes KW - Adaptive cell transfer Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-229307 VL - 18 ER - TY - JOUR A1 - Weißbach, Susann A1 - Heredia-Guerrero, Sofia Catalina A1 - Barnsteiner, Stefanie A1 - Großhans, Lukas A1 - Bodem, Jochen A1 - Starz, Hanna A1 - Langer, Christian A1 - Appenzeller, Silke A1 - Knop, Stefan A1 - Steinbrunn, Torsten A1 - Rost, Simone A1 - Einsele, Hermann A1 - Bargou, Ralf Christian A1 - Rosenwald, Andreas A1 - Stühmer, Thorsten A1 - Leich, Ellen T1 - Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines JF - Cancers N2 - Approximately 20% of multiple myeloma (MM) cases harbor a point mutation in KRAS. However, there is still no final consent on whether KRAS-mutations are associated with disease outcome. Specifically, no data exist on whether KRAS-mutations have an impact on survival of MM patients at diagnosis in the era of novel agents. Direct blockade of KRAS for therapeutic purposes is mostly impossible, but recently a mutation-specific covalent inhibitor targeting KRAS\(^{p.G12C}\) entered into clinical trials. However, other KRAS hotspot-mutations exist in MM patients, including the less common exon-4 mutations. For the current study, the coding regions of KRAS were deep-sequenced in 80 newly diagnosed MM patients, uniformely treated with three cycles of bortezomib plus dexamethasone and cyclophosphamide (VCD)-induction, followed by high-dose chemotherapy and autologous stem cell transplantation. Moreover, the functional impact of KRAS\(^{p.G12A}\) and the exon-4 mutations p.A146T and p.A146V on different survival pathways was investigated. Specifically, KRAS\(^{WT}\), KRAS\(^{p.G12A}\), KRAS\(^{p.A146T}\), and KRAS\(^{p.A146V}\) were overexpressed in HEK293 cells and the KRAS\(^{WT}\) MM cell lines JJN3 and OPM2 using lentiviral transduction and the Sleeping Beauty vector system. Even though KRAS-mutations were not correlated with survival, all KRAS-mutants were found capable of potentially activating MEK/ERK- and sustaining PI3K/AKT-signaling in MM cells. KW - multiple myeloma KW - KRAS KW - MEK/ERK-signaling KW - AKT-signaling KW - amplicon sequencing Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-200617 SN - 2072-6694 VL - 12 IS - 2 ER - TY - JOUR A1 - Herrmann, Thomas A1 - Fichtner, Alina Suzann A1 - Karunakaran, Mohindar Murugesh T1 - An Update on the Molecular Basis of Phosphoantigen Recognition by Vγ9Vδ2 T Cells JF - Cells N2 - About 1–5% of human blood T cells are Vγ9Vδ2 T cells. Their hallmark is the expression of T cell antigen receptors (TCR) whose γ-chains contain a rearrangement of Vγ9 with JP (TRGV9JP or Vγ2Jγ1.2) and are paired with Vδ2 (TRDV2)-containing δ-chains. These TCRs respond to phosphoantigens (PAg) such as (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), which is found in many pathogens, and isopentenyl pyrophosphate (IPP), which accumulates in certain tumors or cells treated with aminobisphosphonates such as zoledronate. Until recently, these cells were believed to be restricted to primates, while no such cells are found in rodents. The identification of three genes pivotal for PAg recognition encoding for Vγ9, Vδ2, and butyrophilin (BTN) 3 in various non-primate species identified candidate species possessing PAg-reactive Vγ9Vδ2 T cells. Here, we review the current knowledge of the molecular basis of PAg recognition. This not only includes human Vγ9Vδ2 T cells and the recent discovery of BTN2A1 as Vγ9-binding protein mandatory for the PAg response but also insights gained from the identification of functional PAg-reactive Vγ9Vδ2 T cells and BTN3 in the alpaca and phylogenetic comparisons. Finally, we discuss models of the molecular basis of PAg recognition and implications for the development of transgenic mouse models for PAg-reactive Vγ9Vδ2 T cells. KW - γδ T cell KW - phosphoantigen KW - BTN KW - butyrophilin 3 KW - butyrophilin 2A1 KW - evolution KW - alpaca KW - human Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-207937 SN - 2073-4409 VL - 9 IS - 6 ER - TY - JOUR A1 - Herrmann, Thomas A1 - Karunakaran, Mohindar Murugesh A1 - Fichtner, Alina Suzann T1 - A glance over the fence: Using phylogeny and species comparison for a better understanding of antigen recognition by human γδ T‐cells JF - Immunological Reviews N2 - Both, jawless and jawed vertebrates possess three lymphocyte lineages defined by highly diverse antigen receptors: Two T‐cell‐ and one B‐cell‐like lineage. In both phylogenetic groups, the theoretically possible number of individual antigen receptor specificities can even outnumber that of lymphocytes of a whole organism. Despite fundamental differences in structure and genetics of these antigen receptors, convergent evolution led to functional similarities between the lineages. Jawed vertebrates possess αβ and γδ T‐cells defined by eponymous αβ and γδ T‐cell antigen receptors (TCRs). “Conventional” αβ T‐cells recognize complexes of Major Histocompatibility Complex (MHC) class I and II molecules and peptides. Non‐conventional T‐cells, which can be αβ or γδ T‐cells, recognize a large variety of ligands and differ strongly in phenotype and function between species and within an organism. This review describes similarities and differences of non‐conventional T‐cells of various species and discusses ligands and functions of their TCRs. A special focus is laid on Vγ9Vδ2 T‐cells whose TCRs act as sensors for phosphorylated isoprenoid metabolites, so‐called phosphoantigens (PAg), associated with microbial infections or altered host metabolism in cancer or after drug treatment. We discuss the role of butyrophilin (BTN)3A and BTN2A1 in PAg‐sensing and how species comparison can help in a better understanding of this human Vγ9Vδ2 T‐cell subset. KW - antigen presentation KW - BTN2 KW - BTN3 KW - butyrophilin KW - evolution KW - γδ TCR Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-218373 VL - 298 IS - 1 SP - 218 EP - 236 ER - TY - JOUR A1 - Whisnant, Adam W. A1 - Jürges, Christopher S. A1 - Hennig, Thomas A1 - Wyler, Emanuel A1 - Prusty, Bhupesh A1 - Rutkowski, Andrzej J. A1 - L'hernault, Anne A1 - Djakovic, Lara A1 - Göbel, Margarete A1 - Döring, Kristina A1 - Menegatti, Jennifer A1 - Antrobus, Robin A1 - Matheson, Nicholas J. A1 - Künzig, Florian W. H. A1 - Mastrobuoni, Guido A1 - Bielow, Chris A1 - Kempa, Stefan A1 - Liang, Chunguang A1 - Dandekar, Thomas A1 - Zimmer, Ralf A1 - Landthaler, Markus A1 - Grässer, Friedrich A1 - Lehner, Paul J. A1 - Friedel, Caroline C. A1 - Erhard, Florian A1 - Dölken, Lars T1 - Integrative functional genomics decodes herpes simplex virus 1 JF - Nature Communications N2 - The predicted 80 open reading frames (ORFs) of herpes simplex virus 1 (HSV-1) have been intensively studied for decades. Here, we unravel the complete viral transcriptome and translatome during lytic infection with base-pair resolution by computational integration of multi-omics data. We identify a total of 201 transcripts and 284 ORFs including all known and 46 novel large ORFs. This includes a so far unknown ORF in the locus deleted in the FDA-approved oncolytic virus Imlygic. Multiple transcript isoforms expressed from individual gene loci explain translation of the vast majority of ORFs as well as N-terminal extensions (NTEs) and truncations. We show that NTEs with non-canonical start codons govern the subcellular protein localization and packaging of key viral regulators and structural proteins. We extend the current nomenclature to include all viral gene products and provide a genome browser that visualizes all the obtained data from whole genome to single-nucleotide resolution. Here, using computational integration of multi-omics data, the authors provide a detailed transcriptome and translatome of herpes simplex virus 1 (HSV-1), including previously unidentified ORFs and N-terminal extensions. The study also provides a HSV-1 genome browser and should be a valuable resource for further research. KW - infected-cell protein KW - messenger RNA KW - binding protein KW - type 1 KW - identification KW - ICP27 KW - translation KW - expression KW - sequence KW - domain Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-229884 VL - 11 ER - TY - JOUR A1 - Schlesinger, Tobias A1 - Weißbrich, Benedikt A1 - Wedekink, Florian A1 - Notz, Quirin A1 - Herrmann, Johannes A1 - Krone, Manuel A1 - Sitter, Magdalena A1 - Schmid, Benedikt A1 - Kredel, Markus A1 - Stumpner, Jan A1 - Dölken, Lars A1 - Wischhusen, Jörg A1 - Kranke, Peter A1 - Meybohm, Patrick A1 - Lotz, Christpher T1 - Biodistribution and serologic response in SARS-CoV-2 induced ARDS: A cohort study JF - PLoS One N2 - Background The viral load and tissue distribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain important questions. The current study investigated SARS-CoV-2 viral load, biodistribution and anti-SARS-CoV-2 antibody formation in patients suffering from severe corona virus disease 2019 (COVID-19) induced acute respiratory distress syndrome (ARDS). Methods This is a retrospective single-center study in 23 patients with COVID-19-induced ARDS. Data were collected within routine intensive care. SARS-CoV-2 viral load was assessed via reverse transcription quantitative polymerase chain reaction (RT-qPCR). Overall, 478 virology samples were taken. Anti-SARS-CoV-2-Spike-receptor binding domain (RBD) antibody detection of blood samples was performed with an enzyme-linked immunosorbent assay. Results Most patients (91%) suffered from severe ARDS during ICU treatment with a 30-day mortality of 30%. None of the patients received antiviral treatment. Tracheal aspirates tested positive for SARS-CoV-2 in 100% of the cases, oropharyngeal swabs only in 77%. Blood samples were positive in 26% of the patients. No difference of viral load was found in tracheal or blood samples with regard to 30-day survival or disease severity. SARS-CoV-2 was never found in dialysate. Serologic testing revealed significantly lower concentrations of SARS-CoV-2 neutralizing IgM and IgA antibodies in survivors compared to non-survivors (p = 0.009). Conclusions COVID-19 induced ARDS is accompanied by a high viral load of SARS-CoV-2 in tracheal aspirates, which remained detectable in the majority throughout intensive care treatment. Remarkably, SARS-CoV-2 RNA was never detected in dialysate even in patients with RNAemia. Viral load or the buildup of neutralizing antibodies was not associated with 30-day survival or disease severity. KW - viral load Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-231348 VL - 15, 2020 IS - 11 ER - TY - JOUR A1 - Riederer, Peter A1 - ter Meulen, Volker T1 - Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses JF - Journal of Neural Transmission N2 - While there is abounding literature on virus-induced pathology in general and coronavirus in particular, recent evidence accumulates showing distinct and deleterious brain affection. As the respiratory tract connects to the brain without protection of the blood–brain barrier, SARS-CoV-2 might in the early invasive phase attack the cardiorespiratory centres located in the medulla/pons areas, giving rise to disturbances of respiration and cardiac problems. Furthermore, brainstem regions are at risk to lose their functional integrity. Therefore, long-term neurological as well as psychiatric symptomatology and eventual respective disorders cannot be excluded as evidenced from influenza-A triggered post-encephalitic Parkinsonism and HIV-1 triggered AIDS–dementia complex. From the available evidences for coronavirus-induced brain pathology, this review concludes a number of unmet needs for further research strategies like human postmortem brain analyses. SARS-CoV-2 mirroring experimental animal brain studies, characterization of time-dependent and region-dependent spreading behaviours of coronaviruses, enlightening of pathological mechanisms after coronavirus infection using long-term animal models and clinical observations of patients having had COVID-19 infection are calling to develop both protective strategies and drug discoveries to avoid early and late coronavirus-induced functional brain disturbances, symptoms and eventually disorders. To fight SARS-CoV-2, it is an urgent need to enforce clinical, molecular biological, neurochemical and genetic research including brain-related studies on a worldwide harmonized basis. KW - coronavirus KW - COVID-19 KW - SARS-CoV-2 brain disorders KW - cardiorespiratory centre KW - brain pathology KW - neurological symptoms/disorders KW - brain stem KW - Parkinson’s disease KW - Parkinsonism KW - Alzheimer’s disease KW - multiple sclerosis KW - movement disorders KW - neuroinvasion KW - therapy KW - neuroprotection KW - depression KW - cognitive dysfunction KW - brain bank KW - postmortem studies Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-314637 SN - 0300-9564 SN - 1435-1463 VL - 127 IS - 9 ER - TY - THES A1 - Zölch, Michael Ludwig T1 - Effekt der Interleukin-1 Rezeptor-assoziierten Kinase 2 (IRAK2)-Mutation N333D auf den Signalweg von TLR4 T1 - The effect of interleukin-1 receptor-associated kinase 2 (IRAK2)-mutation N333D on the signal transduction of TLR4 N2 - IRAK2 besitzt eine Schlüsselrolle im Signalweg des TLR4. Fehlregulationen dieses Signalwegs führen zu fehlgeleiteten Immunreaktionen, die auch die Entstehung und Progression von Krebserkrankungen fördern. Bevor IRAK2 als therapeutisches Ziel in Frage kommen kann, muss erst noch weitere Klarheit über die grundsätzliche Funktionsweise dieses Proteins bestehen. So ist für IRAK2 aufgrund der Substitution einer Aminosäure in der Kinase-Domäne im Vergleich zu IRAK1 noch nicht abschließend geklärt, ob es sich um eine aktive Kinase oder eine Pseudokinase handelt und ob diese Veränderung eine Erhöhung oder eine Erniedrigung der Funktion im TLR4-Signalweg nach sich zieht. Um diese Fragen anzugehen, wurde in dieser Arbeit Asparagin im vermeintlich aktiven Zentrum (Aminosäure 333) wieder zur Asparaginsäure [N333D] revertiert und damit versucht die Phosphorylierungsaktivität zu steigern bzw. vergleichbar zu IRAK1 wiederherzustellen. Das Einbringen der Mutation in IRAK2 erfolgte mittels ortsspezifischer Mutagenese. Mit dieser und anderen Mutanten und mit wildtypischem IRAK2 wurden durch die CRISPR/Cas9-Methode generierte IRAK2-defiziente 264.7 Makrophagen rekonstituiert und damit ein System etabliert, mit dem der Einfluss der Mutation auf den Signalweg des TLR4 nach Stimulation mit LPS quantitativ analysiert werden konnte. Sowohl die indirekte NF-κB-Messung über CD40-Expression als auch die direkte NF-κB-Messung über die NF-κB-getriebene Expression eines Reportergens (cyan fluorescent protein) ergab, dass IRAK2[N333D] die LPS-abhängige NF-κB-Aktivierung über den TLR4 Signalweg schlechter ermöglicht als IRAK2. Insgesamt deuten die Ergebnisse darauf hin, dass die in der Entwicklungsgeschichte aufgetretene Veränderung des aktiven Zentrums von IRAK2 im Vergleich zu IRAK1 zu einer besseren Aktivierung der MyD88-abhängigen NF-κB-Aktivität führte und somit eine erhöhte und länger anhaltende Signalleitung ermöglichte. Diese Erkenntnis kann als weiterer Schritt hin zu einem besseren Verständnis der Funktion des IRAK2-Proteins und zu einer möglichen zukünftigen Verwendung von IRAK2 als Ziel therapeutischer Behandlungen gesehen werden. N2 - Toll-like receptors are fundamental for many immune cells. The protein IRAK2 plays a key role in the signaling pathway downstream of TLR4 and other TLRs. Due to a change at amino acid position 333 of the protein from aspartate (D) to asparagine (N) in the presumed active center of the kinase it is unclear if IRAK2 is an active kinase. In this research the mutation IRAK2-N333D was investigated thereby trying to reconstitute the evolutionarily original version of the protein. Interestingly, overexpression of IRAK2-N333D in IRAK2-deficient RAW 264.7 cells obtained by using the CRISPR/Cas9-system was less effective in activating LPS-induced CD40 expression and NF-κB activity as compared to wild type IRAK2. Our results suggest that the evolutionary alteration in the "catalytic center" of IRAK2 led to improved signal transduction thereby allowing longer-lasting activation of the cells. This knowledge might help to better target IRAK2 in therapies. KW - Toll-like-Rezeptoren KW - CRISPR/Cas-Methode KW - Immunbiologie KW - IRAK2-Mutation N333D KW - IRAK2-defiziente Zellen KW - Toll-like Rezeptor 4 Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-180678 ER - TY - THES A1 - Lieberherr, Christina T1 - Untersuchung der Wirkung potentieller Inhibitoren der Masernvirus-Infektion T1 - Investigation of the effect of potential inhibitors of measles virus infection N2 - Die Infektion mit dem Masernvirus (MV) stellt weltweit immer noch ein großes Problem dar. Trotz des vorhandenen Lebendimpfstoffs, der eine Erkrankung sicher zu verhindern vermag, haben nicht nur die Entwicklungsländer, in denen ein flächendeckender Impfschutz schwieriger zu erreichen ist, mit der Erkrankung und ihren Komplikationen zu kämpfen. Hat sich die Erkrankung klinisch manifestiert gibt es keine kausalen Therapiemöglichkeiten und es kann nur noch symptomatisch behandelt werden. Dies ist v.a. auch in Hinblick auf die schweren Komplikationen der Maserninfektion von Bedeutung. Bei Erstkontakt mit dem Masernvirus ist die Suszeptibilität nicht geimpfter Menschen sehr hoch. Das bedeutet, dass es in 95-98 % der Fälle nach einer Infektion mit dem Masernvirus auch zum klinischen Bild der Masern kommt, unabhängig von Alter und Geschlecht. Das Ziel dieser Arbeit war es daher, potentielle Hemmstoffe der Maserninfektion auf ihre Wirkung zu testen und zu verstehen, wo im Infektions- und Replikationszyklus des MV sie eingreifen. Es wurden eine Reihe Substanzen mit potentiell-inhibitorischen Eigenschaften in Infektions-Hemmtests und im Zytotoxizitätstest untersucht, von denen im Anschluss die drei besten Inhibitoren (JK80, QD6-8 und Droseron) weiter untersucht wurden. JK80 und QD6-8 waren beide mit IC50-Werten um 30 µM und SI-Werten von über 2 nur mäßig spezifisch antiviral wirksam. Während JK80 vermutlich den Eintritt des MV in die Zellen verhindert, hemmt QD6-8 die intrazelluläre Virusreplikation und wäre im Hinblick auf die Entwicklung neuartiger, spezifischer Medikamente gegen die Maserninfektion von grossem Interesse. Eine Zielmolekülanalyse der Substanz und die Testung anderer Derivate könnten Aufschluss darüber geben, wie Substanzen aussehen müssten, die eine spezifische Hemmung der intrazellulären Replikation bewirken können. Der Naturstoff Droseron könnte mit einer spezifischen Hemmung (IC50 ca. 10 µM; SIWert 6 im Fluoreszenzreader, bzw. IC50 ca. 2 µM; SI-Wert 30 in der Titration) eine mögliche Leitsubstanz für einen neuen MV-Inhibitor darstellen. Allerdings waren alle bisher getesteten Droseron-Derivate entweder weniger inhibitorisch wirksam oder deutlich zytotoxischer als Droseron selbst. Die Ergebnisse der Infektionshemmversuche mit Zugabe von Droseron vor, während oder nach der Infektion mit MV sprechen dafür, dass Droseron den Eintritt des Virus in die Zelle stört. N2 - The infection with measles virus (MV) is still a major problem worldwide.The aim of this work was therefore to test potential inhibitors of measles infection for their effect and to understand where in the infection and replication cycle of the MV they intervene.A series of substances with potential inhibitory qualities were investigated in infection inhibition tests and in the cytotoxicity test. The three best inhibitors (JK80, QD6-8 and Droseron) were further investigated.The naphthoquinone Droseron could be a possible lead compound for a new MV inhibitor. KW - Masernvirus KW - Masernvirus Inhibitoren Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-176752 ER - TY - JOUR A1 - Ribechini, Eliana A1 - Eckert, Ina A1 - Beilhack, Andreas A1 - Du Plessis, Nelita A1 - Walzl, Gerhard A1 - Schleicher, Ulrike A1 - Ritter, Uwe A1 - Lutz, Manfred B. T1 - Heat-killed Mycobacterium tuberculosis prime-boost vaccination induces myeloid-derived suppressor cells with spleen dendritic cell–killing capability JF - JCI Insight N2 - Tuberculosis patients and mice infected with live Mycobacterium tuberculosis accumulate high numbers of myeloid-derived suppressor cells (MDSCs). Here, we hypothesized that dead M. tuberculosis vaccines also may induce MDSCs that could impair the efficacy of vaccination. We found that repeated injections of M. tuberculosis vaccines (heat-killed M. tuberculosis in incomplete Freund’s adjuvant, such as Montanide) but not single or control vaccines without M. tuberculosis strongly expanded CD11b\(^+\) myeloid cells in the spleen, leading to T cell suppression of proliferation and killing ex vivo. Dead M. tuberculosis vaccination induced the generation of CD11b\(^+\)Ly6C\(^{hi}\)CD115\(^+\) iNOS/Nos2\(^+\) monocytic MDSCs (M-MDSCs) upon application of inflammatory or microbial activation signals. In vivo these M-MDSCs were positioned strategically in the splenic bridging channels and then positioned in the white pulp areas. Notably, within 6–24 hours, in a Nos2-dependent fashion, they produced NO to rapidly kill conventional and plasmacytoid DCs while, surprisingly, sparing T cells in vivo. Thus, we demonstrate that M. tuberculosis vaccine induced M-MDSCs do not directly suppress effector T cells in vivo but, instead, indirectly by killing DCs. Collectively, we demonstrate that M. tuberculosis booster vaccines induce M-MDSCs in the spleen that can be activated to kill DCs. Our data suggest that formation of MDSCs by M. tuberculosis vaccines should be investigated also in clinical trials. KW - Immunology KW - Infectious disease Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201973 VL - 13 IS - 4 ER - TY - THES A1 - Derakhshani, Shaghayegh T1 - Measles virus infection enhances dendritic cell migration in a 3D environment T1 - Die Masernvirusinfektion verstärkt die Migration dendritischer Zellen in einer 3D-Umgebung N2 - The respiratory system is amongst the most important compartments in the human body. Due to its connection to the external environment, it is one of the most common portals of pathogen entry. Airborne pathogens like measles virus (MV) carried in liquid droplets exhaled from the infected individuals via a cough or sneeze enter the body from the upper respiratory tract and travel down to the lower respiratory tract and reach the alveoli. There, pathogens are captured by the resident dendritic cells (DCs) or macrophages and brought to the lymph node where immune responses or, as in case of MV, dissemination via the hematopoietic cell compartment are initiated. Basic mechanisms governing MV exit from the respiratory tract, especially virus transmission from infected immune cells to the epithelial cells have not been fully addressed before. Considering the importance of these factors in the viral spread, a complex close-to-in-vivo 3D human respiratory tract model was generated. This model was established using de-cellularized porcine intestine tissue as a biological scaffold and H358 cells as targets for infection. The scaffold was embedded with fibroblast cells, and later on, an endothelial cell layer seeded at the basolateral side. This provided an environment resembling the respiratory tract where MV infected DCs had to transmigrate through the collagen scaffold and transmit the virus to epithelial cells in a Nectin-4 dependent manner. For viral transmission, the access of infected DCs to the recipient epithelial cells is an essential prerequisite and therefore, this important factor which is reflected by cell migration was analyzed in this 3D system. The enhanced motility of specifically MV-infected DCs in the 3D models was observed, which occurred independently of factors released from the other cell types in the models. Enhanced motility of infected DCs in 3D collagen matrices suggested infection-induced cytoskeletal remodeling, as also verified by detection of cytoskeletal polarization, uropod formation. This enforced migration was sensitive to ROCK inhibition revealing that MV infection induces an amoeboid migration mode in DCs. In support of this, the formation of podosome structures and filopodia, as well as their activity, were reduced in infected DCs and retained in their uninfected siblings. Differential migration modes of uninfected and infected DCs did not cause differential maturation, which was found to be identical for both populations. As an underlying mechanism driving this enforced migration, the role of sphingosine kinase (SphK) and sphingosine-1-phosphate (S1P) was studied in MV-exposed cultures. It was shown in this thesis that MV-infection increased S1P production, and this was identified as a contributing factor as inhibition sphingosine kinase activity abolished enforced migration of MV-infected DCs. These findings revealed that MV infection induces a fast push-and-squeeze amoeboid mode of migration, which is supported by SphK/S1P axis. However, this push-and-squeeze amoeboid migration mode did not prevent the transendothelial migration of MV-infected DCs. Altogether, this 3D system has been proven to be a suitable model to study specific parameters of mechanisms involved in infections in an in vivo-like conditions. N2 - Die respiratorische System ist ein wesentlicher physiologischer Bestandteil. Durch die direkte und konstante Verbindung der Atemwege mit der äußeren Umgebung sind sie einer der häufigsten Pfade für den Eintritt von Krankheitserregern in den Körper. Luftübertragene Krankheitserreger wie das Masern-Virus (MV), das in Flüssigkeitströpfchen mitgeführt und von Patienten durch Husten oder Niesen ausgeatmet wird, können über die oberen Atemwege in den Körper gelangen und sich bis in die unteren Atemwege und bis zu den Alveolen ausbreiten. Dort werden diese Krankheitserreger von den dort residenten dendritischen Zellen (DC) oder Makrophagen erworben und zu sekundären lymphatischen Organen transportiert, in denen sowohl virus-spezifische Immunantworten, aber auch – wie im Falle von MV – die hämatogene Dissemination initiiert wird. Der Austrittsmechanismus des MV aus den Atemwegen, insbesondere dessen Übertragung von infizierten Immunzellen auf die Epithelzellen und die Faktoren, die diesen Ablauf bestimmen, wurden jedoch bisher unzureichend untersucht. In Anbetracht der Bedeutung dieser Faktoren für die Virusausbreitung wurde ein komplexes, realitätsnahes in-vivo 3D-Modell der menschlichen Atemwege erstellt. Dieses Modell wurde unter Verwendung von de-zellularisiertem Schweinedarmgewebe als biologischem Gerüst und H358 Epithelzellen als Empfänger etabliert. Dieses Grundgerüst wurde mit Fibroblastenzellen eingebettet. Später wurde auf der basolateralen Seite der Modelle eine Endothelzellschicht eingebracht, um eine Umgebung zu schaffen, die der der Atemwege ähnelt. Somit mussten die Virus-Donoren, MV-infizierte DC durch das Kollagengerüst wandern und das Virus auf Epithelzellen in einer Nektin-4 abhängigen Weise übertragen. Für die Virusübertragung ist der Zugang infizierter DC zu den Empfänger-Epithelzellen eine wesentliche Voraussetzung, weshalb dieser wichtige Faktor, der sich in der Zellmigration widerspiegelt, in diesem 3D-System analysiert wurde. Eine erhöhte Beweglichkeit spezifisch MV-infizierter DCs wurde in den 3D-Modellen beobachtet. Dies erwies sich als unabhängig von löslichen Faktoren der anderen Zelltypen in den Modellen. Erhöhte Beweglichkeit infizierten DCs wurde auch in 3D-Kollagenmatrizes gesehen, was auf einen infektionsvermittelten zytoskelettalen Umbau hindeutete, der auch anhand von Zytoskelettpolarisation und Uropodbildung bestätigt wurde. Die MV-Infektion induzierte einen schnellen amöboiden Migrationsmodus in den DCs, der sich als sensitiv gegenüber ROCK-Hemmung erwies. Im Gegensatz zu uninfizierten DCs gleichen Reifungsstadiums waren in infizierten DCs Podosomenstrukturen und Filopodien sowie deren Aktivität stark reduziert. Als potentiell zur verstärkten Motilität infizierter DCs beitragender Faktor wurde die Rolle der Sphingosinkinase (SphK) und des Sphingosin-1-phosphats (S1P) in MV-exponierten Kulturen untersucht. In dieser Arbeit wurde gezeigt, dass die S1P-Produktion durch eine MV-Infektion erhöht wurde, und in der Tat zur für infizierte DCs beobachteten erhöhten Geschwindigkeit beitrug, da diese sensitiv gegenüber Hemmung der Sphingosinkinase-Aktivität war. Diese Ergebnisse zeigen, dass die MV-Infektion einen schnellen amöboid-artigen Migrationsmodus induziert, der von der SphK/S1P-Achse unterstützt wird. Dieser Push-and-Squeeze-Amoeboid-Migrationsmodus verhinderte jedoch nicht die transendotheliale Migration von MV-infizierten DCs. Insgesamt hat sich dieses 3D-System als geeignetes Modell erwiesen, um die spezifische Parameter von Mechanismen von Infektionen in einem in-vivo-ähnlichen Zustand zu untersuchen. KW - Dendritische Zelle KW - Zell Migration KW - Masern-Virus KW - 3D-Modell KW - Sphingosine-1-phosphats KW - Dendritic cell KW - Cell migration KW - Measles virus KW - 3D tissue model KW - Tissue engineering KW - Sphingosine-1-phosphate Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-189182 ER - TY - JOUR A1 - Fux, Robert A1 - Arndt, Daniela A1 - Langenmayer, Martin C. A1 - Schwaiger, Julia A1 - Ferling, Hermann A1 - Fischer, Nicole A1 - Indenbirken, Daniela A1 - Grundhoff, Adam A1 - Dölken, Lars A1 - Adamek, Mikolaj A1 - Steinhagen, Dieter A1 - Sutter, Gerd T1 - Piscine orthoreovirus 3 is not the causative pathogen of proliferative darkening syndrome (PDS) of brown trout (Salmo trutta fario) JF - Viruses N2 - The proliferative darkening syndrome (PDS) is a lethal disease of brown trout (Salmo trutta fario) which occurs in several alpine Bavarian limestone rivers. Because mortality can reach 100%, PDS is a serious threat for affected fish populations. Recently, Kuehn and colleagues reported that a high throughput RNA sequencing approach identified a piscine orthoreovirus (PRV) as a causative agent of PDS. We investigated samples from PDS-affected fish obtained from two exposure experiments performed at the river Iller in 2008 and 2009. Using a RT-qPCR and a well-established next-generation RNA sequencing pipeline for pathogen detection, PRV-specific RNA was not detectable in PDS fish from 2009. In contrast, PRV RNA was readily detectable in several organs from diseased fish in 2008. However, similar virus loads were detectable in the control fish which were not exposed to Iller water and did not show any signs of the disease. Therefore, we conclude that PRV is not the causative agent of PDS of brown trout in the rhithral region of alpine Bavarian limestone rivers. The abovementioned study by Kuehn used only samples from the exposure experiment from 2008 and detected a subclinical PRV bystander infection. Work is ongoing to identify the causative agent of PDS. KW - proliferative darkening syndrome KW - black trout syndrome KW - piscine orthoreovirus KW - orthoreovirus KW - brown trout KW - Salmo trutta fario KW - next generation sequencing KW - RT-qPCR Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-196991 SN - 1999-4915 VL - 11 IS - 2 ER - TY - JOUR A1 - Börtlein, Charlene A1 - Schumacher, Fabian A1 - Kleuser, Burkhard A1 - Dölken, Lars A1 - Avota, Elita T1 - Role of neutral sphingomyelinase-2 (NSM 2) in the control of T cell plasma membrane lipid composition and cholesterol homeostasis JF - Frontiers in Cell and Developmental Biology N2 - The activity of neutral sphingomyelinase-2 (NSM2) to catalyze the conversion of sphingomyelin (SM) to ceramide and phosphocholine at the cytosolic leaflet of plasma membrane (PM) is important in T cell receptor (TCR) signaling. We recently identified PKCζ as a major NSM2 downstream effector which regulates microtubular polarization. It remained, however, unclear to what extent NSM2 activity affected overall composition of PM lipids and downstream effector lipids in antigen stimulated T cells. Here, we provide a detailed lipidomics analyses on PM fractions isolated from TCR stimulated wild type and NSM2 deficient (ΔNSM) Jurkat T cells. This revealed that in addition to that of sphingolipids, NSM2 depletion also affected concentrations of many other lipids. In particular, NSM2 ablation resulted in increase of lyso-phosphatidylcholine (LPC) and lyso-phosphatidylethanolamine (LPE) which both govern PM biophysical properties. Crucially, TCR dependent upregulation of the important T cell signaling lipid diacylglycerol (DAG), which is fundamental for activation of conventional and novel PKCs, was abolished in ΔNSM cells. Moreover, NSM2 activity was found to play an important role in PM cholesterol transport to the endoplasmic reticulum (ER) and production of cholesteryl esters (CE) there. Most importantly, CE accumulation was essential to sustain human T cell proliferation. Accordingly, inhibition of CE generating enzymes, the cholesterol acetyltransferases ACAT1/SOAT1 and ACAT2/SOAT2, impaired TCR driven expansion of both CD4\(^+\) and CD8\(^+\) T cells. In summary, our study reveals an important role of NSM2 in regulating T cell functions by its multiple effects on PM lipids and cholesterol homeostasis. KW - neutral sphingomyelinase-2 KW - T cell receptor KW - plasma membrane KW - lyso-phospholipids KW - diacylglycerol KW - cholesteryl ester Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-190596 SN - 2296-634X VL - 7 IS - 226 ER - TY - THES A1 - Mehrens, Dirk Mathias T1 - Die Bedeutung von PTPN22 für die Differenzierung, Suppressivität und Verteilung von T-Zellen im NOD-Maus-Modell T1 - The role of PTPN22 in differentiation, suppressivity and distribution of t-cells in the NOD mouse model N2 - PTPN22 ist eine Proteinthyrosinphosphatase, die in hämatopoetischen Zellen exprimiert wird und einen negativen regulatorischen Effekt auf die Aktivierung und Differenzierung von Immunzellen ausübt. In genomweiten Assoziationsstudien konnte ein Einzelnukleotidmolymorphismus (SNP) von PTPN22 ermittelt werden (PTPN22 R620W), der mit verschiedenen Autoimmunerkrankungen assoziiert ist, u.a. Typ-1-Diabetes (T1D). Die exakte Wirkweise des SNP ist jedoch nicht bekannt. In Versuchen mit NOD-Mäusen konnte durch einen Knockdown (KD) von PTPN22 ein klinischer Schutz dieser Tiere vor T1D nachgewiesen werden. Die vorliegende Arbeit wurde zur weiteren Untersuchung möglicher zellulärer Ursachen für diesen klinischen Schutz durchgeführt. In Zellkulturen konnte kein Einfluss von PTPN22 auf die Differenzierungseigenschaften von T-Zellen sowie ein nur geringer Einfluss auf die suppressiven Eigenschaften von regulatorischen T-Zellen in suppression assays nachgewiesen werden. In Zellverteilungsversuchen konnte gezeigt werden, dass in Mäusen mit PTPN22-Knockdown eine signifikant verminderte Anzahl an CD8+ und CD4+-Zellen im Pankreas zum Zeitpunkt der Pankreatitis vorlagen, wodurch ein klinischer Schutz erklärt werden könnte. Der Effekt auf das Pankreasinfiltrat könnte auf veränderte Priming-Verhältnisse in pankreatischen Lymphknoten zurückzuführen sein, wobei vermehrte Treg-Zellen eine Auswirkung v.a. auf die Differenzierung von naiven T-Zellen und das Migrationsverhalten von T-Effektor-Zellen haben könnten. N2 - PTPN22 is a protein thyrosine phosphatase, which is expressed in hematopoietic cells. It is a negative regulator of activation and differentiation of immune cells. GWAS detected a single nucleotide polymophism (PTPN22 R620W) that is associated with autoimmunity, e.g. type 1 diabetes. The exact impact of the SNP on immune cells remains unclear. Studies showed that NOD mice with PTPN22-KD were protected from disease. This study was conducted to further investigate this clinical impact. PTPN22-KD had no effect on T cell differentiation and only a minor effect on regulatory T cell suppressivity in vitro but rather led to reduced numbers of CD4+ and CD8+ cells in the pancreas during pancreatitis. Together with changes in cell composition in the pancreatic lymph node PTPN22-KD might have an effect on priming and invasiveness of diabetogenic T cell into the pancreas and thereby lead to protection of T1D in NOD mice. KW - Diabetes Mellitus KW - Typ 1 Diabetes KW - T1D KW - PTPN22 KW - NOD Maus Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-182421 ER - TY - THES A1 - Tiwarekar, Vishakha Rakesh T1 - The APOBEC3G-regulated host factors REDD1 and KDELR2 restrict measles virus replication T1 - Die durch APOBEC3G-regulierten Wirtsfaktoren REDD1 und KDELR2 restringieren die Masernvirus Replikation N2 - Measles is an extremely contagious vaccine-preventable disease responsible for more than 90000 deaths worldwide annually. The number of deaths has declined from 8 million in the pre-vaccination era to few thousands every year due to the highly efficacious vaccine. However, this effective vaccine is still unreachable in many developing countries due to lack of infrastructure, while in developed countries too many people refuse vaccination. Specific antiviral compounds are not yet available. In the current situation, only an extensive vaccination approach along with effective antivirals could help to have a measles-free future. To develop an effective antiviral, detailed knowledge of viral-host interaction is required. This study was undertaken to understand the interaction between MV and the innate host restriction factor APOBEC3G (A3G), which is well-known for its activity against human immunodeficiency virus (HIV). Restriction of MV replication was not attributed to the cytidine deaminase function of A3G, instead, we identified a novel role of A3G in regulating cellular gene functions. Among two of the A3G regulated host factors, we found that REDD1 reduced MV replication, whereas, KDELR2 hampered MV haemagglutinin (H) surface transport thereby affecting viral release. REDD1, a negative regulator of mTORC1 signalling impaired MV replication by inhibiting mTORC1. A3G regulated REDD1 expression was demonstrated to inversely correlate with MV replication. siRNA mediated silencing of A3G in primary human blood lymphocytes (PBL) reduced REDD1 levels and simultaneously increased MV titres. Also, direct depletion of REDD1 improved MV replication in PBL, indicating its role in A3G mediated restriction of MV. Based on these finding, a new role of rapamycin, a pharmacological inhibitor of mTORC1, was uncovered in successfully diminishing MV replication in Vero as well as in human PBL. The ER and Golgi resident receptor KDELR2 indirectly affected MV by competing with MV-H for cellular chaperones. Due to the sequestering of chaperones by KDELR2, they can no longer assist in MV-H folding and subsequent surface expression. Taken together, the two A3G-regulated host factors REDD1 and KDELR2 are mainly responsible for mediating its antiviral activity against MV. N2 - Masern ist eine extrem ansteckende, durch Impfung verhinderbare Infektionskrankheit, die für mehr als 90000 Todesfälle jährlich weltweit verantwortlich ist. Die Zahl der Todesfälle nahm von ca. 8 Millionen in der Prä- Impf-Ära auf wenige Tausend pro Jahr aufgrund dieses effizienten Impfstoffs ab. Dieser ist jedoch aufgrund mangelnder Infrastruktur in vielen Entwicklungsländern nicht ausreichend verfügbar, oder die Impfung wird – vor allem in entwickelten Ländern – verweigert. Spezifische antivirale Substanzen sind noch nicht verfügbar. So könnte nur eine extensive Impfkampagne zu einer Masern-freien Zukunft führen. Um antivirale Substanzen zu generieren wird detailiertes Wissen über Virus-Wirt-Interaktionen benötigt. Diese Studie wurde unternommen um Interaktionen zwischen Masernviren (MV) und dem zellulären Restriktionsfaktor APOBEC3G (A3G), der allgemein bekannt für seine antivirale Wirkung gegen das humane Immundefizienzvirus (HIV) ist, zu charakterisieren. A3G hemmt die MV-Replikation nicht aufgrund seiner Cytidin-Desaminase-Funktion, sondern wir entdeckten eine neue Funktion des A3G, nämlich dass es die Expression zellulärer Faktoren reguliert. Wir fanden, dass unter den A3G-regulierten Wirtszellfaktoren REDD1 die MV-Replikation reduzierte, während KDELR2 den Transport des MV-Hämagglutinins (H) zur Zelloberfläche, und somit die Virusfreisetzung, inhibierte. REDD1, ein negativer Regulator des mTORC1-Signalübertragungswegs, reduzierte die MV-Replikation indem es mTORC1 inhibiert. Die Expression des durch A3G regulierten REDD1 korrelierte umgekehrt mit der MV Replikation. SiRNA-vermittelte Reduktion des A3G in primären humanen Lymphozyten des Bluts (PBL) führte zu einer Abnahme des REDD1 und gleichzeitig zu einer Zunahme des MV-Titers. Ebenso führte direktes Silencing des REDD1 zu einer verstärkten MV-Replikation in PBL, was seine Rolle bei der A3G-vermittelten Restriktion der MV-Replikation unterstreicht. Aufgrund dieser Befunde wurde auch eine neue Funktion des mTORC1-Inhibitors Rapamycin als Inhibitor der MV-Replikation in Vero-Zellen und primären PBL aufgedeckt. Der ER- und Golgi-residente Rezeptor KDELR2 wirkte sich indirekt auf die MV-Replikation aus, indem er mit dem MV-H um die Interaktion mit Chaperonen kompetiert. KDELR2 bindet Chaperone und verhindert so deren Interaktion mit MV-H und den Transport zur Zelloberfläche. Zusammenfassend lässt sich sagen, dass die beiden A3G-regulierten Wirtszellfaktoren REDD1 und KDELR2 hauptsächlich für die antivirale Aktivität des A3G gegen MV verantwortlich sind. KW - measles virus KW - restriction factors KW - APOBEC3G KW - REDD1 KW - KDELR2 Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-179526 ER - TY - JOUR A1 - Otto, C. A1 - Schmidt, S. A1 - Kastner, C. A1 - Denk, S. A1 - Kettler, J. A1 - Müller, N. A1 - Germer, C.T. A1 - Wolf, E. A1 - Gallant, P. A1 - Wiegering, A. T1 - Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells JF - Neoplasia N2 - The transcriptional regulator BRD4 has been shown to be important for the expression of several oncogenes including MYC. Inhibiting of BRD4 has broad antiproliferative activity in different cancer cell types. The small molecule JQ1 blocks the interaction of BRD4 with acetylated histones leading to transcriptional modulation. Depleting BRD4 via engineered bifunctional small molecules named PROTACs (proteolysis targeting chimeras) represents the next-generation approach to JQ1-mediated BRD4 inhibition. PROTACs trigger BRD4 for proteasomale degradation by recruiting E3 ligases. The aim of this study was therefore to validate the importance of BRD4 as a relevant target in colorectal cancer (CRC) cells and to compare the efficacy of BRD4 inhibition with BRD4 degradation on downregulating MYC expression. JQ1 induced a downregulation of both MYC mRNA and MYC protein associated with an antiproliferative phenotype in CRC cells. dBET1 and MZ1 induced degradation of BRD4 followed by a reduction in MYC expression and CRC cell proliferation. In SW480 cells, where dBET1 failed, we found significantly lower levels of the E3 ligase cereblon, which is essential for dBET1-induced BRD4 degradation. To gain mechanistic insight into the unresponsiveness to dBET1, we generated dBET1-resistant LS174t cells and found a strong downregulation of cereblon protein. These findings suggest that inhibition of BRD4 by JQ1 and degradation of BRD4 by dBET1 and MZ1 are powerful tools for reducing MYC expression and CRC cell proliferation. In addition, downregulation of cereblon may be an important mechanism for developing dBET1 resistance, which can be evaded by incubating dBET1-resistant cells with JQ1 or MZ1. KW - Cancer Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-202451 VL - 21 IS - 11 ER - TY - JOUR A1 - Grafen, Anika A1 - Schumacher, Fabian A1 - Chithelen, Janice A1 - Kleuser, Burkhard A1 - Beyersdorf, Niklas A1 - Schneider-Schaulies, Jürgen T1 - Use of acid ceramidase and sphingosine kinase inhibitors as antiviral compounds against measles virus infection of lymphocytes in vitro JF - Frontiers in Cell and Developmental Biology N2 - As structural membrane components and signaling effector molecules sphingolipids influence a plethora of host cell functions, and by doing so also the replication of viruses. Investigating the effects of various inhibitors of sphingolipid metabolism in primary human peripheral blood lymphocytes (PBL) and the human B cell line BJAB we found that not only the sphingosine kinase (SphK) inhibitor SKI-II, but also the acid ceramidase inhibitor ceranib-2 efficiently inhibited measles virus (MV) replication. Virus uptake into the target cells was not grossly altered by the two inhibitors, while titers of newly synthesized MV were reduced by approximately 1 log (90%) in PBL and 70–80% in BJAB cells. Lipidomic analyses revealed that in PBL SKI-II led to increased ceramide levels, whereas in BJAB cells ceranib-2 increased ceramides. SKI-II treatment decreased sphingosine-1-phosphate (S1P) levels in PBL and BJAB cells. Furthermore, we found that MV infection of lymphocytes induced a transient (0.5–6 h) increase in S1P, which was prevented by SKI-II. Investigating the effect of the inhibitors on the metabolic (mTORC1) activity we found that ceranib-2 reduced the phosphorylation of p70 S6K in PBL, and that both inhibitors, ceranib-2 and SKI-II, reduced the phosphorylation of p70 S6K in BJAB cells. As mTORC1 activity is required for efficient MV replication, this effect of the inhibitors is one possible antiviral mechanism. In addition, reduced intracellular S1P levels affect a number of signaling pathways and functions including Hsp90 activity, which was reported to be required for MV replication. Accordingly, we found that pharmacological inhibition of Hsp90 with the inhibitor 17-AAG strongly impaired MV replication in primary PBL. Thus, our data suggest that treatment of lymphocytes with both, acid ceramidase and SphK inhibitors, impair MV replication by affecting a number of cellular activities including mTORC1 and Hsp90, which alter the metabolic state of the cells causing a hostile environment for the virus. KW - measles virus KW - sphingolipids KW - acid ceramidase KW - acid ceramidase inhibitor ceranib-2 KW - sphingosine kinase KW - sphingosine kinase inhibitor SKI-II Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-196099 SN - 2296-634X VL - 7 IS - 218 ER - TY - JOUR A1 - Dasari, Prasad A1 - Koleci, Naile A1 - Shopova, Iordana A. A1 - Wartenberg, Dirk A1 - Beyersdorf, Niklas A1 - Dietrich, Stefanie A1 - Sahagún-Ruiz, Alfredo A1 - Figge, Marc Thilo A1 - Skerka, Christine A1 - Brakhage, Axel A. A1 - Zipfel, Peter F. T1 - Enolase from Aspergillus fumigatus is a moonlighting protein that binds the human plasma complement proteins factor H, FHL-1, C4BP, and plasminogen JF - Frontiers in Immunology N2 - The opportunistic fungal pathogen Aspergillus fumigatus can cause severe infections, particularly in immunocompromised individuals. Upon infection, A. fumigatus faces the powerful and directly acting immune defense of the human host. The mechanisms on how A. fumigatus evades innate immune attack and complement are still poorly understood. Here, we identify A. fumigatus enolase, AfEno1, which was also characterized as fungal allergen, as a surface ligand for human plasma complement regulators. AfEno1 binds factor H, factor-H-like protein 1 (FHL-1), C4b binding protein (C4BP), and plasminogen. Factor H attaches to AfEno1 via two regions, via short conserved repeats (SCRs) 6–7 and 19–20, and FHL-1 contacts AfEno1 via SCRs 6–7. Both regulators when bound to AfEno1 retain cofactor activity and assist in C3b inactivation. Similarly, the classical pathway regulator C4BP binds to AfEno1 and bound to AfEno1; C4BP assists in C4b inactivation. Plasminogen which binds to AfEno1 via lysine residues is accessible for the tissue-type plasminogen activator (tPA), and active plasmin cleaves the chromogenic substrate S2251, degrades fibrinogen, and inactivates C3 and C3b. Plasmin attached to swollen A. fumigatus conidia damages human A549 lung epithelial cells, reduces the cellular metabolic activity, and induces cell retraction, which results in exposure of the extracellular matrix. Thus, A. fumigatus AfEno1 is a moonlighting protein and virulence factor which recruits several human regulators. The attached human regulators allow the fungal pathogen to control complement at the level of C3 and to damage endothelial cell layers and tissue components. KW - complement factor H KW - moonlighting KW - immune evasion KW - plasminogen KW - blocking phagocytosis Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-195612 SN - 1664-3224 VL - 10 ER - TY - JOUR A1 - Derakhshani, Shaghayegh A1 - Kurz, Andreas A1 - Japtok, Lukasz A1 - Schumacher, Fabian A1 - Pilgram, Lisa A1 - Steinke, Maria A1 - Kleuser, Burkhard A1 - Sauer, Markus A1 - Schneider-Schaulies, Sibylle A1 - Avota, Elita T1 - Measles virus infection fosters dendritic cell motility in a 3D environment to enhance transmission to target cells in the respiratory epithelium JF - Frontiers in Immunology N2 - Transmission of measles virus (MV) from dendritic to airway epithelial cells is considered as crucial to viral spread late in infection. Therefore, pathways and effectors governing this process are promising targets for intervention. To identify these, we established a 3D respiratory tract model where MV transmission by infected dendritic cells (DCs) relied on the presence of nectin-4 on H358 lung epithelial cells. Access to recipient cells is an important prerequisite for transmission, and we therefore analyzed migration of MV-exposed DC cultures within the model. Surprisingly, enhanced motility toward the epithelial layer was observed for MV-infected DCs as compared to their uninfected siblings. This occurred independently of factors released from H358 cells indicating that MV infection triggered cytoskeletal remodeling associated with DC polarization enforced velocity. Accordingly, the latter was also observed for MV-infected DCs in collagen matrices and was particularly sensitive to ROCK inhibition indicating infected DCs preferentially employed the amoeboid migration mode. This was also implicated by loss of podosomes and reduced filopodial activity both of which were retained in MV-exposed uninfected DCs. Evidently, sphingosine kinase (SphK) and sphingosine-1-phosphate (S1P) as produced in response to virus-infection in DCs contributed to enhanced velocity because this was abrogated upon inhibition of sphingosine kinase activity. These findings indicate that MV infection promotes a push-and-squeeze fast amoeboid migration mode via the SphK/S1P system characterized by loss of filopodia and podosome dissolution. Consequently, this enables rapid trafficking of virus toward epithelial cells during viral exit. KW - dendritic cell KW - cell migration KW - measles virus KW - 3D tissue model KW - sphingosine-1-phosphate Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201818 VL - 10 IS - 1294 ER - TY - JOUR A1 - Tiwarekar, Vishakha A1 - Fehrholz, Markus A1 - Schneider-Schaulies, Jürgen T1 - KDELR2 competes with measles virus envelope proteins for cellular chaperones reducing their chaperone-mediated cell surface transport JF - Viruses N2 - Recently, we found that the cytidine deaminase APOBEC3G (A3G) inhibits measles (MV) replication. Using a microarray, we identified differential regulation of several host genes upon ectopic expression of A3G. One of the up-regulated genes, the endoplasmic reticulum (ER) protein retention receptor KDELR2, reduced MV replication ~5 fold when it was over-expressed individually in Vero and CEM-SS T cells. Silencing of KDELR2 in A3G-expressing Vero cells abrogated the antiviral activity induced by A3G, confirming its role as an A3G-regulated antiviral host factor. Recognition of the KDEL (Lys-Asp-Glu-Leu) motif by KDEL receptors initiates the retrograde transport of soluble proteins that have escaped the ER and play an important role in ER quality control. Although KDELR2 over-expression reduced MV titers in cell cultures, we observed no interaction between KDELR2 and the MV hemagglutinin (H) protein. Instead, KDELR2 retained chaperones in the ER, which are required for the correct folding and transport of the MV envelope glycoproteins H and fusion protein (F) to the cell surface. Our data indicate that KDELR2 competes with MV envelope proteins for binding to calnexin and GRP78/Bip, and that this interaction limits the availability of the chaperones for MV proteins, causing the reduction of virus spread and titers. KW - measles virus KW - KDELR2 KW - calnexin KW - GRP78 KW - surface transport Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-197468 SN - 1999-4915 VL - 11 IS - 1 ER - TY - JOUR A1 - Streng, Andrea A1 - Goettler, David A1 - Haerlein, Miriam A1 - Lehmann, Lisa A1 - Ulrich, Kristina A1 - Prifert, Christiane A1 - Krempl, Christine A1 - Weißbrich, Benedikt A1 - Liese, Johannes G. T1 - Spread and clinical severity of respiratory syncytial virus A genotype ON1 in Germany, 2011–2017 JF - BMC Infectious Diseases N2 - Background The Respiratory Syncytial Virus (RSV) A genotype ON1, which was first detected in Ontario (Canada) in 2010/11, appeared in Germany in 2011/12. Preliminary observations suggested a higher clinical severity in children infected with this new genotype. We investigated spread and disease severity of RSV-A ON1 in pediatric in- and outpatient settings. Methods During 2010/11 to 2016/17, clinical characteristics and respiratory samples from children with acute respiratory tract infections (RTI) were obtained from ongoing surveillance studies in 33 pediatric practices (PP), one pediatric hospital ward (PW) and 23 pediatric intensive care units (PICU) in Germany. RSV was detected in the respiratory samples by PCR; genotypes were identified by sequencing. Within each setting, clinical severity markers were compared between RSV-A ON1 and RSV-A non-ON1 genotypes. Results A total of 603 children with RSV-RTI were included (132 children in PP, 288 in PW, and 183 in PICU). Of these children, 341 (56.6%) were infected with RSV-A, 235 (39.0%) with RSV-B, and one child (0.2%) with both RSV-A and RSV-B; in 26 (4.3%) children, the subtype could not be identified. In the 341 RSV-A positive samples, genotype ON1 was detected in 247 (72.4%), NA1 in 92 (26.9%), and GA5 in 2 children (0.6%). RSV-A ON1, rarely observed in 2011/12, was the predominant RSV-A genotype in all settings by 2012/13 and remained predominant until 2016/17. Children in PP or PW infected with RSV-A ON1 did not show a more severe clinical course of disease compared with RSV-A non-ON1 infections. In the PICU group, hospital stay was one day longer (median 8 days, inter-quartile range (IQR) 7–12 vs. 7 days, IQR 5–9; p = 0.02) and duration of oxygen treatment two days longer (median 6 days, IQR 4–9 vs. 4 days, IQR 2–6; p = 0.03) for children infected with RSV-A ON1. Conclusions In children, RSV-A ON1 largely replaced RSV-A non-ON1 genotypes within two seasons and remained the predominant RSV-A genotype in Germany during subsequent seasons. A higher clinical severity of RSV-A ON1 was observed within the group of children receiving PICU treatment, whereas in other settings clinical severity of RSV-A ON1 and non-ON1 genotypes was largely similar. KW - Children KW - Respiratory tract infection KW - RSV-A ON1 KW - Epidemiology KW - Disease severity Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201516 VL - 19 ER - TY - JOUR A1 - Avota, Elita A1 - de Lira, Maria Nathalia A1 - Schneider-Schaulies, Sibylle T1 - Sphingomyelin breakdown in T cells: role of membrane compartmentalization in T cell signaling and interference by a pathogen JF - Frontiers in Cell and Developmental Biology N2 - Sphingolipids are major components of cellular membranes, and at steady-state level, their metabolic fluxes are tightly controlled. On challenge by external signals, they undergo rapid turnover, which substantially affects the biophysical properties of membrane lipid and protein compartments and, consequently, signaling and morphodynamics. In T cells, external cues translate into formation of membrane microdomains where proximal signaling platforms essential for metabolic reprograming and cytoskeletal reorganization are organized. This review will focus on sphingomyelinases, which mediate sphingomyelin breakdown and ensuing ceramide release that have been implicated in T-cell viability and function. Acting at the sphingomyelin pool at the extrafacial or cytosolic leaflet of cellular membranes, acid and neutral sphingomyelinases organize ceramide-enriched membrane microdomains that regulate T-cell homeostatic activity and, upon stimulation, compartmentalize receptors, membrane proximal signaling complexes, and cytoskeletal dynamics as essential for initiating T-cell motility and interaction with endothelia and antigen-presenting cells. Prominent examples to be discussed in this review include death receptor family members, integrins, CD3, and CD28 and their associated signalosomes. Progress made with regard to experimental tools has greatly aided our understanding of the role of bioactive sphingolipids in T-cell biology at a molecular level and of targets explored by a model pathogen (measles virus) to specifically interfere with their physiological activity. KW - T cell KW - sphingomyelinase KW - activation KW - motility KW - measles virus Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-199168 SN - 2296-634X VL - 7 IS - 152 ER - TY - JOUR A1 - Hollmann, Claudia A1 - Wiese, Teresa A1 - Dennstädt, Fabio A1 - Fink, Julian A1 - Schneider-Schaulies, Jürgen A1 - Beyersdorf, Niklas T1 - Translational approaches targeting ceramide generation from sphingomyelin in T cells to modulate immunity in humans JF - Frontiers in Immunology N2 - In T cells, as in all other cells of the body, sphingolipids form important structural components of membranes. Due to metabolic modifications, sphingolipids additionally play an active part in the signaling of cell surface receptors of T cells like the T cell receptor or the co-stimulatory molecule CD28. Moreover, the sphingolipid composition of their membranes crucially affects the integrity and function of subcellular compartments such as the lysosome. Previously, studying sphingolipid metabolism has been severely hampered by the limited number of analytical methods/model systems available. Besides well-established high resolution mass spectrometry new tools are now available like novel minimally modified sphingolipid subspecies for click chemistry as well as recently generated mouse mutants with deficiencies/overexpression of sphingolipid-modifying enzymes. Making use of these tools we and others discovered that the sphingolipid sphingomyelin is metabolized to ceramide to different degrees in distinct T cell subpopulations of mice and humans. This knowledge has already been translated into novel immunomodulatory approaches in mice and will in the future hopefully also be applicable to humans. In this paper we are, thus, summarizing the most recent findings on the impact of sphingolipid metabolism on T cell activation, differentiation, and effector functions. Moreover, we are discussing the therapeutic concepts arising from these insights and drugs or drug candidates which are already in clinical use or could be developed for clinical use in patients with diseases as distant as major depression and chronic viral infection. KW - sphingolipids KW - CD4+ T cells KW - regulatory T cells (Treg) KW - CD8+ T cells KW - anti-depressant drug Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-198806 SN - 1664-3224 VL - 10 IS - 2363 ER - TY - JOUR A1 - John, Vini A1 - Kotze, Leigh A. A1 - Ribechini, Eliana A1 - Walzl, Gerhard A1 - Du Plessis, Nelita A1 - Lutz, Manfred B. T1 - Caveolin-1 controls vesicular TLR2 expression, p38 signaling and T cell suppression in BCG infected murine monocytic myeloid-derived suppressor cells JF - Frontiers in Immunology N2 - Monocytic myeloid-derived suppressor cells (M-MDSCs) and granulocytic MDSCs (G-MDSCs) have been found to be massively induced in TB patients as well in murine Mtb infection models. However, the interaction of mycobacteria with MDSCs and its role in TB infection is not well studied. Here, we investigated the role of Cav-1 for MDSCs infected with Mycobacterium bovis Bacille-Calmette-Guerín (BCG). MDSCs that were generated from murine bone marrow (MDSCs) of wild-type (WT) or Cav1\(^{−/−}\) mice upregulated Cav-1, TLR4 and TLR2 expression after BCG infection on the cell surface. However, Cav-1 deficiency resulted in a selective defect of intracellular TLR2 levels predominantly in the M-MDSC subset. Further analysis indicated no difference in the phagocytosis of BCG by M-MDSCs from WT and Cav1\(^{−/−}\) mice or caveosome formation, but a reduced capacity to up-regulate surface markers, to secrete various cytokines, to induce iNOS and NO production required for suppression of T cell proliferation, whereas Arg-1 was not affected. Among the signaling pathways affected by Cav-1 deficiency, we found lower phosphorylation of the p38 mitogen-activated protein kinase (MAPK). Together, our findings implicate that (i) Cav-1 is dispensable for the internalization of BCG, (ii) vesicular TLR2 signaling in M-MDSCs is a major signaling pathway induced by BCG, (iii) vesicular TLR2 signals are controlled by Cav-1, (iv) vesicular TLR2/Cav-1 signaling is required for T cell suppressor functions. KW - myeloid-derived suppressor cell (MDSC) KW - caveolin-1 (Cav-1) KW - TLR2 KW - TLR4 KW - BCG KW - T cell suppression Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-195528 SN - 1664-3224 VL - 10 IS - 2826 ER - TY - THES A1 - Bergfeld, Arne T1 - Das pH-regulierte Protein 1 (Pra1) von \(Candida\) \(albicans\) moduliert CD4\(^+\) T-Zell-Antworten der Maus in vitro durch direkte Bindung an die T-Zell-Oberfläche T1 - The pH-regulated protein 1 (Pra1) of \(Candida\) \(albicans\) modulates mouse CD4\(^+\) T cell responses in vitro by directly binding to the T cell surface N2 - Infektionen durch C. albicans auf den Schleimhäuten sind eine häufige Erkrankung bei Patienten mit einer Schwächung der T-Zellimmunität. Blutstrominfektionen mit der Hefe C. albicans (Candidämie) stellen, vor allem bei Patienten auf Intensivstationen, eine nach wie vor bedrohliche Komplikation mit hoher Letalität dar. Das pH-regulierte Antigen 1 (Pra1) ist ein Protein, das von C. albicans produziert wird, auf der Oberfläche des Pilzes gebunden vorkommt und auch vom Pilz in den Überstand sezerniert wird. Im humanen System bindet das Protein an T-Zellen an das Oberflächenprotein CD46. Es ist des Weiteren bekannt, dass das Pra1 an bestimmte Immunzellen der Maus (Monozyten und Phagozyten) binden kann. Eine Bindung an T-Zellen der Maus ist bisher nicht beschrieben. Eine genaue Charakterisierung der Interaktion von Pra1 mit Immunzellen der Maus ist interessant, da die Maus als biologischer Modellorganismus zur Erforschung der Infektion mit C. albicans dient. In dieser Arbeit konnte gezeigt werden, dass rekombinantes Pra1 (rPra1) auch an Maus-CD4+ T-Zellen binden kann. Es wurden Einflussfaktoren auf die gefundene Bindung von Pra1 an CD4+ T- Zellen gesucht. Als ein Einflussfaktor wurde Zink identifiziert. Pra1 kann an freies Zink binden und durch Zugabe von ZnCl2 während der Inkubation von Pra1 mit T-Zellen kann das Signal von gebundenem Pra1 an CD4+ T-Zellen erhöht werden. Aspf2, ein Protein aus Aspergillus fumigatus mit großer Homologie zu Pra1, kann nicht an diese Zellen binden. Im in-vivo-Experiment mit Tieren, die mit C. albicans infiziert wurden, konnte kein wildtypisches sezerniertes Pra1 gebunden an T-Zellen nachgewiesen werden. Zellkulturüberstände von C. albicans zeigten nach Inkubation in vitro mit T-Zellen ein Signal für gebundenes Pra1 an CD4+ T-Zellen. Die Bindungskinetik von Pra1 an T-Zellen zeigte eine über die Zeit der Inkubation konstante Zunahme des Signals von zellgebundenem rPra1 an CD4+ T-Zellen. In der off-Kinetik fand sich eine Abnahme des Signals über die Zeit bis an die Grenze der Nachweisbarkeit. Der Bindungspartner von Pra1 auf T-Zellen konnte nicht identifiziert werden. Die strukturell und funktionell verwandten Oberflächenproteine Crry, CD59a und CD55 wurden auf Bindungsfähigkeit an T-Zellen in entsprechenden Knockout- Mäusen getestet, konnten jedoch als Rezeptor für Pra1 ausgeschlossen werden. Durch die Bindung von sezerniertem Pra1 an neutrophile Granulozyten wird die Fähigkeit dieser Zellen zur Phagozytose eingeschränkt. Die Bindung von Pra1 an CD4+ T-Zellen führt zur Kostimulation der T-Zellen, also zur verstärkten Zellaktivierung und Proliferation. Durch die Zugabe von 10 μM Zinkchlorid wird die kostimulatorische Aktivität von Pra1 verstärkt. Während der Zellaktivierung von Effektor-Memory-CD4+ T-Zellen reduziert rPra1 die Sekretion von IFN-γ. Diese Reduktion von IFN-γ-produzierenden Zellen entsteht nicht durch einen Einfluss von Pra1 während der Zellaktivierung von naiven CD4+ T-Zellen zu Th1-Zellen und auch nicht durch die Auslösung von Apoptose in IFN-γ-produzierenden Th1-Zellen. Die Bindung von Pra1 an CD4+- T-Zellen, die über den T-Zell-Rezeptor aktiviert werden, reduziert in vitro die Sekretion des Zytokins. Zusätzlich werden weitere Zytokine in ihrer sezernierten Menge reduziert wie IL-2 und TNF-α. N2 - Infections caused by C. albicans on mucosal surfaces are a common disease in patients suffering from suppression of the T cell immune defense. Blood stream infections by the yeast C. albicans (candedemia) represent still a severe complication in patients in intensive care units with high rates of lethality. The pH-regulated antigen 1 (Pra1) is a protein produced by C. albicans which is present on the surface of the fungi and is secreted into the supernatant of fungal cultures as well. Pra1 can bind to human T cells via the surface protein CD46. It is known, that this protein can also bind to certain immune cells of mice (monocytes and phagocytes). Binding to T cells of mice is not yet known. A characterization of the interaction of Pra1 with immune cells of mice would be valuable, because mice act as a biological model system for the investigation of infections with C. albicans. In this paper, it could be shown that recombinant Pra1 (rPra1) can bind to mouse CD4+ T cells as well. After the finding that rPra1 can bind to CD4+ T cells, different parameters determining this binding have been studied. Zinc was found to be one influencing factor on the binding. Pra1 can bind free zinc ions and by the addition of ZnCl2 while incubating T cells with Pra1 the signal of bound Pra1 to CD4+ T cells could be increased. Aspf2, a protein from Aspergillus fumigatus with high homology to Pra1, was not able to bind to these cells. In in-vivo-experiments with animals infected with C. albicans, no wild-typic secreted Pra1 was found bound to T cells. Supernatant from C. albicans cultures produced, after incubation in vitro, a signal for cell-bound Pra1 on CD4+ T cells. Kinetics of the binding of rPra1 to T cells showed a constant increase of signal over the time of incubation. The off-kinetics revealed a decrease of cell-bound rPra1 over time to the edge of detectability. The receptor of Pra1 on T cells has not been identified yet. The structurally and functionally comparable surface proteins Crry, CD59a and CD55 were tested in knockout mice for each of these proteins and could be excluded as possible receptors. After binding of secreted Pra1 to neutrophilic granulocytes these cells experience a decreased capacity to phagocytose pathogens. The binding of Pra1 to CD4+ T cells leads to a costimulation of T cells, which results in increased cell activation and proliferation. This costimulatory capacity of Pra1 can be augmented by adding 10 μM zinc chloride. During activation of naïve CD4+ T cells Pra1 reduces the secretion of IFN-γ. The reduction of IFN-γ-producing cells is not due to an influence of Pra1 during cell activation of naive CD4+ T cells to Th1 cells and is also not due to induction of apoptosis in IFN-γ-producing Th1 cells. The binding of Pra1 to ex-vivo isolated CD4+ T cells reduces the in vitro secretion of IFN-γ after stimulating these cells via their T cell receptor. Additionally, the secretion of IL-2 and TNF-α was reduced. KW - Candida albicans KW - T-Lymphozyt KW - Interferon KW - Tumor-Nekrose-Faktor KW - Interleukin 2 KW - C. albicans KW - CD4+ KW - T-Zelle KW - IFN-g KW - Pra1 Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-169716 ER -